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Cancer accounts for nearly one-quarter of deaths in the United States, exceeded
only by heart disease. In 2005, there were over half a million cancer deaths in the
US. It is estimated that about 1.4 million new cases of cancer will be diagnosed in
2008. Although cancer death rates have declined since the 1990s, the rate of decline
currently remains comparatively low; at 2.6% for men and 1.8% for women1.
Cancer is a distinct type of genetic disease in which a cell must acquire a number
of mutations in order to transform from a normal to a cancerous phenotype. In
a seminal review published in 2000, Hanahan and Weinberg (49) characterized six
hallmarks of cancer. These include self-sufficiency in growth signal, insensitivity
to anti-growth signals, evading apoptosis, limitless replicative potential, sustained
angiogenesis and invasion and metastasis. A solid tumor must undergo a phase of
sustained angiogenesis, in order to progress from a relatively benign stage to an
invasive and potentially fatal phenotype. Conversely, without a vascular system,
tumors can not grow beyond a critical size or metastasize to another organ (19).
Therefore, the field of angiogenesis continues to generate intense interest, in an effort
to develop and maximize the effects of anti-angiogenic therapies.
Tumor-induced angiogenesis is a highly complex process operating on several time
1Data taken from Cancer Facts and Figures 2008 report by the American Cancer Society.
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and length scales. It involves an intricate interplay between biochemical and biome-
chanical processes. At the biochemical level, there is transcription and release of
pro-angiogenic factors by the tumor cells, their uptake by vascular endothelial cells
(ECs) lining neighboring vasculature, the activation of cell surface receptors and
the myriad downstream signalling pathways initiated as a result. These translate
into specific behavior by the cells, such as proliferation, migration, differentiation,
gene transcription, and the release of factors further regulation angiogenesis. Biome-
chanical mechanisms such as cell-cell interactions, cell-matrix interactions, result in
cooperative interactions of the cells with their micro-environments and play a key
role in regulating angiogenesis.
Experimental investigations into the processes governing angiogenesis have been
carried out in earnest over the last few decades and have resulted in the accumulation
of a large volume of data. This information exists at various levels; at the tissue level,
where tumors grow and vascular networks are formed, at the cellular level, where cell
behavior such as migration, proliferation, survival, differentiation are studied, and at
the molecular level, where pro- and anti-angiogenic molecules and their downstream
signalling pathways are investigated. The integration of this information with the aim
of developing anti-cancer and anti-angiogenic therapies is a major challenge facing
the scientific community today. Mathematical modelling provides a powerful tool in
elucidating the mechanisms of interactions between tumor and endothelial cells with
the host environment, while taking into account the mechanical and chemical aspects
of angiogenesis. Consequently, it has an enormous potential in the development and
testing of therapeutic strategies targeting angiogenesis.
The research conducted for this dissertation concentrates on the development of
a multiscale model of tumor-induced angiogenesis, with particular emphasis on in-
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corporating key molecular signalling pathways at the sub-cellular level, and the bio-
chemical interactions between pro-angiogenic molecules such as VEGF and CXCL8
and endothelial cells, that regulate these pathways. The model then integrates the
sub-cellular and cellular level responses into a tissue level behavior. The therapeutic
potential of specific proteins and chemokines is also investigated as possible targets
of anti-angiogenic therapy.
The dissertation is organized in the following manner. Chapter II provides a back-
ground to the biology of tumor-induced angiogenesis. The importance of angiogenesis
in the progression of a tumor from a benign avascular stage to a malignant vascu-
larized cancer is highlighted. The significance of VEGF, CXCL8, and extracellular
matrix in promoting and regulating angiogenesis is discussed in particular.
In Chapter III, we present a survey of existing mathematical techniques used to
model various aspects of angiogenesis. These models are divided into two categories;
continuum models that treat endothelial cell density and chemokine concentrations
as continuous variables, that evolve according to reaction-diffusion systems, and
discrete, cell-based models that track the movements of individual cells or sprout
tips. The strengths and limitations of these models are discussed. The need for
incorporation of greater biological and biochemical detail in order to keep up with
the current state of knowledge in the field forms the motivation for our choice of a
delay differential equation model of angiogenesis.
VEGF has been the most studied pro-angiogenic chemokine. In Chapter IV,
we present a detailed molecular model of the uptake of VEGF by its cell surface
receptors. We begin with a biological background of the VEGF molecule and its
transmembrane receptor tyrosine kinases. This is followed by an overview of the
mathematical models of angiogenesis that have focussed on the role of chemokines
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such as VEGF. However, these models make a number of simplifying assumptions
when dealing with VEGF-endothelial cell interactions that can potentially effect
simulation results. We present a detailed mathematical investigation of the validity
of these assumptions, while presenting our own model of VEGF-VEGF receptor
interactions. In particular, the validity of the quasi steady state assumption in the
context of VEGF binding to its cell surface receptors is investigated.
Recent experiments show that VEGF is the crucial mediator of downstream events
that ultimately lead to enhanced endothelial cell survival and increased vascular
density within many tumors. The newly discovered pathway involves up-regulation
of the anti-apoptotic protein Bcl-2, which in turn leads to increased production
of CXCL8. The VEGF - Bcl- 2 - CXCL8 pathway suggests new targets for the
development of anti-angiogenic strategies. In Chapter V, we present and validate
a mathematical model designed to predict the effect of the therapeutic blockage of
VEGF, CXCL8, and Bcl-2 at different stages of tumor progression. Specifically, a
system of delay-differential equations is derived to describe the temporal dynamics
of the cells, growth factors and chemokines involved in tumor induced angiogenesis.
Techniques developed in Chapter IV to model VEGF-receptor interaction are applied
here.
Endothelial cell apoptosis plays a critical role in the disruption of blood vessels
mediated by natural inhibitors of angiogenesis and by anti-vascular drugs. In Chapter
VI, we apply the model of angiogenesis developed in Chapter V, to answer a critical
question that arises with regards to the evaluation of these anti-angiogenic agents.
What is the minimum percentage requirement of vascular endothelial cell apoptosis
for microvascular regression? We adapt the model developed in the previous chapter
so that it represents the experimental system designed to answer this question. It
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is then used to evaluate experimentally inaccessible ratios. The combined use of
biological experimentation with our mathematical modelling highlights the flexibility
and applicability of our modelling framework.
Pro- and anti- apoptotic proteins in the Bcl family, such as Bad and Bcl-2, are key
regulators of programmed cell death. It is the interaction between these molecules
that determine cellular response to apoptotic signals, making them attractive targets
for therapeutic intervention. In recent experiments designed to study intra-tumoral
angiogenesis, Bcl-2 up-regulation in endothelial cells was shown to be a critical medi-
ator of vascular development. In Chapter VII, we extend the model of intra-tumoral
angiogenesis developed in Chapter V to explicitly incorporate the cellular response
to variations in pro- and anti-apoptotic proteins in the Bcl family, as well as the
administration of specific anti-angiogenic therapy in the form of a small molecule
inhibitor BL193 targeted against the Bcl-2 molecule. The model is validated by
comparing its predictions to in vitro experimental data. Finally, a sensitivity analy-
sis carried out on drug design parameters reveals that developing a better inhibitor
of Bcl-2 has greater therapeutic potential than improving its permeability across the
cell membrane.
Thus far, we have concentrated on a delay differential equation model of tumor
angiogenesis, and assumed spatial homogeneity. However, the vascular structure
within a tumor is highly unorganized and spatially heterogeneous, and it would be
instructive to extend our model to include spatial variations in cell densities, chemical
concentrations and vascular development. To this end, in Chapter VIII we develop a
hybrid model of tumor-induced angiogenesis, based on the theory of reinforced ran-
dom walks. We include in our model, the chemotactic response of endothelial cells to
VEGF bound to cell-surface receptors, rather than approximating this as a function
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of free VEGF concentrations. We also propose a novel and more biologically rea-
sonable functional form for the chemotactic sensitivity of cells, than those currently
used. We begin with the motion of a single endothelial cell under the influence of
a gradient of VEGF. Biologically observed phenomena such as the ability of ECs to
sense a chemical gradient as low as 1% across their lengths and their resulting polar-
ization and movement is captured by our model. To our knowledge, this is the first
instance of the inclusion of this level of molecular detail in a spatial model of tumor
angiogenesis. Later, we modify the motion of a single endothelial cell to model the
capillary network formation under the influence of VEGF. Events such as branching
and anastomoses, which are observed to occur in vivo, are incorporated explicitly in
the model. Empirically observed proliferative regions behind developing sprout tips
match those in our simulations, thereby validating our model. This multiscale model
is a first step in incorporating cellular and sub-cellular events in hybrid models of
tumor angiogenesis, in an effort to understanding relationship between intra-cellular
molecular pathways and multicellular behavior.
We conclude with a summary chapter which discusses the impact of this research
and proposes future directions for the extension of our model.
CHAPTER II
Biological Background to Angiogenesis
2.1 Stages of Tumor Growth
The growth of solid tumors can be characterized as having three distinct stages;
an avascular stage of diffusion limited growth, a phase of blood vessel growth, and a
vascularized stage where the tumor cells may become highly invasive and metastatic
(Figure 2.1). In the first stage, solid tumors begin as avascular spheroids, and rely
on diffusion for the supply of oxygen and nutrients, as well as waste product removal
from neighboring vessels for growth. As they grow, nutrient requirements of the
tumor cells increase and the flux of nutrients through the tumor surface is unable
to meet these demands. Consequently, the interior of these spheroids becomes pro-
gressively lacking in oxygen (hypoxic), and in glucose (hypoglycemic). This results
in the formation of a necrotic core, and the tumor reaches a steady state size of 1-3
mm in diameter. This may be termed as the avascular growth stage, and is diffusion
limited (63; 84).
Sustained tumor growth requires an adequate supply of nutrients and an effective
means of the removal of metabolic wastes. This need is met by the establishment
of a blood supply to the tumor, which the tumor cells may accomplish in a variety
of ways. For instance, the tumor cells may themselves grow around existing vessels,
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Figure 2.1: Figure showing the cascade of events leading to intra-tumoral angiogenesis adapted
from (57)
forming a perivascular cuff in a process known as vessel co-option (8). Alternatively,
extra-cellular matrix-rich vascular channels may develop, that lack endothelial cells,
but contain circulating red blood cells. This is known as vascular mimicry (124).
Circulating endothelial cell precursors derived from the bone marrow may also con-
tribute to vascular development within the tumor (109). Frequently, the tumor will
stimulate new blood vessel growth from existing vasculature, in a process known as
angiogenesis, described in greater detail below.
Often, in response to the hypoxia, the tumor cells begin to secrete a variety of
polypeptidic angiogenic factors, such as such as Vascular Endothelial Growth Factor
(VEGF) and basic Fibroblast Growth Factor (bFGF) (135). These factors diffuse
from the tumor to nearby vessels, and result in the activation of endothelial cells
(ECs) lining vessel walls. The vasculature surrounding the tumor undergoes the
angiogenic switch. At first, vascular permeability increases, resulting in extravascular
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deposition of fibrin. This is followed by the removal of pericytes that comprise
the vessel wall. Next, basement membrane and extra cellular matrix (ECM) are
degraded by proteases such as matrix metalloproteinases. New matrix may be laid
down, and existing ECM remodelled to facilitate the migration and proliferation of
the ECs. This is aided by the presence of growth factors sequestered in the matrix
and released due to its degradation, or released by the tumor cells. The ECs will
migrate chemotactically up the gradient of the growth factors, towards the tumor.
After sufficient division, the ECs are able to organize themselves into a monolayer
and form tube like structures or the capillary lumen. Neighboring capillary sprouts
may fuse together (anastomosis) resulting in the circulation of blood. The immature
vessels may further branch or fuse creating a complex vascular network, that will
eventually reach and penetrate the tumor. The process of sprouting is followed by
a phase of maturation in which cell proliferation is inhibited, and migration ceases.
Pericytes or smooth muscle cells are recruited to form the basement membrane and
vessel walls. Vessels uncovered by pericytes regress. This process of vessel maturation
is controlled by the angiopoietin/Tie system (84; 109; 124).
Angiogenesis results in the vascularization of the spheroid. Thus the tumor has
established an effective means for the supply of nutrients for growth of the tumor
cells, and waste product removal. The newly formed vasculature is also a route
for the tumor cells to spread to other parts of the body in a process known as
metastasis (84). Angiogenesis is thus a crucial step in the progression of cancer, and
a better understanding of the processes which control it is vital for the development
of effective anti-tumor therapy. In the sections that follow, the principle aspects of
tumor angiogenesis are discussed in greater detail.
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2.2 The Role of VEGF in Angiogenesis
The most common angiogenic factor released by tumor cells is Vascular Endothe-
lial Growth Factor (VEGF). VEGF is the most crucial regulator of angiogenesis and
is highly up-regulated in most human cancers (37; 96; 106; 109; 124). As mentioned
earlier, oxygen tension plays a key role in the regulation of VEGF gene expression.
Briefly, oxygen promotes the hydroxylation of the hypoxia-inducible factor (HIF-1α),
which leads to its eventual proteosomal degradation. However, under conditions of
hypoxia, this fails to occur, and there is a resultant build up in HIF-1α levels. HIF-
1α is then able to form dimers with HIF-1β, and initiate the transcription of target
genes including the VEGF gene (37; 124). Several growth factors including fibroblast
growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth
factor (TGF-β), and epidermal growth factor (EGF) have also been shown to up-
regulate VEGF expression. Furthermore, mutations of the Ras proto-oncogene which
occur in a variety of human cancers, lead to increased VEGF expression via the ac-
tivation of the Ras-Mek-Erk MAP kinase pathway (124).
VEGF diffuses from the tumor to nearby vessels, and binds to receptors on the
surface of the vascular endothelial cells. These are transmembrane receptor tyro-
sine kinases (RTKs) including VEGFR-1 (flt-1) and VEGFR-2 (KDR/flk-1), which
are activated through ligand binding. This facilitates receptor dimerization and
autophosphorylation of tyrosine residues in the cytoplasmic portion. The phospho-
tyrosine residues either enhance receptor catalytic activity or provide docking sites
for downstream signaling proteins (85). VEGF mediates multiple responses from
activated endothelial cells, which are illustrated in Figure 2.2.
It has been demonstrated that VEGF increases vascular permeability, which al-
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Figure 2.2: Figure showing the intracellular domains of dimerized and activated VEGF receptors
(VEGFR1/2/3), taken from (102). Binding of signalling molecules to certain phospho-
rylation sites initiates downstream signalling pathways, resulting in specific biological
responses.
lows for the extravasation of plasma proteins, such as fibrinogen, and other clotting
proteins. This results in the deposition of fibrin in the avascular space, which leads
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to the formation of ECM, facilitating EC migration (17; 52). VEGF has also been
shown to increase the expression of urokinase and tissue-type plasminogen activators
(uPA and tPA). These are serine proteases involved in the degradation of ECM. The
expression of plasminogen activator inhibitor (PAI) type-1 is also increased, which
is an inhibitor of uPA and tPA. Additionally, VEGF stimulates the production of
matrix degrading metalloproteinases, interstitial collagenase. All these components
actively participate in the remodelling of the ECM, aiding in EC migration and
sprouting (84; 109).
VEGF exerts a number of different effects on EC, including inducing changes in
EC morphology, cytoskeleton alteration, and stimulation of EC migration. VEGF
is also a highly specific mitogen for vascular endothelial cells and stimulates their
proliferation (52). It also acts as a survival factor for ECs by activating the PI3K-
Akt (Phosphoinositide 3-kinase/protein kinase B) pathway. This results in the up-
regulation of anti-apoptotic proteins such as Bcl-2, which in turn prevents cellular
apoptosis (52; 97; 138).
VEGF and its receptors have been shown to play a pivotal role in angiogenesis.
Activation of the VEGF-receptor pathway triggers a variety of downstream signalling
events that promote EC survival, proliferation, and migration. VEGF also enhances
vascular permeability and plays an important role in ECM remodelling. In the model
of angiogenesis developed here, VEGF will be treated as the principal tumor-secreted
chemokine that promotes angiogenesis. The effects of the VEGF-receptor pathway
on ECs will be explicitly incorporated in our model.
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2.3 Interleukin-8 in Tumoral Angiogenesis
CXCL8 or Interleukin-8 is a member of the chemokine family. These are small
cytokines produced by a variety of cells including macrophages and endothelial cells.
They are characterized by their ability to induce chemotaxis in responsive cells.
In particular, CXCL8 is a potent chemotactic factor for neutrophils, basophils, T
lymphocytes, and microvascular endothelial cells (15; 97). It is known to play an
important role in autoimmune, inflammatory, and infectious diseases. Therefore, its
production is tightly regulated, and its constitutive levels in normal tissue are very
low (15).
CXCL8 is also a potent mediator of tumor angiogenesis. Its expression is found to
be up-regulated in certain cancers, such as non-small cell lung cancer, and melanoma (109).
Further, it has been shown that VEGF is able to induce over-expression of CXCL8
mRNA in human dermal microvascular endothelial cells (HDMECs), via the PI3K/Akt
signalling pathway. Activation of this pathway results in the increased intra-cellular
levels of IκB kinase-α and -β (IKKBs), which in turn cause phosphorylation of I-κB,
leading to its proteosomal degradation. I-κB is a natural cytosolic inhibitor of the
transcription factor nuclear factor-κB (NF-κB). Thus, NF-κB is released into the
nucleus of the EC, where it initiates transcription of the CXCL8 gene (15; 59).
CXCL8 mediates its biological functions by interacting with specific G-protein-
coupled CXC chemokine receptors CXCR1 and CXCR2 (Figure 2.3). These are
expressed on a variety of cell types including macrophages and endothelial cells (15).
CXCL8 acts as a promoter of angiogenesis by inducing EC proliferation, migration
and survival. It is believed that the pro-angiogenic effects of CXCL8 are due to the
presence of a Glu-Leu-Arg (ELF) domain. This has been demonstrated by observing
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Figure 2.3: Figure showing the CXCL8 mediated signaling pathways in endothelial cells, taken
from (15). Binding of CXCL8 to its transmembrane G-protein-coupled receptors
CXCR1/2 induces angiogenic properties including cell proliferation, chemotaxis, sur-
vival, and protease activation.
that mutant forms of CXCL8 lacking in the ELF domain are unable to stimulate
angiogenesis in vivo, while its introduction into an ELF-negative chemokine bestows
angiogenic properties on the chemokine (15). Finally, CXCL8 has also been shown to
stimulate the expression of matrix metalloproteinases-2 and -9 (MMP-2/9) in ECs.
As mentioned earlier, the MMPs degrade basement membranes of vessels, as well as
ECM, promoting cell invasion and migration (15; 109).
CXCL8 has been demonstrated to be a potent pro-angiogenic chemokine. It is
therefore incorporated explicitly in our model of tumoral angiogenesis. In particular,
we will focus on the role of CXCL8 as a mitogenic and chemotactic factor for ECs,
and investigate its therapeutic potential as a possible target for the development of
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anti-angiogenic therapy.
2.4 Extra Cellular Matrix in Tumoral Angiogenesis
The ECM is a dynamic macromolecular system integral to the structure and
function of vessels. In addition to providing structural support to the vessel, the
ECM is responsible for the mechanical properties of the vessel wall. Two critical
steps in angiogenesis - the proliferation of ECs, and their migration into the stroma
also require the adherence of the cells to the ECM (137; 150). Therefore, there
has been considerable interest in elucidating the mechanisms by which the ECM
modulates angiogenesis.
The ECM is comprised of various types of molecules. These include structural
proteins such as collagen and elastin, and specialized proteins such as fibronectin,
laminin, thrombospondins, and proteoglycans (84). Each of these molecules is a
key determinant in triggering specific cellular responses. For instance, fibronectin
effects endothelial cell adhesion, growth, migration, and survival. It binds to VEGF
and enhances VEGF-induced angiogenesis. Other matrix molecules such as laminin,
collagens, and vitronectin also promote EC adhesion and survival (137). On the other
hand, some ECM proteins including thrombospondin-1 (TSP-1), and thrombospondin-
2 (TSP-2) can function as inhibitors of angiogenesis. Additionally, the proteolytic
fragments of matrix molecules have been identified as having antiangiogenic prop-
erties. Two such fragments are angiostatin, which is generated on cleavage of plas-
minogen, and endostatin, which is generated on the cleavage of the ECM protein,
collagen type XVIII (150). The ECM also functions as a reservoir of angiogenic fac-
tors such as FGF-2 and heparin- binding forms of VEGF, that bind to and remain
sequestered in the ECM until their release due to ECM degradation. This has the
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effect of further promoting angiogenesis (137).
During the process of angiogenesis, the ECM is continually remodelled and con-
ditioned by endothelial cells. In response to growth factors such as VEGF, ECs
release proteolytic enzymes like the MMPs that cleave the matrix. This could have
the effect of releasing growth factors or inhibitors sequestered in the matrix. They
can also synthesize ECM components like fibronectin and collagen (84). Thus, a full
understanding of the interactions between ECM and ECs, and how ECM proteins
influence EC behaviors is essential in providing a complete picture of angiogenesis.
2.5 Other Factors affecting Angiogenesis
2.5.1 The Angiopoietins and Tie Receptors
In addition to the chemokines and proteins discussed above, several other factors
have been shown to mediate tumoral angiogenesis. These include the angiopoietins
and Tie receptors, that are implicated in vessel maturation. Two Tie receptors
(Tie1 and Tie2) have been identified so far. These are receptor tyrosine kinases, and
are specific to vascular endothelial cells. Genetic studies have demonstrated that
initial vessel growth occurs in Tie1 deficient mice. However, this vasculature fails
to mature and undergo remodelling. Thus Tie1 is necessary for vascular integrity
and EC survival. Tie2 deficient mice have exhibited underdeveloped hearts, and
vasodilation. Furthermore, Tie2 has been found to be crucial for vessel branching and
sprouting. The ligands for Tie2 are the angiopoietins (Ang1-4), while those for Tie1
are not known. Ang1 is the most extensively characterized angiopoietin. It’s over-
expression induces vessel branching and increases vessel girth, while making them
resistant to leakage by agents such as VEGF. Ang2 blocks Ang1-mediated activation
of Tie2 on endothelial cells, and acts as a check to prevent excessive branching of
blood vessels by promoting their destabilization. It has also been postulated that
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Ang1 makes ECs more sensitive to VEGF signalling by antagonizing Ang2/Tie1
function (84; 109).
2.5.2 Additional Membrane-bound Molecules
Membrane-bound molecules such as integrins, cadherins and ephrins also play an
important role in angiogenesis. For instance, the Eph receptor family together with
their membrane bound ligand ephrin controls positional guidance cues on vascular
endothelial cells aiding in the establishment of arterio-venous asymmetry (51). The
integrins are transmembrane receptors that act as adhesion molecules, allowing the
anchorage of the EC to the ECM. Binding of integrins to the ECM also triggers the
expression of numerous cytosolic kinases such as mitogen-activated protein kinase
which elicits a range of cellular responses including promoting cell survival, cell
migration, and inducing cell proliferation (143). Finally, endothelial cells must be
able to adhere to each other tightly in order to maintain a barrier between the blood
in the blood vessels and extravascular space, and to control the permeability of blood
vessel walls. The mechanism for such adherence is through an adhesion molecule
located at junctions between ECs, called vascular endothelial (VE)-cadherin (149).
In 1971, Judah Folkman postulated that blocking tumor angiogenesis would pre-
vent expansion of the tumor or, at best cause it to regress to a manageable size.
Since the publication of this visionary hypothesis, angiogenesis has remained a field
of intense research. Today there are over 20 anti-angiogenic compounds in various
phases of clinical trials. However the survival benefits of these treatments are rel-
atively modest. In addition the cost and potential toxic side effects due to chronic
use are indicative of problems that still remain in the clinical applications of an-
giogenic inhibitors (63). In order to develop effective strategies for the treatment
of angiogenesis-dependent diseases such as cancer, a better understanding of their
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pathogenesis at a molecular and cellular level is essential. Mathematical modelling
such as that developed in this research provides a powerful tool to elucidate the
mechanisms of angiogenesis.
In the following chapters, we will develop continuous and hybrid models of tumor-
induced angiogenesis to gain deeper understanding of the processes that operate at
multiple scales to make tumor vascularization possible. Our model operates on three
scales:
• Intracellular Signalling: We investigate signal transduction pathways oper-
ating within a single endothelial cell, eliciting pro-angiogenic responses from the
cell such as proliferation, migration, differentiation and survival. In particular,
we focus on the VEGF - Bcl-2 - CXCL8 signaling pathway. The response of the
cell to these chemical cues will be the output of this model.
• Cellular Level: We model the uptake of chemokines such as VEGF and CXCL8
by ECs, and the production and release of CXCL8 into the tumor microenvi-
ronment by the ECs. Upon uptake by the ECs, these chemokines lead to the
activation of downstream signalling pathways, thus providing input to the in-
tracellular model.
• Tissue Level: We scale the model up to a population level, so that the behavior
predicted by the single cell model may be used to determine the response of a
population of cells to their microenviroment.
A primary objective of our modelling effort is to provide us with a better quanti-
tative understanding of the role of the intra-cellular molecular pathways mentioned
above, in determining vascular development in tumors. This information will then be




Mathematical Models of Angiogenesis
The use of mathematical models to describe various aspects of tumor growth be-
gan in earnest several decades ago. Modelling techniques paralleled the surge in the
understanding of the mechanisms driving the progression of cancer. Today, cancer
is recognized to be a disease that operates at various scales; at intracellular, in-
tercellular, and tissue levels. This has led to the development of novel multiscale
quantitative models of tumorigenesis, with the aim of facilitating a deeper under-
standing of the onset and progression of the disease, and evaluating the potential of
treatment strategies.
In this chapter, we present a brief overview of a few of these models, that have
pioneered innovative approaches to modelling cancer, and have motivated several
others. Since the central theme of this research is the biochemical forces driving
angiogenesis in tumors, we will limit our review to models of angiogenesis.
Models describing tumor-induced angiogenesis can be broadly classified into two
categories.
1. Continuum models that treat model variable densities as continuous, and track
their temporal and/or spatial evolution governed by reaction-diffusion systems.
2. Discrete or hybrid models, that track the motion of individual endothelial cell
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and capillary sprouts densities, while treating chemical species as continuous
variables.
3.1 Continuum Models
Continuous mathematical models of angiogenesis can be dated back to at least
the late 1970’s (29). These models rely on the principles of mass conservation and
chemical kinetics, and can predict the behavior of certain averaged quantities such
as vessel and tip densities and capillary extension speeds.
One of the first models of tumor-induced capillary growth was proposed by Balding
and McElwain in 1985 (11). Their model comprised of three equations in 1 dimension,
for the sprout tip density, the capillary density, and tumor angiogenic factor (TAF)
concentration. This approach had the novel idea that sprout tips guide capillary
formation, thereby accounting for the experimental observation that EC proliferation
occurs mainly behind the sprout tip. It captured the fact that there is an increased
frequency of branching at the edge of the network as the capillary sprouts get closer
to the tumor, termed as the brush-border effect (93). Model parameters could be
fitted to reproduce observed vessel lengths and tip speeds.
Byrne and Chaplain (18) modified the above approach to incorporate explicitly
for the first time in models of tumor angiogenesis, the experimentally observed phe-
nomena of branching, and tip-sprout anastomoses. Tip proliferation was assumed to
occur only above a certain threshold TAF concentration, and was localized behind
the moving tip. Also, a term was incorporated for the uptake of TAF by the tip
cells.
One of the first two-dimensional models of tumor angiogenesis was developed by
Orme and Chaplain in 1997 (103). A square domain geometry was used (D = [0, L]×
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[0, L]), with the parent vessel located at y = 0, and a line of tumor cells, (source of
the TAFs) at y = L. A novel feature of this model was that it accounted for for cell-
matrix interactions by incorporating haptotaxis, a process by which ECs migrate up
gradients of fibronectin. The model described the evolution of endothelial cell density
that comprised newly developing vasculature, TAF concentration (assumed to be
at steady state), and fibronectin concentration. EC growth was assumed to occur
logistically. An important result of the paper was that haptotaxis was important
for successful angiogenesis, and in its absence, anastomoses occurred too early for
normal development of the vasculature.
In 1998, Anderson and Chaplain published another continuous two-dimensional
model of tumor-induced angiogenesis (5). As in (103), EC density and fibronectin
concentration were kept track of, while the TAF was assumed to be quasi steady
state. The same domain geometry as in (103) was used. A receptor kinetic law
was used to model the chemotaxis sensitivity of ECs to the TAF, reflecting the de-
sensitization of EC receptors at high chemical concentrations. Two kinds of tumor
sources were considered a small circular tumor and a row of tumor cells. Numerical
simulations of this model were performed and several interesting observations were
made. In the absence of haptotaxis, the endothelial cells migrated directly across
the domain towards the tumor, with very little lateral motion. Including haptotaxis
slowed down the migration, and lateral movement became very apparent, interpreted
by the authors as branching of the vasculature. Further, by choosing appropriate
concentrations of tumor angiogenic factors at which endothelial cells become desensi-
tized, the authors were able to reproduce experimental observations that endothelial
cells will not reach the tumor when cells are not allowed to proliferate.
While these models represented significant advances in terms of simulating neo-
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vascularization, they had some major drawbacks:
• A number of models ignored chemokine uptake by the ECs, and many used
steady state profiles of the TAFs. The justification for this was that the dif-
fusion time-scale for the TAFs is much smaller than that for ECs or sprout
tips. However, in biologically realistic situations, the source of TAFs may not
be constant. Factors effecting TAF production rates include increased levels of
local oxygen concentration provided by newly developed vasculature, and anti-
angiogenic therapy targeted against the TAFs or their receptors. Further, as
mentioned earlier, a significant percentage of TAFs such as VEGF may remain
sequestered by the ECM and is biologically unavailable to the cells. In this case,
uptake of the unbound TAFs by the ECs could create steep local gradients in
the chemokine profile and alter the resulting vascular development significantly.
• A generic chemokine was used to represent an entire set of angiogenic factors.
Whilst different chemokines can produce similar qualitative effects, such as in-
ducing cell proliferation or migration, the degree of the effect varies and makes
the choice of parameters difficult. For instance, the numbers of cell surface
receptors, the rate constants for receptor-ligand interaction, the degree of pro-
liferative and chemotactic response can vary considerably between a wide variety
of angiogenic factors. Further, a key motivation behind simulating angiogenesis
in silico is to provide valuable insights into understanding the processes that
govern it so that new methods of promoting or reversing it may be investi-
gated. In the case of tumoral angiogenesis, for example, the development of
anti-angiogenic therapy is the focus of much interest. Such therapy may target
a particular chemokine, or its receptors. For VEGF in particular, a number of
antagonist compounds are currently undergoing clinical trials. To accurately
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simulate these, specific characteristics of VEGF would have to be modelled in-
stead of a generic growth factor that combines the traits of many diffusible
angiogenic chemokines.
• The biochemistry of interactions between ligands and their receptors has of-
ten not been considered. With an increasing availability of experimental data,
our knowledge of the cellular and sub-cellular processes governing angiogen-
esis is growing, and a number of new targets for the development of pro-
and anti-angiogenic therapy have come to light. One such example is the
VEGFR2-mediated VEGF-Bcl-2-CXCL8 signaling pathway (98), which elicits a
pro-angiogenic and pro-survival response in ECs. Bcl-2 has been identified as a
promising target for anti-angiogenic therapy. The incorporation of a molecular
level of detail in quantitative models is required if we are to accurately simulate
such pro- or anti-angiogenic compounds that target the TAFs, their receptors,
or act further downstream. It is essential that Mathematics keeps up with the
recent advances in this field, in order to be useful as a predictive tool in an in
vivo setting.
3.1.1 A Biochemically Motivated Approach
The first few models of tumor-induced angiogenesis to incorporate the detailed
interactions between growth factors such as VEGF and their cell surface receptors
were developed by Levine et al (73; 74; 75). A distinguishing feature of their models
was the fact that the movement of cells was based on the theory of reinforced ran-
dom walks. Phenomenological choices of the chemotactic sensitivity function were
made, to mimic a receptor-kinetic law of the form
χ
(1 + γ1 v)(1 + γ2 v)
, where v is
the chemokine concentration. Using this approach, in (74), the authors presented a
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model of the initiation and development of vasculature in tumors, under the influence
of a number of factors, including VEGF, a proteolytic enzyme, protease inhibitor,
fibronectin and angiostatin. In (73), this model was extended to incorporate the dy-
namics of angiostatin, pericytes and macrophages. The law of mass action was used
in these models to derive the set of equations governing receptor-ligand reactions.
However, for the sake of simplicity, Michaelis-Menten kinetics were assumed for these
reactions where cell-surface receptors function the same way an enzyme functions in
classical enzymatic catalysis. Further, it was assumed that a single molecule of
VEGF binds and activates a receptor monomer and results in the production of a
single proteolytic enzyme molecule. This issue was partly addressed in (75), where a
single molecule of VEGF signalled a cascade of intracellular events, that resulted in
the production of several (perhaps hundreds) of molecules of proteolytic enzymes.
The level of detail of the biochemistry of angiogenesis incorporated meant that
these models were a significant improvement over previous models. They were able to
account for capillary sprout initiation from parent vessels based solely on biochemical
considerations, and the subsequent vascular development. However, there were a few
issues with this approach. It did not account for the fact that VEGF induces receptor
dimerization, and that it is these dimerized receptors that are in an activated state.
Further, Michaelis-Menten like kinetics were assumed throughout. However, it is not
necessary that in in vivo systems, the ligand concentration will always be significantly
greater than receptor density, in which case the quasi-steady state assumption is no
longer valid. The degradation of a number of the protein was not included, whereas
they could have very short half-lives in tissue. For instance, the half-life of VEGF in
tissue is approximately 60 min (132). The diffusion of the chemokines is ignored, with
the justification that it takes place on a much slower time-scale than the reactions.
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However, diffusion of ECs is incorporated even though this occurs at even slower
time-scale than that of the chemokines.
3.2 Discrete Models
Models of the continuum, deterministic framework were capable of capturing some
features of angiogenesis such as average sprout density and network expansion rates,
permitting a detailed qualitative comparison with in vivo observations concerning the
spatio-temporal distribution of capillary sprouts within the network. However, they
were unable to provide more detailed information concerning the actual structure
and morphology of the capillary network. In order to capture certain important
events such as repeated sprout branching and hence the overall dendritic structure
of the network, the model should recognize the existence of individual sprouts. This
has been made possible by the advent of hybrid models of tumor angiogenesis.
One of the first discrete models of angiogenesis was published by Stokes and Lauf-
fenburger in 1991 (140). They based their model on stochastic differential equations
that governed the velocity of each tip. Thus, the motion of individual sprouts could
be followed, thereby allowing realistic capillary networks to be generated based on
rules for sprout branching and looping. The model incorporated random motility
and chemotaxis as mechanisms for cell migration. Since parameters were estimated,
as far as possible, from available experimental data, this model permitted both qual-
itative and quantitative comparisons with in vivo networks. However, the model was
unable to reproduce the brush-border effect.
Anderson and Chaplain (5) adopted a different approach to the development of
a discrete mathematical model of tumoral angiogenesis. They discretized the model
equations developed for the continuous case (described in section 3.1), on a five
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point stencil, using standard finite-difference methods. The resulting coefficients in
the endothelial cell equation were used to generate movement probabilities of the
cells, resulting in a biased random walk governing the motion of each cell. In turn,
it was assumed that each tip cell pulled behind it a capillary. Biologically motivated
rules for branching and anastomoses were prescribed. Numerical simulations of the
model showed that as in the continuous case, including haptotaxis leads to a slow
migration rate of tips, and increased frequency of branching near the tumor source.
Further, as observed experimentally, the sprout tips reach a relative steady state
before reaching the tumor, in the absence of cell proliferation. When cell mitosis
is included in the model, a well developed branching network is observed to form
earlier and this does connect with the tumor.
However, this method suffers from a major disadvantage - the choice of numerical
schemes used to discretize the diffusion-advection equations can influence the simu-
lation results. The choice of numerical scheme is not straightforward if the advection
velocities are non-constant, and written in the conservative form. Since the approach
followed by Anderson and Chaplain relies on the scheme being explicit, they use a
central-differencing scheme to discretize the cellular velocity, which is uncondition-
ally unstable in this case. Further, while cell division has been incorporated in the
model, it is assumed to occur only once every 18 hours, and results in a forward mo-
tion of the developing sprout by a single cell length. This implies that in any sprout,
only a single cell is undergoing mitosis at any given time point. This is contrary
to experimental observations that up to 30% of the cells in a sprout are undergoing
mitosis at any given time (134).
An alternative approach is based on the theory of reinforced random walks, applied
to model the movement of cells under the influence of a chemical attractant in their
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local environment by Othmer et al (105). Plank and Sleeman (116) modified this
technique to simulate tumoral angiogenesis. They began with a probability master
equation describing a biased random walk of an endothelial cell. The translation
probabilities were assumed to be functions of VEGF, a proteolytic enzyme, and
angiostatin - an angiogenesis inhibitor. If a constant mean waiting time for the cell
at a lattice site was assumed, it could be shown that the master equation translates
to the familiar diffusion-chemotaxis equation for the motion of a cell, of the form
used in continuum models of angiogenesis. Using this approach, capillary networks
in qualitative agreement with experimental observations could be generated. A novel
feature of this model is the explicit inclusion of cell proliferation and cell death.
From the above review, it is clear that mathematical modelling of tumor angio-
genesis has come a long way since the publication of the first model. However, as
new experimental data becomes available, and new therapeutic strategies are being
developed, there is a need to expand the scope of these models to include the current
knowledge in the field. In this research, we will focus on the following:
• The uptake and binding of chemokines to cell surface receptors will be studied
in greater detail. For instance, the validity of assuming a monomeric uptake
of VEGF by VEGFR2 instead of a biochemically correct dimeric uptake will
be investigated. The validity of the quasi steady state assumption applied to
VEGF-VEGFR2 binding reaction will also be studied.
• All the models reviewed here have the common feature that EC or sprout tips
react to free chemokine concentrations. However, it is the presence of activated
receptors on the cell surface that elicit a response from ECs. For instance,
during the process of chemotaxis, ECs actually sense a gradient of chemokine
bound to their surface, which results in their polarization, and bias to movement
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in a particular direction. Responses such as proliferation are a result of the
integration of the total amounts of activated receptors on their surfaces (47).
This issue will be addressed in our model as well.
• A truly multiscale model of angiogenesis will be developed, that will incorporate
details of newly discovered intracellular signalling pathways such as the VEGF-
Bcl-2-CXCL8 pathway. It will therefore be possible to quantitatively analyze
the potential of various apoptosis-inducing anti-angiogenic therapies under de-
velopment, which are targeted at the Bcl-2 family of proteins.
• Currently, the receptor-kinetic law remains the most popular choice for the
chemotaxis sensitivity of ECs to growth factors. However, this suffers from
three major drawbacks. The sensitivity of cells is at its maximum when the
chemokine concentration is zero. It also makes the assumption that ECs migrate
in response to free chemokine concentrations. Finally, it does not account for
the fact that the level of chemokine at which desensitization of receptors occurs,
should in fact be a function of the EC density. 0.1 pM VEGF may be enough
to saturate the receptors of a single cell, but it might not be enough for 10 cells.
In the later part of this thesis, a hybrid model of tumor neovascularization will
be developed, using a biologically realistic chemotaxis sensitivity function.
CHAPTER IV
Modelling Vascular Endothelial Growth Factor Binding
Dynamics
Vascular Endothelial Growth Factor (VEGF) is an endothelial cell (EC) specific
pro-angiogenic cytokine. It is a crucial regulator of physiological angiogenesis, during
embryonic development, cartilage vascularization, skeletal growth and endochondral
bone formation, ovarian angiogenesis and wound healing. It also plays a central
role in several pathologic conditions such as vascularization of solid tumors and
hematologic malignancies, and has been implicated in various inflammatory disorders
and the development of brain edema (37). An accurate description of the mechanism
by which VEGF exerts its biological influence, would therefore be a valuable addition
to any mathematical representation of VEGF’s role in angiogenesis. To this end, we
develop a detailed molecular level model of VEGF binding and activating cell surface
receptors.
4.1 The VEGF Molecule
The human VEGF family consists of five glycoproteins; namely VEGF-A, VEGF-
B, VEGF-C, VEGF-D, and placental growth factor (PlGF). VEGF-A, also referred
to as VEGF, is a tumor-secreted homodimeric glycoprotein, with a molecular mass
of approximately 45 kDa (20). Alternative exon splicing of the VEGF gene yields
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Figure 4.1: (A) Ribbon representation of the receptor-binding domain of the VEGF monomer as
observed by X-ray crystallography (89). (B) Ribbon representation of the structure of
the receptor-binding domain of the VEGF dimer (90). (C) Alternative exon splicing
results in the generation of several isoforms of VEGF-A (143).
several mature isoforms. Of these, the principal forms are VEGF121, VEGF165,
VEGF189, and VEGF206. While VEGF121 is freely diffusible, VEGF189 and VEGF206
are almost completely bound to, and sequestered in the extra cellular matrix (ECM).
VEGF165 is the predominantly expressed isoform, and is over-expressed in a variety
of solid tumors in humans (106). It is partially diffusible in vivo, and about 50-
70% remains bound to the ECM and cell surface, giving it optimal characteristics of
bioavailability and biological potency (37; 124). Figures 4.1A, and B show ribbon
representations of the VEGF monomer and dimer, respectively, taken by X-ray crys-
tallography. Figure 4.1C shows a comparison of structures of the various isoforms of
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VEGF.
In vitro, VEGF has been shown to induce capillary-like tubule formation by mi-
crovascular endothelial cells grown on collagen gels (97; 111). In addition to eliciting
a mitogenic response, it induces cell chemotaxis and exerts a pro-survival effect by
up-regulating intracellular levels of anti-apoptotic proteins such as Bcl-2 and sur-
vivin (20; 97; 98; 106). In vivo, VEGF also causes vasodilation and increases vas-
cular permeability, thereby, allowing the leakage of plasma proteins which further
promote cell growth (20; 106). For the reasons stated above, we will focus on VEGF
(specifically the VEGF165 isoform) in this study. A brief introduction to the other
VEGF glycoproteins is however, presented below.
VEGF-B, which is also called VEGF-related factor (VRF), is expressed beginning
early in fetal development. It also appears to be required for normal heart function
in adults. It has been shown to modulate EC mitosis and vessel growth, however,
its precise role in vivo remains unclear (106; 124; 159). VEGF-C, also called VEGF-
related protein, and VEGF-D, also referred to as c-Fos-induced growth factor (FIGF),
have both been shown to induce lymphangiogenesis (159). VEGF-C signalling is,
in fact, crucial to the migration and survival of lymphatic endothelial cells, and
formation of lymph sacs. Additionally, both are known to induce EC mitogenesis,
migration and survival (106; 124; 159). The final member of the VEGF family,
PlGF, is a homodimeric glycoprotein like VEGF-A. It was originally discovered in
the human placenta, and is also expressed in the heart and lungs, and a variety of
tumors. It enhances VEGF signaling, and its expression may diminish the efficacy
of therapy targeted against VEGF (124; 159).
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Figure 4.2: (A) Ribbon representation of a dimerized VEGF-VEGFR1 receptor complex. Two
monomers of VEGF (blue and yellow) are shown bound to domain 2 of VEGFR1 (green)
(155). (B) Backbone representation of structures of the kinase domains of VEGFR2
(85). (C) Class averages (top) and graphic representations (bottom) of the VEGFR-2
extracellular domain in complex with VEGF. Visualization of proteins carried out by
negative-stain electron microscopy. Scale bar, 15 nm (124)
4.1.1 VEGF Receptors
The biological effects of VEGF are mediated by interactions with its cell surface
receptors. These are the receptor tyrosine kinases (RTKs), VEGFR1 (fms-like tyro-
sine kinase/Flt-1) and VEGFR2 (kinase insert domain-containing receptor/Flk-1),
which are selectively expressed on vascular endothelial cells and the non-enzymatic
neuropilin receptors NP1 and NP2, which are expressed on vascular endothelium
and neurons (106). Activation of VEGF RTKs occurs through ligand binding, which
facilitates receptor dimerization and autophosphorylation of tyrosine residues in the
cytoplasmic portion. The phosphotyrosine residues either enhance receptor catalytic
activity or provide docking sites for downstream signaling proteins (85).
VEGFR1 is a 210 kDa protein, which binds VEGF with a high affinity. Fig-
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ure 4.2A shows a ribbon representation of the structure of the complex formed when
VEGF binds two VEGFR1 monomers. It is expressed in various cell types, including
ECs, osteoblasts, and macrophages. Its expression is up-regulated by hypoxia via
a hypoxia-inducible factor-1 (HIF-1) dependent mechanism. Even though VEGFR1
has a higher affinity for VEGF than VEGFR2, it only undergoes weak tyrosine au-
tophosphorylation in response to ligand induced activation. Furthermore, it has been
shown that this does not directly effect cell proliferation. Therefore, it has been pro-
posed that a key function of VEGFR1 is to act as a decoy receptor by preventing
VEGF from binding VEGFR2, rather than regulating angiogenesis (37; 106; 124).
VEGFR2 is a 200 kDa protein (139), and is considered to be the principal medi-
ator of the chemotactic, angiogenic, and permeability enhancing effects of VEGF. It
undergoes ligand-induced dimerization, and strong tyrosine autophosphorylation (96;
124). Figure 4.2B shows a ribbon representation of the kinase domains of VEGFR2,
as observed by X-ray crystallography. Figure 4.2C shows photographs of the extra-
cellular domains of VEGFR2 bound to VEGF, taken by negative-stain electron mi-
croscopy. VEGFR2 activation elicits a proliferative response from ECs through acti-
vation of the Raf-Mek-Erk pathway. It has also been shown that in human umbilical-
vein endothelial cells (HUVECs), and human dermal microvascular endothelial cells
(HDMECs), VEGFR2 signalling induces an anti-apoptotic effect through the PI-3
kinase-Akt pathway (37; 97; 106). Figure 4.3 shows a schematic diagram illustrating
some of the downstream intracellular signalling pathways activated as a result of
dimerization of VEGFR2 by VEGF.
The neuropilins NP1 and NP2 are glycoproteins with a molecular weight of 120-
140 kDa, and are expressed on certain ECs, neurons, and tumor cells (37; 124).
They are VEGF165 isoform specific receptors which enhance the binding of VEGF to
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VEGFR2, by forming complexes with VEGFR1. This has been proposed as a possi-
ble explanation for increased effectiveness of VEGFR2 mediated signal transduction
when the neuropilins are co-expressed in cells with VEGFR2. (37; 106).
Figure 4.3: Schematic diagram illustrating downstream VEGFR2 signalling pathways, adapted
from (105; 143).
4.2 Previous Mathematical Investigations
To date, there have been a number of mathematical models that explicitly incor-
porate the effects of growth factors such as VEGF on ECs in both, tumor-induced
and wound healing angiogenesis. The early models treated the entire panel of angio-
genic factors as a single chemokine. In the case of tumor induced angiogenesis, these
were collectively referred to as tumor angiogenic factors (TAFs). One of the earliest
models of tumor-induced angiogenesis was published by Balding and McElwain in
1985 (11). In this, the TAF concentration was held at a steady state, and binding
36
and uptake by ECs was neglected. Diffusion of the chemokines was the only mech-
anism by which such a steady state profile was reached. Stokes and Lauffenburger
published the first stochastic model of angiogenesis in 1991 (140). In this model too,
the TAF concentration was held fixed in time. Subsequent models added features
such as production and decay of TAFs (133), decay of TAFs only (118; 103), and
their removal by newly developed vasculature (112), continuing however, to neglect
the uptake of TAFs by ECs.
Chaplain and Stuart (23) was one of the first models to explicitly incorporate
a term in the TAF evolution equation corresponding to loss due to uptake by ECs.
They assumed that this decay rate was governed by Michaelis-Menten kinetics. Other
models of angiogenesis used similar Michaelis-Menten like terms for the uptake of
TAFs (24; 53), or simplified this still further to a constant rate of uptake (113; 5;
145; 117).
These models represented significant advances in the field of angiogenesis mod-
elling. However, they suffered from several drawbacks, as discussed in Chapter III.
Many ignored the uptake of chemokines by the ECs, sometimes assuming them to
be in a quasi steady state. A generic chemokine was used to represent an entire
panel of angiogenic factors. This meant that the traits of many diffusible angiogenic
chemokines are presented as a combined effect of the generic chemokine. However,
the current trend in anti-angiogenic therapy research is to develop antagonistic com-
pounds directed against specific chemokines. To accurately simulate these, specific
characteristics of that chemokine would have to be modelled. Finally, there is now
an abundance of data relating to cellular and subcellular processes governing angio-
genesis. This has resulted in the identification of new targets for the development
of anti-angiogenic therapy. In order to investigate the therapeutic potential of these
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targets, there is a need to expand the current models of angiogenesis to incorporate
these advances.
Levine et al (73; 74; 75) published the first models of angiogenesis to incorporate
details of interaction of angiogenic growth factors such as VEGF with growth factor
receptors on the surface of endothelial cells. Specifically, in (73) it is assumed that
one molecule of VEGF binds to a receptor on an endothelial cell surface to produce
an intermediate complex. This complex is considered to be an activated state of the
receptor that results in the production and secretion of a proteolytic enzyme and a
modified intermediate receptor. The intermediate receptor is subsequently removed
from the cell surface after which it may be recycled to form the original receptor or
a new one is synthesized and moves to the cell surface. Michaelis-Menten kinetics
are assumed for this standard catalytic reaction where receptors at the surface of the
cell function the same way an enzyme functions in classical enzymatic catalysis. The
model of angiogenesis presented in (74; 117) makes similar assumptions regarding
receptor-ligand interactions. In (75), the fact that a single molecule of VEGF signals
a cascade of intracellular events, which results in the production of several (perhaps
hundreds) of molecules of proteolytic enzymes, is addressed. However, there are two
main issues with this approach: it does not account for VEGF induced receptor
dimerization, and assumes Michaelis-Menten kinetics throughout. This is not a valid
assumption in cases where the ligand concentration is not significantly greater than
its receptor density.
Mac Gabhann et al (78; 79; 80; 81) were the first to develop computational models
of VEGF binding to cell surface receptors at a molecular level. Their models pri-
marily focussed on in vitro assays. The first of these (78) described the competitive
binding between VEGF and PlGF to VEGFR1, whilst another (79) described the
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interactions of VEGF isoforms VEGF121 and VEGF165 with VEGFR2 and NP1. In
both, it was assumed that VEGF binds to and activates pre-dimerized receptors in
a single binding step, referred to as the 1:1 binding model. The 1:1 ligand-receptor
binding model was compared to several possible mechanisms of receptor dimerization
in (80), including ligand binding to pre-dimerized receptors (static pre-dimerization
or SPD, in which VEGF binds pre-dimerized receptors in two steps), receptors dimer-
izing and dissociating independent of ligand (dynamic pre-dimerization or DPD), and
ligand-induced receptor dimerization (LID). They concluded that the average frac-
tional occupancy of receptors and variability in the binding for each mechanism was
similar to the 1:1 binding model. Recent studies demonstrate that VEGF receptors
can aggregate in the absence of ligand (95). This means that both the DPD and
LID mechanisms may exist for ligand induced receptor activation. Mac Gabhann
and Popel conducted a study in (81), to try and determine the dominant mecha-
nism. Simulation results suggested the existence of a threshold level of initial VEGF
concentration below which all three mechanisms (1:1, DPD, LID) predicted similar
binding to cell surface. Above this threshold, a high-dose inhibition was observed
for the LID model, due to increase in inactive monomeric receptor-ligand complexes.
This lack of observed difference between the 1:1 and other dimerization models of
VEGF uptake could be due to three main assumptions in the framework of these
models:
• In both (80) and (81), it was assumed that on average there are 25,000 VEGF
receptors (VEGFR2) per cell. However, the number of receptors on the EC sur-
face varies considerably with cell type, tissue, and vessel of origin. For instance,
in microvascular ECs used in many experiments, designed to study angiogenesis,
this number is as high as 231,300 (152).
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• In most simulations, it was assumed that the ligand was in far greater concen-
tration than its receptors.
• Finally, in (80), receptor-ligand internalization was ignored. Natural decay of
the ligand was ignored in (80) as well as (81). Thus, unbound ligand concen-
tration would remain largely unaffected by receptor uptake.
If any of the above conditions are relaxed, so that the ligand concentration falls
relative to the receptor numbers, a divergence of results is possible when investigating
1:1 binding versus ligand-induced receptor dimerization.
4.3 Modelling VEGF Uptake by VEGFR2
A review of the modelling literature shows that existing models of intra-tumoral
and wound healing angiogenesis which incorporate the effects of pro-angiogenic chemokines
such as VEGF, continue to ignore ligand-induced receptor dimerization. These mod-
els use a variety of biologically unrealistic uptake forms (constant rate, and Michaelis-
Menten like terms), or ignore it altogether. Given that it is impossible to overstate
the role played by VEGF in angiogenesis, it is important to accurately describe
VEGF receptor dimerization and its cellular uptake. Here, we present a model of
VEGF binding to VEGFR2, the primary receptor shown to be capable of promoting
angiogenesis, and compare binding data to that obtained by assuming monomeric up-
take. We also present a quantitative analysis to illustrate the invalidity of Michaelis-
Menten like kinetics in many biologically realistic environments. To the best of our
knowledge, this is the first such analysis of its kind.
Mac Gabhann et al have developed models of angiogenesis occurring within skele-
tal muscles (82), where molecular level details of VEGF uptake by its receptors are
included. However, as noted earlier, in these the 1:1 binding data was found to be
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similar to LID or DPD models of receptor dimerization. This may not be true for
all cell types, or in every experimental condition, as we will demonstrate by our
simulations.
4.3.1 Model Development
Due to a lack of experimental data from which ligand-free receptor dimerization
rates may be obtained (as the authors in (81) note), we assume ligand-induced dimer-
ization to be the dominant mechanism by which VEGF activates VEGFR2, as shown
in Figure 4.4.
Figure 4.4: A schematic of VEGF-VEGFR2 interactions. VEGF binds to and dimerizes its cell
surface receptor VEGFR2. The activated receptor-ligand complex is subsequently in-
ternalized, and free receptors recycled.
Lower case letters are used to represent individual molecules and upper case letters
are used to represent their concentration (in moles per liter), so that A = [a] is
VEGF concentration, Ra = [ra] is VEGFR2 concentration, Ca = [ca] is VEGFR2-
VEGF monomer complex concentration, and Da = [da] is VEGFR2-VEGF-VEGFR2
dimer complex concentration. The above reaction diagram can be converted to the
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following system of equations using the law of mass action.
dA
dt
= −2 kaf1 ARa + kar1 Ca(4.1)
dRa
dt
= −2 kaf1 ARa + kar1 Ca − kaf2 Ca Ra + 2 kar2 Da + 2 kap Da(4.2)
dCa
dt
= 2 kaf1 ARa − kar1 Ca − kaf2 Ca Ra + 2 kar2 Da(4.3)
dDa
dt
= kaf2 Ca Ra − 2 kar2 Da − kap Da(4.4)
where
kaf1 is an association rate constant and has units (VEGF concentration)
−1 (time)−1
kar1 is a dissociation rate constant and has units (time)
−1
kaf2 is an association rate constant and has units (Complex Ca concentration)
−1 (time)−1
kar2 is a dissociation rate constant and has units (time)
−1
kap is the rate of receptor internalization/recycling and has units (time)
−1
The multiplicative factor of 2 in some of the equations accounts for the possibility
that there may be two ways for that product to form. For example, in equation (4.2),
there are two ways for a VEGF dimer molecule to bind to a single receptor molecule,
since there are two binding sites on the VEGF molecule. In experimental assays, the
weights of chemokines are often measured in picograms or nanograms. Further, the
length scale of experiments is in millimeters. Thus, the above equations are scaled to
units of pg/mm3 by appropriate constants (ηai ). These represent ratios of the weights
of the different molecules involved in the reaction. The values of these constants are
given in the table below.
The scaled equation can be written as follows.
42
Table 4.1: List of parameter values relating to the molecular weights of VEGF and VEGFR2
Parameter Value Units
ηa0 0.1101 pg of VEGF per
pg of VEGFR2-VEGF-VEGFR2 complex
ηa1 0.2250 pg of VEGF per
pg of receptor monomer
ηa2 0.1837 pg of VEGF per
pg of VEGFR2-VEGF complex
ηa3 0.8163 pg of receptor monomer per
pg of VEGFR2-VEGF complex
ηa4 0.4494 pg of receptor monomer per
pg of VEGFR2-VEGF-VEGFR2 complex
ηa5 1.2250 pg of VEGFR2-VEGF complex per
pg of receptor monomer
ηa6 0.5506 pg of VEGFR2-VEGF complex per
pg of VEGFR2-VEGF-VEGFR2 complex
ηa7 2.2250 pg of VEGFR2-VEGF-VEGFR2 complex per
pg of receptor monomer
dA
dt
= −2 ηa1 kaf1 A Ra + ηa2 kar1 Ca(4.5)
dRa
dt
= −2 kaf1 ARa + ηa3 kar1 Ca − kaf2 Ca Ra + 2 ηa4 kar2 Da + 2 ηa4 kap Da(4.6)
dCa
dt
= 2 ηa5 k
a





f2 Ca Ra − 2 kar2 Da − kap Da(4.8)
4.3.2 Parameter Estimation
The parameter values for VEGF binding dynamics are taken from studies on





f1 has a value of 30.375 pg per mm
3 of VEGF (152). Cell-free experiments
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using human ligand and immobilized human receptors in (78), give kaf1 = 6.9120 per
VEGF concentration per day and kar1 = 11.5776 per day. However, these give a value
of 1.675 pg per mm3 of VEGF for kaD, thus both of these individual rates are scaled
by the same constant to get kaf1 = 1.6232 per VEGF concentration per day and
kar1 = 49.3025 per day so that their ratio is 30.375 pg per mm
3 of VEGF. Due to a
lack of experimental data, the values for kaf2 and k
a
r2 are difficult to estimate, and a
sensitivity analysis on the effects of varying these parameters is carried out. We do
however, make the following assumption regarding bounds for their values: VEGF
binding is known to induce receptor aggregation; therefore, it is reasonable to assume
that the rate of formation of a dimerized receptor-ligand complex (kaf2) is greater
than the rate of formation of a monomer receptor-ligand complex (kaf1). It should
be noted that choosing kaf2 >> k
a
f1 would approximately simulate the static pre-
dimerization case. Further, because the dimerized complex Da is the signaling form
of the receptor, it is reasonable to assume that Da is more stable than the monomer
complex Ca. Therefore k
a
r2 is taken to be less than k
a
r1. For baseline simulations, k
a
f2
is chosen to be greater than kaf1 by a factor of about 100, and likewise, k
a
r2 is taken to
be slower than kar1 by a factor of about 100. It takes on average, 90 minutes for the
receptor-ligand complexes to be internalized and the receptors to be re-released out
of the cell (152), which gives a value for kap . The average receptor density per cell R
a
t
is taken to be 230000 (78). The tissue half-life of VEGF is about 64 minutes (132).
4.4 Results
4.4.1 Dimeric versus Monomeric Uptake of VEGF in In Vitro Conditions
The model of angiogenesis developed in subsequent chapters is motivated by work
carried out by Nör et al (97; 98; 99). Parameter estimation for the full model of
angiogenesis presented in Chapters VI and VII is based on in vitro experiments
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described therein. These tend to be typically low cell density experiments, by which
we mean that VEGF concentrations are far in excess of cell, and hence receptor
densities. This is typical of most in vitro settings, including those described in the
Mac Gabhann papers. In these cases, monomeric uptake of VEGF by VEGFR2
differs significantly from dimeric uptake. To see this, cell density is fixed at 200
cells per mm3. Initial concentration of free VEGF is taken as 50 pg per mm3.
These numbers correspond to initial cell and chemokine concentrations in the in
vitro experiments in (98).
Figure 4.5 shows graphs of fractional occupancy of activated receptors and free
VEGF density versus time, for the two kinds of uptake of VEGF. It can be seen
that whilst there does not appear to be any significant difference in free VEGF
concentrations (Figure 4.5B), the fractional occupancies of activated cell surface re-
ceptors are very different (Figure 4.5A). If the natural decay of VEGF is ignored, and
ligand-receptor complexes are assumed not to internalize, the fractional occupancy
of receptors reaches a steady state that is about 59% higher in the dimer model than
the monomer model of VEGF uptake (Figure 4.5C). Correspondingly, the concentra-
tion of VEGF in activated receptor complexes reaches a steady state that is about
25% higher in the monomer model than the dimer model of VEGF uptake. Again,
the free VEGF densities do not differ significantly (Figure 4.5D). These results can
be explained as follows. In the dimer model, each VEGF molecule occupies two re-
ceptors, as opposed to just the one in the monomer model. The assumed stability of
the dimer complex may be a contributing factor to the observed differences as well.
Free VEGF densities however remain fairly similar across all simulations because in
this framework, there is a much higher VEGF concentration than available receptor
density.
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Figure 4.5: Dimeric (black) versus monomeric (red) uptake by of VEGF by VEGFR2 for low cell
density experiments, in the case when natural decay of VEGF and receptor-ligand
complex internalization are included (A,B), and when they are excluded (C,D). (A,B)
VEGFR2 dimerization predicts higher fractional occupancies of receptors (A), even
though free VEGF concentration profiles in the two forms of uptake are very similar
(B). (C,D) Ignoring loss of VEGF due to natural decay and receptor-ligand complex
internalization predicts a steady state of fractional occupancies of VEGFR2 that is 59%
higher in the dimeric uptake model as compared to the monomeric uptake model (C).
Free VEGF concentration profiles remain similar (D).
Next, the effects of varying the association rate constant kaf2, and disassociation
rate constant kar2 on fractional occupancy of VEGFR2 and free VEGF density is
studied in the dimer model (Figure 4.6). As kaf2 is varied through a range of val-
ues from kaf1 × 102 to kaf1 × 100, with kar2 kept constant, fractional occupancy of
receptors varies significantly, with maximum values ranging from 0.89 to 0.35, an
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Figure 4.6: Effect of association rate constant kaf2, and disassociation rate constant k
a
r2 on dimeric
uptake of VEGF, for low cell density experiments. (A) As the value of kaf2 is increased
from kaf1 × 102 to kaf1 × 100, keeping kar2 fixed, fractional occupancies of VEGFR2
vary from 89% to 35%. (B) Free VEGF concentrations remain unaffected. (C) As




0, keeping kaf2 constant, fractional
occupancies of VEGFR2 vary from 89% to 76%. (D) Again, Free VEGF concentrations
remain unaffected.
overall change of 61%, as seen in Figure 4.6A. Correspondingly, maximum values of
bound VEGF density vary from 1.50 pg per mm3 to 0.59 pg per mm3. However, free
VEGF concentration does not differ appreciably (Figure 4.6B). The rate constant
kaf2 is a measure of how rapidly a VEGFR2 monomer-VEGF complex binds another
VEGFR2 monomer, to create an activated complex. Thus, in cells where clustering
of VEGF receptors is observed, kaf2 would have a higher value. Consequently, higher
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levels of receptor activation would be predicted. Finally, kar2 is varied through a
range of values from kar1/10
2 to kar1/10
0, with kaf2 kept constant. Maximum values
of the fractional occupancy of receptors vary from 0.89 to 0.76, an overall change
of only 14%, as seen in Figure 4.6C. Correspondingly, maximum values of bound
VEGF densities range from 1.50 pg per mm3 to 1.28 pg per mm3. Thus kar2 does
not appear to have a significant impact on the uptake of VEGF. Again, free VEGF
concentration appears unaffected (Figure 4.6D).
4.4.2 Simulating VEGF-VEGFR2 Interactions in In Vivo Conditions
In vivo experiments may involve higher cell numbers per unit volume, that is, high
receptor density compared to VEGF concentration. In these cases, when natural de-
cay of VEGF and recycling of bound receptors is included in the model, monomeric
uptake of VEGF does not appear to differ significantly from dimeric uptake. To see
this, cell density is fixed at 17000 cells per mm3. Initial concentration of free VEGF
is taken as 50 pg per mm3. These numbers correspond to initial cell and chemokine
concentrations in the in vivo experiments in (98). Figure 4.7 shows graphs of frac-
tional occupancy of activated receptors and free VEGF density versus time, for the
two kinds of uptake of VEGF. Now, the receptor occupancies do not appear to sig-
nificantly differ in the two models (Figure 4.7A), although free VEGF concentration
decays faster for dimeric uptake of VEGF (Figure 4.7B). However, maximum VEGF
bound in activated complexes is 4.51 pg per mm3 in the dimer model, as opposed
to 3.87 pg per mm3 in the monomer model - a difference of 17%. This may still be
enough to influence simulation results when one uptake law is chosen over the other.
If the natural decay of VEGF is ignored, and ligand-receptor complexes are assumed
not to internalize, the receptor occupancy reaches a steady state that is about 10%
lower in the monomer model than the dimer model of VEGF uptake (Figure 4.7C).
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The association rate constant kaf2 and disassociation rate constant k
a
r2 do not have a
discernible impact on VEGF uptake (results not shown).
Figure 4.7: Dimeric (black) versus monomeric (red) uptake by of VEGF by VEGFR2 for high
cell density experiments, in the case when natural decay of VEGF and receptor-ligand
complex internalization are included (A,B), and when they are excluded (C,D). (A,B)
VEGFR2 dimerization predicts higher fractional occupancies of receptors (A), and a
faster decay in free VEGF concentration (B). (C,D) Ignoring loss of VEGF due to
natural decay and receptor-ligand complex internalization predicts a steady state of
fractional occupancies of VEGFR2 that is 10% higher in the dimeric uptake model as
compared to the monomeric uptake model (C). Free VEGF concentration shows a rapid
decay in the dimeric uptake model as compared to the monomeric uptake model (D).
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4.4.3 The Quasi Steady State Assumption
In 1989, Segel and Slemrod (131) published a detailed perturbation analysis of the
quasi steady state assumption (QSSA) in the case of a monomeric substrate-enzyme
binding model. This assumption states that if the rate of reaction is approximately
constant over the time period of interest, then some of the dependant variables (the
enzyme, or in our case the free and complexed receptor densities) may be regarded in
steady state with respect to the instantaneous values of the other dependant variable
(the substrate or free VEGF concentration). The rationale behind the QSSA is
as follows. If the substrate is in sufficiently large quantities, it will quickly bind
to free enzyme, in what is called the ’pre steady-state period’. A steady state is
then achieved for which the enzyme is always saturated with substrate. Segel and
Slemrod argue that this naturally introduces two time-scales into the problem - a
fast time-scale corresponding to the pre steady-state period, and a slow time-scale,
corresponding to the decay of the substrate. The QSSA is then valid only if the slow
time-scale is much larger than the fast time-scale. This leads to the identification
of a parameter, say ε, representing the ratio of the fast to the slow time-scales.
Once the reaction equations are non-dimensionalized, with the time variable being
rescaled by the slow time-scale, standard methods of singular perturbation theory
can then applied to obtain series solutions of the resulting enzyme and substrate
concentrations, in terms of ε. If ε << 1, first order and higher terms can be ignored,
so that the enzyme concentration remains approximately constant over the slow
time-scale. This is equivalent to assuming the rate of reaction of the enzyme is
negligible. The main result in (131) is the identification of ε = E0/(Km + S0), where
S0 is initial substrate concentration, E0 is initial enzyme concentration, and Km
is the concentration of the substrate at which half the true maximum velocity of
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the enzyme-substrate reaction is achieved , which is often called Michaelis-Menten
constant for the binding of substrate to enzyme.
To reduce complexity of our model of VEGF binding VEGR2, the possibility of
simplifying the reaction equations (4.5)-(4.8) using the QSSA as described above,
is investigated. In order to calculate the slow and fast time scales, an analytical
solution of the non-linear system of differential equations (4.6)- (4.8) is required.
However, such a solution is difficult to obtain, and it is not possible to replicate the
analysis in (131) for our dimeric substrate-enzyme binding model. Instead, we adopt
a numerical approach to test the validity of the QSSA.
As per the discussion above, if the QSSA is valid, the rates of change of free
receptors (dRa/dt), intermediate complex (dCa/dt), and dimerized receptor-VEGF
complex (dDa/dt) can be ignored to first order. The left hand sides of equations (4.6)-
(4.8) are set to zero, and the equations solved to obtain Ra, Ca and Da in terms of
A. As the EC population is held fixed, with no cell death or multiplication assumed







t M0, where R
a
t is the total number of receptors per endothelial
cell and M0 is EC density. The remaining two equations can be scaled to appropriate
units and added to get the following expression for Ra.
−2 kaf1 ARa + kar1 (Rat M0 −Ra − 2 ηa4 Da) + kap ηa4 Da = 0(4.9)
⇒ kar1 Rat M0 − (2 kaf1 A + kar1) Ra + ηa4 (kap − 2 kar1) Da = 0(4.10)
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Adding equations (4.6) and (4.8) gives −2 kaf1 ARa + ηa3 kar1 Ca = −kp ηa4 Da, and this
can be used in (4.5) to get the rate of change of free VEGF concentration.
dA
dt
= −2 ηa1 kaf1 ARa + ηa2 kar1 Ca(4.21)
= −ηa0 kap Da(4.22)
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where Da has the expression given in (4.15). As proven in (131), the QSSA is valid
when receptor concentration is low compared to ligand concentration. We now test
whether this assumption is valid in the two cases we have considered - low and high
cell density experiments. For the first set of simulations, cell density is fixed at 200
cells per mm3, and initial VEGF concentration is taken as 50 pg per mm3. Fig-
ure 4.8A,B compares receptor occupancy, and free VEGF concentration respectively
for the full versus the QSSA model. Internalization and subsequent recycling of re-
ceptors is included, and natural decay of VEGF is ignored. The two models appear
to be in excellent agreement, and the QSSA is valid, in this case. However, if the
natural decay of VEGF is now included, while free VEGF concentrations are still
in good agreement (Figure 4.8C), the fractional receptors occupancy begins to differ
(Figure 4.8D).
Next, the cell density is increased to 17000 cells per mm3, keeping the initial
VEGF concentration at 50 pg per mm3. As before, activated receptor complex
internalization is included initially, while natural decay of VEGF is ignored. In this
case, the QSSA is not valid. This can be seen from Figure 4.9A,B, where time course
data of both receptor occupancy and free VEGF concentration are very different
in the two models. Including VEGF decay has little effect on receptor occupancy
(Figure 4.9C). However, free VEGF concentration goes to zero marginally quicker
than in the previous case (Figure 4.9D).
4.4.4 A Comparison of the LID and the 1:1 Binding Models
Finally, the validity of the 1:1 uptake of VEGF as described in Mac Gabhann et
al (78; 79; 80; 81) is tested for the two experimental cases that we are considering.
As mentioned earlier, the 1:1 model makes the simplifying assumption that a VEGF
molecule binds to pre-dimerized receptors in a single step. Figure 4.10 presents a
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Figure 4.8: Full dimer model (black) versus QSSA (blue) uptake by of VEGF by VEGFR2 for low
cell density experiments, in the cases when natural decay of VEGF is excluded (A,B),
or included (C,D). (A,B), Both, fractional occupancies of VEGFR2 (A) and free VEGF
concentration (B) have similar profiles when the full dimer model is solved or the QSSA
is applied. (C,D) However, including the natural decay of VEGF predicts different time
courses for fractional occupancies of VEGFR2 in the cases when the full dimer model is
solved, as compared to applying the QSSA (C). Free VEGF concentration profiles still
appear to be similar (D).
schematic of the 1:1 model.
In the first set of simulations, the low cell density environment is considered,
and predictions of the 1:1 model are compared to the full dimer or LID model (Fig-
ure 4.11). If the natural decay of VEGF and the internalization of activated receptors
is included, we observe that while free VEGF concentrations for both models are sim-
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Figure 4.9: Full dimer model (black) versus QSSA (blue) uptake by of VEGF by VEGFR2 for high
cell density experiments, in the cases when natural decay of VEGF is excluded (A,B),
or included (C,D). (A,B), The QSSA no longer appears to be valid, as the fractional
occupancies of VEGFR2 follow divergent temporal profiles when the full dimer model
is solved, as compared to applying the QSSA (A). Free VEGF concentrations are also
predicted to be dissimilar in the two cases (B). (C,D), Including the natural decay
of VEGF does not change the results observed in the previous case. Both receptor
occupancies (C) and free VEGF concentrations (D) follow different profiles when the
full dimer model is solved.
ilar (Figure 4.11B), there is a marked difference in receptor occupancies. In the 1:1
case, the maximum occupancy of receptors is only 52% of that in the case of LID
(Figure 4.11A). The two models would be in agreement only if the disassociation
constant kaD in the 1:1 case were decreased to 0.122 pg per mm
3 of VEGF, which is
much lower even than the value of 1.675 pg per mm3 of VEGF considered in (78). To
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Figure 4.10: VEGF uptake by pre-dimerized endothelial cell surface receptors, as per the 1:1 model
of Mac Gabhann et al (81).
replicate conditions in (81), we now ignore natural decay of VEGF. In this case, both
fractional occupancy of receptors (Figure 4.11C), and unbound VEGF concentration
(Figure 4.11D) profiles are highly dissimilar for the two models. In the LID case,
VEGF levels decay to zero much faster compared to the 1:1 case. These results are
in direct contrast to those observed in (81).
Finally, a high cell density environment is simulated. When natural decay of
VEGF is included, both models predict similar receptor occupancies (Figure 4.12A),
although unbound VEGF profiles are quite different (Figure 4.12B). If the decay of
VEGF is ignored, the profiles of receptor occupancy begin to diverge from each other
(Figure 4.12C), even though their maximum values differ only by 5%.
4.5 Discussion
VEGF is one of the most potent, specific and intensively studied tumor angiogenic
factors. Together with its receptors, it plays a crucial role in vascular development,
both pathologic, as well as physiological. We have developed a model of VEGF’s
interaction with VEGFR2, investigating in particular, the importance of incorporat-
ing ligand-induced receptor dimerization and activation in models of VEGF’s role in
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Figure 4.11: A comparison of the LID model (black) and 1:1 model (red) for low cell density ex-
periments. If the natural decay of VEGF and receptor-ligand complex internalization
are included, maximum receptor occupancy in the 1:1 model is only 52% of the max-
imum occupancy in the LID case (A). Free VEGF profiles look similar in both cases
(B). However, both fractional occupancies (C) as well as free VEGF concentration (D)
follow very dissimilar profiles in the two models if natural decay of VEGF is excluded.
angiogenesis.
The VEGF receptors, like all receptor tyrosine kinases, require dimerization to
be activated, ligand-independent pre-associated receptor dimers are not active (82).
We therefore assumed ligand-induced dimerization to be the dominant mechanism
by which VEGFR2 is activated by VEGF. The law of mass action was used to derive
a system of ordinary differential equations governing the interactions between VEGF
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Figure 4.12: A comparison of the LID model (black) and 1:1 model (red) for high cell density exper-
iments. If the natural decay of VEGF and receptor-ligand complex internalization are
included, both models predict similar receptor occupancies (A), although free VEGF
concentrations are very different (B). Ignoring the decay of VEGF causes the profiles
of receptor occupancies to diverge for the two models (C). Free VEGF profiles remain
very different (D).
and VEGFR2. Endothelial cells have a pro-angiogenic response to VEGF due to the
presence of activated receptors on their surfaces. Despite this, most existing models
of tumor or wound-healing angiogenesis incorporate cellular response to angiogenic
cues, as being a function of free or unbound chemokine concentration. Therefore,
we kept track of temporal changes in the fraction of activated receptors on the cell
surface, as well as free VEGF concentration in all our simulations.
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In models of tumor induced angiogenesis including (73; 74; 75; 117), wherein de-
tails of VEGF-VEGF receptor interactions are included, the form of the loss term
in the VEGF evolution equation is derived by assuming that VEGF binds and acti-
vates a receptor monomer. We tested the validity of this assumption, by presenting a
comparison of the binding data obtained by assuming a monomeric uptake of VEGF,
with that obtained from our model. Typically, parameters relating to EC response
to VEGF that are used in models of angiogenesis occurring in vivo, are derived from
in vitro experiments. Therefore, comparison of the monomeric and dimeric models
was carried out for both cases. In simulations representing in vitro assays, where
the initial concentration of VEGF was assumed to be much higher than cell density,
free VEGF concentration profiles remained fairly similar for both models. These
profiles were observed to diverge slightly when the cell density was taken to be high
compared to initial VEGF concentration. This is typical of situations in vivo (80).
However, the fractional occupancies of activated receptors followed very different
trajectories in both in vitro, as well as in vivo simulations, especially if the natural
decay of VEGF, and activated receptor complex internalization and subsequent re-
cycling of receptors was ignored. These results underscore the fact that a free VEGF
concentration-dependent endothelial cell response may not be a valid assumption.
In fact, endothelial cells have a proliferative or chemotactic response dependant on
the concentration of activated receptor complexes on their surface. Choosing the
correct form of VEGF binding and uptake is essential for accurately capturing these
cellular responses. A sensitivity analysis performed on the rate constants relating
to the formation of the VEGF-VEGFR2 dimer complex, revealed that cells where
receptors tend to cluster, rather than be distributed throughout the plasma mem-
brane, exhibited higher levels of activation. This could have a significant impact on
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models of angiogenesis incorporating VEGF, especially if cells only respond when
their activation level reaches a minimum threshold.
Next, the possibility of using the quasi steady state assumption as a model sim-
plification was investigated. In low cell density experiments where VEGF was far in
excess of receptor density, the QSSA appeared to be valid. However, if the natural
decay of VEGF was included, the QSSA was observed to be invalid. This is possi-
bly due the fact that in this case, the time-scale of the decay of VEGF is lowered,
and may no longer be significantly greater than the time-scale of VEGF binding
to VEGFR2. As expected, the QSSA was found to be invalid in high cell density
experiments. This was irrespective of inclusion of the natural decay of VEGF, pos-
sibly due to an abundance of VEGF receptors, causing it to be taken up by the ECs
at a rate faster than the time-scale of its decay. These results accentuate the need
for the inclusion of greater molecular level detail when considering the uptake of
chemoattractants such as VEGF by ECs, and their resultant activation, in models
of angiogenesis. Approximating the effects of the chemokines through their unbound
concentrations, or using Michaelis-Menten like kinetics to approximate their uptake,
could lead to erroneous results.
Finally, the validity of simplifying the model by assuming that a VEGF molecule
bound to, and activated pre-dimerized receptors in a single step (1:1 model) was
tested. In simulations of a low cell density environment, fractional occupancies of
activated receptors were seen to differ considerably. The fraction of activated recep-
tors in the ligand-induced dimerization (LID) model was higher than that in the 1:1
model. This could be due to the assumption made in the LID case, whereby the
dimerized receptor-VEGF complex is assumed to be very stable as compared to the
monomer receptor-VEGF complex. Ignoring the natural decay of VEGF had the
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effect of causing free VEGF to decay faster in the LID case as compared to the 1:1
model. This could be due to additional sequestering of VEGF on the cell surface
in the form of receptor monomer-VEGF complexes. These quickly form the more
stable receptor dimer-VEGF complexes, which are then internalized into the cell.
This intermediate step thus appears to facilitate the uptake of VEGF from the cell’s
environment, leading to a more rapid consumption of the chemokine. Simulations of
a high cell density environment predicted a faster decay of VEGF in the LID case as
compared to the 1:1 model, independent of the inclusion of natural decay of VEGF.
As explained above, this difference can be accounted for by the facilitated uptake of
VEGF by ECs in the LID model.
We have presented a detailed quantitative analysis of the validity of various as-
sumptions commonly made in modelling VEGF interactions with VEGFR2. The
results of our model evince the impact of incorporating ligand-induced dimerization
on the binding of VEGF to VEGFR2, and the formation of active signaling receptor
complexes. Simulations with various initial conditions demonstrate that receptor
numbers and initial concentration of ligand have a considerable influence on the ac-
tivation of ECs. During angiogenesis, both these variables are expected to be highly
dynamic. This highlights the impact of incorporating molecular level detail on a
model of cellular response to VEGF, say during angiogenesis. In Chapters V and
VII, we develop models of intra-tumoral angiogenesis, in which VEGF is assumed to
be the principle tumor-secreted chemokine. For the reasons outlined in this chapter,
ligand-induced dimerization of VEGFR2 is applied to both these models. This is
an improvement over existing models of angiogenesis is several ways. Our models
incorporate a much higher level of biochemical detail. ECs are activated by, and
respond to VEGF bound on their surface receptors, rather than to free VEGF. Fur-
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ther, anti-angiogenic therapy which results in the decrease of EC population, or of
VEGF concentrations, may easily be tested without worrying about the validity of
the QSSA. Finally, the models are sensitive enough to differentiate response to inhi-
bition of VEGFR2, from inhibition of the VEGF molecule itself. Thus, they provide
a useful framework in which to test the potential of anti-VEGF therapies that may
target VEGFR2 (for instance the small molecule inhibitor PTK787/ZK222584), or




5.1 Novel Experimental Techniques in Intra-tumoral Angiogenesis
Recent advances in tissue engineering have allowed for the development of novel
approaches to study the in vivo growth of human blood vessels within a mouse model
system. Human dermal microvascular endothelial cells (HDMECs) along with oral
squamous cell carcinoma (OSCC-3) or Kaposi’s Sarcoma (SLK) are transplanted
into severe combined immunodeficient (SCID) mice on biodegradable polymer ma-
trices, fabricated from poly-l-lactic acid (PLLA) (97; 98; 99) (Figure 5.1A). These
matrices have an average pore diameter of 250 µm, which allows for easy penetration
and entrapment of the HDMECs. The PLLA sponges thus function as temporary
scaffolds that maintain transplanted cells in a defined space and therefore guide new
tissue growth and organization. HDMECs transplanted in this way differentiate into
functional human microvessels that anastomose with the mouse vasculature thus
generating human tumors vascularized with human microvessels. A graphical rep-
resentation of this experimental system is shown in Figure 5.1B. It is interesting to
note that 7 days post transplantation, 60% of the microvessels within the implants




Figure 5.1: (A) Graphic representation of a poly-l-lactic acid matrix, seeded with HDMECs and
OSCC-3 cells. The insert is a photograph showing HDMECs dispersed in the scaffold
taken by a scanning electron microscope (96). (B) Graphic representation of the ex-
perimental system described in (96; 97; 98). HDMECs along with OSCC-3 or SLK
cells are transplanted subcutaneously in the flank region of SCID mice. These implants
eventually develop into human tumors, populated with human microvessels.
Using such experimental systems, Nör et al have shown that the pro-angiogenic
growth factor VEGF mediates a strong survival signal to the HDMECs, by up-
regulating the expression of the anti-apoptotic intracellular protein Bcl-2 (97). A
series of experiments are carried out (described in (98)), in order to substantiate
these findings. Briefly, HDMECs stably transduced to over-express Bcl-2, were im-
planted along with OSCC-3 in SCID mice. The resultant tumors were observed to
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be significantly larger in volume and weight as compared with tumors in implants
containing empty vector control HDMEC-LXSN and OSCC-3. (Figure 5.2C,D). Fur-
ther, the implants populated with HDMEC-Bcl-2 and tumor cells displayed a higher
degree of vascularization, and a reduction in the number of endothelial cells under-
going apoptosis, than implants containing HDMEC-LXSN and tumor cells.
Nör et al have also demonstrated that Bcl-2 can function as a proangiogenic
signalling molecule, independent of its ability to enhance cell survival (59). It ac-
tivates nuclear factor-κB (NF-κB), which regulates the expression of chemotactic
cytokines or chemokines, by the cell. In particular, the activation of NF-κB results
in up-regulated production and secretion of interleukin-8 (CXCL8) (98). CXCL8
is a proangiogenic chemokine that simulates both endothelial cell proliferation and
migration (67; 136). Experiments designed to assess the contribution of CXCL8
expression to tumor growth in vivo, are described in (98). Briefly, SLK cells were
implanted together with HDMECs in PLLA scaffolds, into SCID mice. Polyclonal
antihuman CXCL8 antibody was delivered to these mice either by intraperitoneal
injections given on alternate days, or locally by incorporating the antibody to the
scaffolds before implantation. After 1 week of therapy, a 50% reduction in tumor
weight compared to control implants, was reported in both cases. Mice treated sys-
tematically with i.p. injections showed a 33% reduction in tumor volume, whilst
implants passively immunized by the anti-CXCL8 antibody showed a 50% reduction
in tumor volume. Tumors treated with anti-CXCL8 antibody showed a dramatic
reduction in intratumoral microvascular density, as can be seen in Figure 5.2A,B.
Thus, VEGF has been demonstrated to be the crucial mediator of downstream
events that ultimately lead to enhanced endothelial cell survival and increased vas-
cular density within many tumors. The newly discovered pathway involves up-
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Figure 5.2: Results from experiments designed to assess the contribution of Bcl-2 and CXCL8 over-
expression to tumor growth, taken from (97). (A,B), Anti-CXCL8 antibodies decrease
intratumoral microvascular density and reduce tumor growth. Sponges seeded with
HDMECs and SLK tumor cells were implanted in SCID mice. Polyclonal antihuman
CXCL8 antibody was delivered by passive immunization with i.p. injections every 2
days. Photomicrographs of representative fields at ×200 magnification showing CD34
(reddish-orange) staining of microvessels (black arrows) in tumors populated with HD-
MECs and SLK cells of SCID mice that were injected with PBS (A) or injected with a
polyclonal antihuman CXCL8 antibody (B). (C,D), Tumors populated with HDMECs
over-expressing Bcl-2 (C) are significantly larger than those populated with control HD-
MECs (D). Macroscopic view of representative implants at the time of retrieval from
SCID mice are shown.
regulation of the anti-apoptotic protein Bcl-2, which in turn leads to increased pro-
duction of CXCL8. The VEGF - Bcl-2 - CXCL8 pathway suggests new targets for the
development of anti-angiogenic strategies, including short interfering RNA (siRNA)
that silence the CXCL8 gene and small molecule inhibitors of Bcl-2. Quantitative
modelling of this pathway may have profound implications for the development of
novel therapies directed against specific proteins and chemokines to alter tumor pro-
gression.
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Figure 5.3: Tumor cells under conditions of hypoxia produce VEGF, which binds to endothelial cells
via cell surface receptors and causes receptor dimerization and activation. This elicits a
proliferative, chemotactic, and pro-survival response from the endothelial cells, and also
results in up-regulation of CXCL8 production by them. CXCL8 in turn induces cell
proliferation and chemotaxis. The endothelial cells begin to aggregate and differentiate
into microvessels, that eventually fuse with mouse vessels and become blood borne,
resulting in oxygenation of the tumor.
5.2 Model Development
Mathematical models of intra-tumoral angiogenesis have been developed in a num-
ber of papers including (5; 11; 24; 27; 53; 73; 74; 75; 94; 103; 116; 118; 133; 140; 145).
The focus of these studies has mainly been the growth of capillary sprout tips or the
initiation of capillary sprout formation from pre-existing vasculature in close prox-
imity of a tumor. Here, we develop a quantitative model based on the experiments
in (97; 98), wherein the vasculature that develops within the tumor space arises from
free human endothelial cells, rather than from pre-existing mouse vessels. Therefore,
this model needs to capture the process of microvessel formation from individual en-
dothelial cells which align themselves to form blood vessels, which then anastomose
with the existing mouse vasculature. A primary objective of our modelling is to bet-
ter understand the precise role the VEGF - Bcl-2 - CXCL8 pathway plays in tumor
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development and to predict the anti-angiogenic effect of the therapeutic blockade of
VEGF, CXCL8, and Bcl-2 at early and late stages of tumor progression.
The mathematical model describes the temporal changes in tumor cell density
N(t), HDMEC density M(t), free VEGF concentration A(t), free CXCL8 concentra-
tion L(t), and microvessel density V (t). A system of delay differential equations is
used to model the evolution of these species with time. A partial model schematic
is shown in Figure 5.3. The different components of the model equations, beginning
with the effects of oxygen and blood-bearing vessels on growing tumor cells, followed
by the molecular events associated with the chemical mediators as well as the en-
dothelial cell response to these chemokines, and finally the microvessel formation
rate are discussed below, along with the assumptions that underlie them.
5.2.1 Tumor Cell Equation
Following (44; 155), an empirical model is used to govern tumor cell growth,
as given in equation (5.1). The tumor cells proliferate and undergo apoptosis at
rates which depend on the local oxygen concentration, C. As oxygen concentra-
tion increases to a maximum value (normoxia), the rate of tumor cell proliferation
increases until it reaches a maximum value, while the programmed cell death rate
decreases to a minimum level. The cell death rate also reflects the limited carrying















To simplify the model, oxygen concentration is treated as a function of blood-bearing
vessel density. That is, oxygen is supplied to the implant by the microvessels that
have blood flow established in them. The exact form relating the oxygen density C
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and microvessel density V is taken from (94), and is given in equation (5.2).
C = C(V ) = Cm
V0 + V
k + V0 + V
(5.2)
Here, Cm is the maximum oxygen concentration, under normoxia (20% oxygen (44)).
Because mouse vessels surround the scaffold, and some oxygen may diffuse through
to the tumor cells from these, a fixed minimum vessel density V0 is assumed in the
region of the implant.
5.2.2 VEGF Uptake and Binding
A model for the binding of VEGF to receptors (VEGFR2), their subsequent dimer-
ization, and activation, has already been developed in Chapter IV. Briefly, A is free
VEGF concentration, Ra is VEGFR-2 density, Ca is density of the complex formed
when VEGF binds a single molecule of VEGFR-2, and Da is density of the complex
formed when VEGF binds two receptor molecules. As before, the units of concen-
tration have been chosen as pg per mm3. This introduces scaling factors ηai that
represent ratios of the weights of the different molecules involved in the reaction.
dA
dt










= −2 kaf1 ARa + ηa3 kar1 Ca − kaf2 Ca Ra + 2 ηa4 kar2 Da + 2 ηv4 kap Da(5.4)
dCa
dt
= 2 ηa5 k
a





f2 Ca Ra − 2 kar2 Da − kap Da(5.6)
Also included in equation (5.3) is the rate of decay λa of VEGF in tissue. (The tissue
half-life of VEGF is about 64 minutes (132)). Further, oxygen tension has been
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shown to play a key role in regulating the expression of VEGF in tumor cells (124;
135). Briefly, under conditions of hypoxia, the intracellular levels of hypoxia inducible
factor-1α (HIF-1α) are up-regulated. This results in the initiation of the transcription
of various target genes including VEGF (124). Therefore , we assume that VEGF is
produced by tumor cells under conditions of hypoxia, which occurs when the density
of the microvessels is very low. Specifically, the production of VEGF is ’switched
on’ when the microvessel density falls below a threshold level Vchar, and ’switched
off’ when the density exceeds this value. It should be noted that this angiogenic
switch causes the microvessel density to stabilize at a maximum level, at around
Vchar. Thus, a production term is added in the equation (5.3) governing free VEGF
concentration, following (112).
Note that conservation of total receptor numbers is ensured by setting the sum of
the free and bound receptor densities equal to the product of the average VEGFR2
density per endothelial cell and the total (free + differentiated) endothelial cell den-
sity. That is, we require the following condition to be satisfied.
Ra + η
a
3 Ca + 2 η
a
4 Da = R
a
t (M + α1 V )(5.7)
Here, Rat is the total VEGFR2 density in pg per cell, and α1 is the average num-
ber of endothelial cells per microvessel. This introduces production and loss terms
corresponding to changes in HDMEC density in equations (5.4)- (5.6). The altered
equations are presented in section 5.2.5.
5.2.3 CXCL8 Uptake
A novel feature of this model is the incorporation of a second potent angiogenic stim-
ulator, CXCL8. CXCL8 is an 8kDa chemokine (83) produced by many cell types
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Figure 5.4: (A) Schematic diagram showing the restrained minimized average structure of the
CXCL8 monomer as obtained by nuclear magnetic resonance, adapted from (118), and
RCSB Protein Data Bank. (B) Ribbon representation CXCR1 structure, after homol-
ogy modelling and energy minimization taken from (34). (C) Schematic diagram of
some of the intracellular signalling pathways activated by CXCRs, adapted from (145)
including monocytes, T cells, neutrophils, endothelial cells, and epithelial cells (89).
It has been shown to induce cell migration, and proliferation, more so than VEGF for
HDMECs (67; 136; 141). CXCL8 binds to two distinct membrane bound receptors,
CXCR1 (molecular weight 62kDa (127)) and CXCR2 (molecular weight 60kDa (55)),
that mediate signal transduction through G proteins (89). These receptors dimerize
independently of the presence of the ligand (147; 157) and they undergo hetero-
dimerization as well (157). Figure 5.4A and B show the structure of the CXCL8
monomeric unit, and a ribbon representation of CXCR1, respectively. Figure 5.4C
shows a graphical representation of a typical receptor for CXCL8, embedded in the
lipid bilayer of the cell surface. For simplicity, CXCR1 and CXCR2 are not distin-
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guished between in the model. Further, there is no conclusive evidence that two
CXCL8 molecules are required to internalize this complex. Thus it is assumed that
one molecule of CXCL8 is sufficient to activate its receptors, as shown in Figure 5.5
Figure 5.5: A schematic of CXCL8-CXCL8R1/2 interactions. CXCL8 binds to its cell surface recep-
tors CXCL8R1/2 . The activated receptor-ligand complex is subsequently internalized,
and the free receptor recycled.
Lower case letters are used to represent individual molecules and upper case letters
are used to represent their concentration (in moles per liter), so that L = [l] is CXCL8
concentration, Rl = [rl] is CXCR1/2 density, and Cl = [cl] is CXCL8-CXCR1/2
complex density. The above reaction diagram can be converted to the following
system of equations using the law of mass action.
dL
dt
= −klf L Rl + klr Cl(5.8)
dRl
dt
= −klf L Rl + klr Cl + klp Cl(5.9)
dCl
dt
= klf LRl − klr Cl − klp Cl(5.10)
where,
klf is the association rate constant and has units (CXCL8 concentration)
−1 (time)−1
klr is the dissociation rate constant and has units (time)
−1
klp is the rate of receptor internalization/recycling and has units (time)
−1
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As earlier, the above equations are scaled to units of pg/mm3 by appropriate
constants (ηli). The choice of units of concentration introduces scaling factors η
l
i that
represent ratios of the weights of the different molecules involved in the reaction.
The scaled equation can be written as follows.
dL
dt
= −ηl1 klf LRl + ηl2 klr Cl − λl L + βl M + βa φa M(5.11)
dRl
dt





f LRl − klr Cl − klp Cl(5.13)
where,




A natural decay rate λl of CXCL8 in tissue is also included in equation (5.11). Fur-
ther, it is known that HDMECs maintain a basic concentration of CXCL8, through
a background production rate βl. It’s production by the endothelial cells is up-
regulated, in response to up-regulation of Bcl-2 by VEGF. Due to its intracellular
nature, Bcl-2 concentration is taken to be directly proportional to HDMEC density,
and a separate equation for Bcl-2 is not included Instead, it’s effects are modelled
using activated VEGF-receptor complex concentration per cell, φa, as defined in
equation (5.14). Here, Da(t) is the overall concentration of activated VEGF-receptor
complexes, as given by equation (5.6). This is divided by the total endothelial cell
density which includes free cells as well as those cells that have differentiated to
form microvessels. Note that vessel cells are capable of binding VEGF, and although
they may not necessarily respond by proliferating, we assume that VEGF leads to
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up-regulated survival in the cells lining immature vessels as well. The parameter α1
is the number of cells on average per microvessel.
Again, conservation of total receptor numbers is ensured by setting the sum of the
free and bound receptor densities equal to the product of the average VEGFR2 den-
sity per endothelial cell and the total (free + differentiated) endothelial cell density.
That is, we require the following condition to be satisfied.
Rl + η
l
3 Cl = R
l
t (M + α1 V )(5.15)
Here, Rlt is the total CXCL8R1/2 density in pg per cell. This introduces production
and loss terms corresponding to changes in HDMEC density, in equations (5.12)-
(5.13). The altered equations are presented in section 5.2.5.
5.2.4 Endothelial Cell Response to VEGF and CXCL8
In contrast to other models which assume that endothelial cell proliferation de-
pends on extra-cellular growth factor concentrations or on monomeric binding of
VEGF, our model assumes that HDMEC proliferation and death rates as well as the
CXCL8 production rate are directly proportional to the amount of VEGF bound (in
dimer form) to receptors on cell surfaces. In the previous chapter, we have presented
simulations of biologically realistic situations where choosing an unbound chemokine
concentration-dependant endothelial cell proliferation rate is an invalid assumption.
In fact, endothelial cells have a proliferative or chemotactic response dependant on
the concentration of activated receptor complexes on their surface. To our knowl-
edge this has never before been considered in a mathematical model of tumor-induced
angiogenesis or vascular tumor growth. The rate of change of the free HDMEC pop-
ulation is represented in equation (5.16). The units of endothelial cell (M(t)) and
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vessel (V (t)) densities are number per mm3. It should be noted that we have sim-
plified the vascular network into a series of equal length units, and ’a microvessel’ is















The HDMECs are assumed to grow logistically, as the carrying capacity M0 of this
experimental environment is limited. M0 is estimated to be 17,000 cells per mm
3 from
the experiments in (98). The endothelial cells lining the microvessels also compete
with the free endothelial cells for space and nutrients. This is incorporated into the
logistic term by reducing the carrying capacity by the density of endothelial cells
lining the microvessels, α1V . Note that the vessel density is bounded near a level at
which the tumor is nourished by enough vessels to be in normoxia, so α1V does not
exceed 2,000 cells per mm3. Since the value of M0 is far greater than that of α1V ,
the effective carrying capacity of the environment, M0 − α1V , will never become
negative.
The first two terms in equation (5.16) give endothelial cell proliferation rates.
While there is no explicit experimental evidence to prove that effects of VEGF and
CXCL8 on HDMECs are additive, we believe that this is a reasonable assumption
in the absence of data to the contrary. Our rationale for making this choice stems
from the knowledge that VEGF is a potent mitogenic and chemokinetic factor for
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endothelial cells, and that CXCL8 alone is also capable of inducing cell proliferation
and differentiation (97). These cellular responses are a result of the activation of
cell surface receptors for these two chemokines. Hence, the proliferation rate of
HDMECs due to VEGF is taken to be proportional to the average density of activated
VEGF-receptor complexes per cell (φa, as defined in equation (5.14)). Likewise,
the proliferation rate of HDMECs due to CXCL8 is taken as proportional to the
average density of activated CXCL8-receptor complexes per cell (φl, as defined in
equation (5.17)). It should be noted that vessel cells also have receptors for CXCL8,
so its uptake by these cells is included. This reduces the amount of free CXCL8
available to free endothelial cells. Here Cl(t) is the overall concentration of activated
CXCL8-receptor complexes, as given by equation (5.13).
Moving now to the third term in equation (5.16), λm gives the natural death
rate of endothelial cells. The anti-apoptotic effect of the intracellular protein Bcl-2,
whose expression is up-regulated in presence of VEGF, is also incorporated here. As
mentioned in the previous section, the effects of Bcl-2 are modelled using activated
VEGF-receptor complex concentrations and the natural death rate λm of HDMECs
is reduced by a factor dependant on φa. Conservation of receptors ensures that
the total number of VEGF receptors per cell Rat is fixed; this also ensures that the
densities of VEGF-receptor complexes per mm3 - Ca and Da - are bounded above by
Rat ×M0, and that the density of activated VEGF-receptor complexes per cell φa is
bounded above by Rat . Since the Bcl-2 dependent death rate of HDMECs cannot be
negative, this gives a natural upper bound (λm/R
a
t ) for the multiplicative factor δ.
5.2.5 Microvessel Formation and Degradation
As endothelial cells grow in number, they begin to come together and arrange
themselves into microvessels during the process of vascular inclusion. Previous mod-
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els of angiogenesis have looked at microvessel formation in response to growth factor
stimuli from a hypoxic tumor including (5; 24; 94) or in the context of wound heal-
ing (112; 113). In their model of angiogenesis in wound healing, Pettet et al (112;
113) assume an initial condition of preformed capillary tips, that migrate towards the
hypoxic center of a wound, pulling behind them blood vessels contiguous with parent
vessels. Anderson et al (5) begin with a tumor source located at a certain distance
from parent vessels. It is assumed that sprout tips have already formed along this
vessel and these tips migrate toward the tumor in response to growth factors. Both
papers address blood vessel formation which results from pre-existing vasculature.
However, here we need to model the process of microvessel formation via alignment
and differentiation of individual endothelial cells. Nagy (94) incorporates the for-
mation of new vessels that arise from (free) activated vascular endothelial cells at a
constant rate, independent of growth factor concentration. In our model however,
growth factor concentration is taken into account during vessel formation. Further
in (94), the vessel degradation rate depends on limitations of space and growth fac-
tor availability. Here, the limitation of resources have already been included in the
logistic term of equation (5.16).
Equation (5.18) gives the rate of change of microvessel density. VEGF and CXCL8
are both believed to be strong chemoattractants for the HDMECs, so that the cells
align and form microvessels at a rate dependant on the activated receptor density
functions φa and φl, which appear in the first two terms of equation (5.18). This pro-
cess of vascular inclusion results in a corresponding decrease in the free endothelial
cell density. Thus, a vascular inclusion term is subtracted from the endothelial cell
equation and equation 5.16 changes to equation (5.19). Here, α1 is the average num-
ber of cells per microvessel. Vessel maturation is not part of this model. Therefore,
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when cells lining an immature vessel die, it is assumed to become dysfunctional at
rate, α4. In addition, the microvessel degradation rate includes a term to study the
anti-apoptotic effect of Bcl-2. Like the death term in the free endothelial cell equa-
tion (5.19), up-regulated levels of Bcl-2, i.e., high numbers of active VEGF-receptor
complexes on the cells lining the microvessels reduce their death rate. The density
of cells that have rolled up to form microvessels is given by α1V .
Since the ODE model presented here is independent of space, chemotaxis is not
included explicitly. Budding and anastomoses have also not been included in this
model, since this would present further unknown parameters, and there does not ap-
pear to be any conclusive evidence that these processes significantly affect microvessel
densities within the implant.
dV
dt
= (α2 φa + α3 φl) Mτ − α4 (λm − δ φa) α1 V(5.18)
dM
dt






−α1 (α2 φa + α3 φl) Mτ
An assumption of this model is that the numbers of VEGF and CXCL8 receptors
per cell are constant. Therefore, as HDMECs grow due to proliferation, or are lost
due apoptosis, and as microvessels regress, total receptor (bound + free) densities
change correspondingly. For instance, the creation of an EC would add to the free
VEGFR2 and CXCL8R1/2 densities, while the death of an EC would lead to loss
of free and bound VEGFR2 and CXCL8R1/2 densities. Thus the equations (5.4)-
(5.6), (5.12)- (5.13) governing the rates of change of these receptors densities need




= −2 kaf1 ARa + ηa3 kar1 Ca − kaf2 Ca Ra + 2 ηa4 kar2 Da + 2 ηv4 kap Da(5.20)
+Rat Prod(M,V )−
Ra
Ra + ηa3 Ca + 2 η
a
4 Da
Rat Death(M, V )
dCa
dt
= 2 ηa5 k
a
f1 ARa − kar1 Ca − ηa5 kaf2 Ca Ra + 2 ηa6 kar2 Da(5.21)
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= −klf L Rl + ηl3 klr Cl + ηl3 klp Cl(5.23)
+Rlt Prod(M, V )−
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f LRl − klr Cl − klp Cl(5.24)
− Cl
Rl + ηl3 Cl
Rlt Death(M, V )
Here, Prod(M, V ) is the rate of production of free and differentiated HDMECs, while
Death(M, V ) is the rate of loss of free and differentiated HDMECs. These rates can
be obtained from equations (5.19) and (5.18) as follows. Note that the number of
differentiated HDMECs is given by α1 V .











+ α1 α1 α4 (λm − δ φa) V(5.26)
We can ensure that the equations (5.20)- (5.22) do in fact conserve VEGFR2 numbers











equations (5.20)- (5.22) it can be seen that the chemical binding terms cancel, and







, as given by equations (5.18) and (5.19). Thus, the
condition (5.7) is met. A similar computation shows that the condition for the
conservation of CXCL8R1/2 given by (5.15) is also satisfied by the equations (5.23)-
(5.24).
A delay τ is incorporated in the vessel formation rate, to account for experimen-
tally observed time delay between an endothelial cell receiving a signal in the form
of activated cell surface receptors, and differentiating to form mature, blood-bearing
microvessels. The principle steps leading to the formation of microvessels via the
processes of vasculogenesis and angiogenesis are described in (108). Briefly, the cells,
upon receiving a chemical stimulus, may proliferate or migrate towards this signal in
a process known as chemotaxis. As the cells begin to align together, they abandon
their invasive phenotype, and begin forming cell-cell adhesions and reassociate with
the extracellular matrix, via cell surface molecules such as integrins. This is followed
by stretching and thinning of the cells, and their alignment in bipolar mode. The
next step is vacuole and lumen formation. As more and more cells come together
intracellular vacuoles fuse, and the lumens enlarge to generate tubular structures. Fi-
nally, these structures are stabilized, by specialized cells such as pericytes and smooth
muscle cells that assist in basement membrane formation, to produce a microvessel
capable of carrying blood. The steps involved in capillary formation detailed above
are accounted for by the inclusion of a delay in vessel formation. Time delays in
vessel formation/regression terms have been used previously in (27) wherein ODE
models are presented for tumor induced angiogenesis.
In the experiments in (98), the first vessels in the scaffold are seen only about 5
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days after implantation, indicating that the value for the delay τ is 5. It should be
noted that a delay of zero days implies that endothelial cells differentiate into vessels
as soon as any chemical stimulus is provided, in essence completing all the steps that
must precede the differentiation instantaneously. Further, the first of these vessels
would already be blood bearing. Whilst blood flow can only be established once the
vasculature within the implant has had time to anastomose with neighboring mouse
vessels.
For a complete list of model equations, please refer to Appendix B.
5.3 Parameter Estimation
Where possible, the choice of parameter values is based on estimates derived
from experimental data or from values given in the literature. In cases where no
experimental data could be found, those values of parameters were chosen for which
the solution profiles best fit the experimental observations.
5.3.1 Parameters Associated with CXCL8
As mentioned previously, the molecular weight of CXCL8 is 8 kDa, while that of its
receptors is taken to be the average of the molecular weights of CXCR1 and CXCR2,
equal to 61 kDa. This allows us to calculate the scaling constants ηli appearing in
equations (5.11)- (5.13). These values are given in Table 5.1.
In the absence of data available for endothelial cells, some of the parameter values
relating to the binding kinetics of CXCL8 and its receptors CXCR1/2 are taken from





has a value of 0.8 nM, or 6.4 pg of CXCL8 per mm3 (54). Since it takes 60 minutes
for a CXCL8 receptor to internalize and reappear (89), klp is taken to have a value of
24 per day. Due to a lack of available data, the natural decay rate of CXCL8 is taken
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to be the same as that of VEGF, so that λl = 15.5958 per day. Finally, the total
receptor density is taken to be 31000 × endothelial cell density (54). Thus, taking
Rlt to be the weight of receptors per EC, we have R
l
t = .00041 pg per HDMEC.
This still leaves us with a number of unknown parameters, which are estimated
by fitting simulation results of the model to experiments. In a series of in vitro
capillary sprouting assays described in (97), 3 × 105 human dermal microvascular
endothelial cells (HDMECs) were seeded with 1.5 ml collagen (type I), in the absence
of any chemokine, and were observed to maintain their numbers and appeared to be
in steady state over a period of 7 days. We can reduce the full model system to
represent this, for parameter estimation purposes. The resulting equations are listed














= −ηl1 klf LRl + ηl2 klr Cl − λl L + βl M(5.28)
dRl
dt
= −klf LRl + ηl3 klr Cl + ηl3 klp Cl(5.29)
+Rlt Prod(M)−
Rl






f LRl − klr Cl − klp Cl(5.30)
− Cl







Death(M) = λm M(5.32)
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The death rate of HDMECs is 0.12 per day (74). Thus, the unknown parameters
in the above equations are µl (CXCL8 dependent HDMEC proliferation rate), k
l
f
and βl (constitutive production rate of CXCL8 by HDMECs). Since the cells are
assumed to be in steady state, the left hand sides of the above equations may be
set to zero. This implies that Michaelis-Menten like kinetics must be valid for the
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is the Michaelis-Menten constant for the binding of CXCL8
with CXCLR1/2. We solve for βl in terms of the other parameters, and the steady


















The value for Ms may be read off the experimental data, so that we have reduced
the number of parameters to be fitted to just two. A table of the known parameters
is given in Table 5.1.
In order to estimate the remaining parameters, we again consider experimental
data from (97). Here 3 × 105 HDMECs are now seeded with 1.5 ml collagen (type
I), and grown in the presence of CXCL8 for seven days. Their numbers are recorded
2In the absence of experimental data, the half-life of CXCL8 was taken to be the same as that of VEGF for
purposes of simplicity.
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Table 5.1: List of parameter values associated with CXCL8 uptake by HDMECs
Parameter Value Units Source
λm 0.12 per day (74)
klp 24.0 per day (89)
ηl1 0.1311 pg CXCL8 per pg Rl (55), (83), (127)
ηl2 0.1159 pg CXCL8 per pg Cl (55), (83), (127)
ηl3 0.8841 pg Rl per pg Cl (55), (83), (127)
ηl4 1.1311 pg Cl per pg Rl (55), (83), (127)
λl 15.5958 per day (132)2
at daily intervals. CXCL8 dosage of 50 ng per ml, or 50 pg per mm3 is given every
two days. However, to fit the parameters in this model, only the first 4 days worth
of data is considered, since after this the HDMEC cell numbers are seen to decline,
which is attributed to a hostile in vitro environment. This is something we chose
not to factor into the model as this might lead to further undetermined parameters.
The equations (5.27)- (5.30) reflect this setup as well, with the only change that a
dosage term needs to be added to equation (5.28), to mimic the treatment regime.
The unknown parameters are klf and µl, together with that given by equation (5.37).
These are determined by fits in the least squares sense to experimental data presented
in (97). The resultant fit is shown in Figure 5.6A. The parameter values thus obtained
are listed in Table 5.2.
Table 5.2: List of parameter values associated with CXCL8 uptake by HDMECs contd.
Parameter Value Units
µl 12.8810 HDMECs per pg of Cl per day
klf 6.7587 per CXCL8 concentration per day
klr 43.2557 per day
βl 8.0924×10−4 pg of CXCL8 per HDMEC per day
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Figure 5.6: Fits to time-course data taken from in vitro capillary sprouting assays described in (96),
with HDMECs cultured in the presence of either 50 ng/ml CXCL8 (A), or 50 ng/ml
VEGF (B)
5.3.2 Parameters Associated with VEGF
The kinetic parameters relating to VEGF uptake by VEGFR2 have already been
estimated in Chapter IV. We present here an estimation of the parameters relating to
the effect of VEGF on HDMEC behavior. We again look at the capillary sprouting
assays described in (97). In a final set of experiments, Nor et al seeded 3× 105 HD-
MECs with 1.5 ml collagen (type I), and treated them with 50 pg/mm3 VEGF every
two days. The total (free + differentiated) number of HDMECs were counted every
day. The full model system is reduced to represent this, for parameter estimation




















= −2 ηa1 kaf1 ARa + ηa2 kar1 Ca − λa A(5.39)
dRa
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= −2 kaf1 ARa + ηa3 kar1 Ca − kaf2 Ca Ra + 2 ηa4 kar2 Da + 2 ηv4 kap Da(5.40)
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= −ηl1 klf LRl + ηl2 klr Cl − λl L + βl M + βa Da(5.43)
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dt
= −klf LRl + ηl3 klr Cl + ηl3 klp Cl(5.44)
+Rlt Prod(M)−
Rl
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The unknown parameters are µa (VEGF dependent HDMEC proliferation rate), δ
(measure of the protective effect of VEGF on HDMECs, due to Bcl-2 up-regulation),
and βa (rate of CXCL8 production by HDMECs, under the influence of up-regulated
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levels of Bcl-2). These are determined by fits in the least squares sense to experimen-
tal data presented in (97). The resultant fit is shown in Figure 5.6B. The parameter
values thus obtained are listed in Table 5.3.
Table 5.3: List of parameter values associated with VEGF uptake by HDMECs
Parameter Value Units
µa 14.0875 # HDMECs per pg of Da per day
δ 21.56 # HDMECs per pg of Da per day
βa 3.3766 pg of CXCL8 per pg of Da per day
5.3.3 Vessel Formation
The estimation of parameters relating to HDMEC differentiation into microvessels
are presented in Chapter VI.
5.3.4 Tumor Cell Growth Parameters
Parameters relating to the proliferation and death of tumor cells, appearing in
the equation (5.1) governing the rate of change of tumor cell density are taken from
Gammack et al (44). These are presented in Table 5.4.
Table 5.4: List of parameter values associated with tumor growth.
Parameter Value Units Source
r1 1.2924 per day (44)
C1 0.1 Oxygen concentration (44)
r2 0.001 per Tumor cell density per day 3
σ 1.0029 dimensionless (44)
C2 0.054 Oxygen concentration (44)
Cm 0.2 Oxygen concentration (44)
k 8.0 # Microvessels per mm3 3
3In the absence of experimental data, biologically realistic values for these parameters were chosen so that the
solution profiles best fit experimental observations.
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5.4 Results
5.4.1 Vascular Tumor Growth
All numerical simulations of the model described in the previous section were
carried out using RADAU IIA methods adapted to solve delay differential equations,
as implemented by the numerical package RADAR5 Version 2.1 (48). Two key
indicators of tumor development were studied in particular - maximal steady state
values of tumor cell and vessel densities, and the time taken to reach these.
First, a series of numerical simulations are performed to illustrate tumor growth
dynamics in the absence of anti-angiogenic or any other anti-cancer therapies. Two
parameters were varied: tumor cell sensitivity to oxygen deprivation, that is the rate
at which cells become necrotic in a low oxygen environment (r2), and tumor cell
ability to produce VEGF which captures the variation in the production of VEGF
by different tumor cell lines (r3). The results are summarized below.
With parameters at their baseline values, the tumor cell density reaches it’s maxi-
mum level (1.149×104 cells per mm3) about 28 days after implantation (Figure 5.7A).
The first blood-bearing vessels are seen 5 days after implantation, reaching their
steady state of about 53 vessels per mm3, 19 days later (Figure 5.7B). During the
first five days, the scaffold is hypoxic and a transient decrease in tumor cell density
is observed that may be attributed to necrosis (Figure 5.7A, inset).
Next, a sensitivity analysis is carried out on the tumor cell oxygen sensitivity
parameter (r2). Numerical simulations indicate that maximal tumor cell density
reached is exponentially related to r2. As r2 is varied from 10% to 150% of its
control value, the maximal tumor cell densities decrease from 11.58 × 104 cells per
mm3 to 0.76 × 104 cells per mm3 - a change of about 93%. However, the maximal
vascular densities reached vary only from 54 to 52 vessels per mm3 - change of only
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Figure 5.7: Vascular tumor growth in the absence of therapeutic intervention. (A) Tumor cell
density reaches its steady state of 1.149×104 cells per mm3 about 28 days post implan-
tation. A transient decrease in tumor cell density is observed due to hypoxic conditions
within the implant for the first week (inset). (B), Blood borne vessels are first seen 5
days after implantation, and reach their maximal level of 53 vessels per mm3 about 24
days post implantation.
4% - and appear to be linearly related to the oxygen sensitivity parameter. These cell
and vessel densities are normalized by their respective maximum values, and plotted
versus r2. (Figure 5.8A). For the same variation in the oxygen sensitivity parameter,
the time taken by the tumor cells to reach maximal density increases from 18 to
62 days, and the time taken to reach maximum vascular densities increases from 12
to 57 days (Figure 5.8B). Thus, tumor growth and vascular development occur at a
similar pace, and seem to vary exponentially with tumor cell sensitivity to oxygen
deprivation. These results can be explained by the fact that a delay in tumor cell
growth results in a delay in VEGF concentration reaching its maximum level, which
correspondingly causes a delay in vasculature development. However, tumor cells
are still producing VEGF at the same rate, and while the VEGF concentration falls
with a reduction in tumor cell density, the change is not large enough to significantly
alter the steady state reached by the vasculature. Therefore, tumor cells that are
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more sensitive to local oxygen concentrations give rise to tumors that have very low
tumor cell density, but are still highly vascularized. On the other hand, tumor cells
with greater resistance to hypoxic conditions produce highly vascularized tumors
with very high tumor cell densities.
Finally, a sensitivity analysis is carried out on the rate of VEGF production (r3).
This captures the variation in production of VEGF by different types of cancer cells
and can also describe therapeutic intervention associated with administering small
molecule inhibitors of VEGF. As expected, the numerical simulations predict that
decreasing VEGF production rate delays tumor growth and vascular development.
As VEGF production by tumor cells is decreased, the time taken by the tumor cells
to reach maximum densities increases, from 17 days to 61 days, and time taken by
the vessels to reach maximum densities increases from 13 to 57 days (Figure 5.8D).
The relationship between VEGF production rate and both these times appears to
be exponential. On the other hand, maximum tumor cell densities reached decrease
by only 1%, from 1.157× 104 to 1.144× 104 per mm3, and maximum vessel densities
reached decrease by about 4% from 54 to 52 per mm3, for the same variation in r3.
These cell and vessel densities are normalized by their respective maximum values,
and plotted versus r3. (Figure 5.8C). Thus, decreasing VEGF production rate has a
far greater impact on the time taken to reach maximal cell and vessel densities than
on their actual maximum values. This indicates that the fall in VEGF production is
enough to significantly retard vessel formation, but not enough to affect the steady
state reached by the vessel density. Since the other parameters including tumor cell
growth and necrosis rates are kept fixed, the tumor cells are able to grow to roughly
the same steady states.
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Figure 5.8: Tumor cells with high oxygen deprivation sensitivity give rise to highly vascularized
tumors with low tumor cell densities. Decreasing tumor cell VEGF production rate
delays tumor growth significantly. (A,B), Effect of increasing tumor cell oxygen depri-
vation sensitivity from 10% to 150% of its baseline value is simulated. Numerical results
predict a 93% reduction in maximal tumor cell density. The corresponding reduction
in maximal vessel density is only 4% (A). The time taken to reach maximal tumor cell
density increases by a factor of 3.5, while that to reach maximal vessel density increases
by a factor of 4.8 (B). (C,D), Effect of decreasing VEGF production rate from 500% to
62.5% of its baseline value is simulated. Numerical results predict a reduction of only
1% in maximal tumor cell density and a reduction of only 4% in maximal vessel density
(C). However, the corresponding increase in time taken to reach maximal tumor cell
and vessel density is as much as 3.6 and 4.4 fold respectively (D).
5.4.2 Anti-angiogenic Therapy Targeted at the VEGF-BCL-2-CXCL8 Pathway
The main focus of this model is to investigate the importance of the downstream
effect of the VEGF - Bcl-2 - CXCL8 pathway in tumor progression. The pathway
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suggests two targets for the development of anti-angiogenic therapies: inhibiting the
production of CXCL8 by HDMECs and blocking the VEGF mediated up-regulation
of Bcl-2 by HDMECs. Numerical simulations of both these cases are carried out
keeping all previously introduced parameters fixed at their estimated pre-treatment
values. The results are presented and discussed below.
Anti CXCL8 Therapy
The effect of inhibiting the production of CXCL8 from the first day of implantation
is investigated. Experimental data is taken from (98), where polyclonal antihuman
CXCL8 antibody was delivered locally, by incorporation into the scaffolds implanted
in the SCID mice. The mice were then sacrificed after 21 days and vascular densities
noted. The vasculature in treated tumors reached a density of around 20 vessels per
mm3 after 21 days, as opposed to a tumor that was allowed to grow without the
application of any anti-cancer therapy, in which the density was double this value,
at around 42 vessels per mm3 after the same length of time (Figure 5.9C). The anti-
CXCL8 antibody binds to free CXCL8, effectively reducing the bio-availability of
free CXCL8 for endothelial cells. In modelling terms, this can be thought of as a
reduction in the production rate of CXCL8, which would mean lower levels of free
CXCL8 available to the endothelial cells. Thus, anti CXCL8 therapy can be modelled
via a parameter εl, which is a measure of therapy efficacy, and multiplies the CXCL8
production term in equation (5.11). It varies from 1 (no therapy applied) to 0 (100%




= −ηl1 klf LRl + ηl2 klr Cl − λl L + εl (βl M + βa φa M)(5.48)
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Numerical simulations show that as εl is varied from 1 to 0, the vessel density after 21
days changes from 42 to 12 vessels per mm3. Comparison with experimental results
allows us to calculate that the in vivo therapy in (98) has an efficacy level between
20% (εl = 0.8) and 100% (εl = 0) (Figure 5.9C, εl = 0.589, efficacy level of 41.1%).
This range of values for εl is obtained from experimental error bars. The tumor
cell density in a tumor growing without treatment is 48% higher than in a tumor
treated with the above level of anti CXCL8 therapy after in 21 days (Figure 5.9A).
Correspondingly, the treated tumor is nourished by only half the vasculature in a
non-treated tumor, at this point of time (Figure 5.9B).
It is also important to determine how varying CXCL8 therapy levels affects the
delay in tumor development. As can be seen from Figure 5.9D, time taken to reach
maximal tumor cell and vessel densities appears to vary linearly with εl. A 100 %
efficacious therapy level, corresponding to εl = 0 introduces a delay of 6 days in tumor
development, while the delay is only 2 days corresponding to the in vivo therapy
in (98) (εl = 0.589). Note that in Figure 5.9D, εl varies from 1 to 0 on the abscissa,
which should be interpreted as level of therapy increasing from 0 to 100%. Thus, anti
CXCL8 therapy delays tumor growth, but the delay is not very large. Further, the
maximal levels of tumor cell and vessel densities remain unaffected upon application
of therapy. This can be explained by observing that CXCL8 is not directly related
to enhanced endothelial cell survival, it induces cell proliferation and migration.
But these functions are also performed by VEGF which in addition exerts a pro-
survival effect on the endothelial cells though up-regulation of Bcl-2. So, reducing
CXCL8 levels can be expected to produce a delay in vascular development, which
correspondingly delays tumor cell growth. However, tumor cell VEGF production
rate remains unchanged, which explains the relatively small value of the delay, and
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also accounts for the unchanged maximal vessel density. This in turn means that
maximal tumor cell density remains unchanged, since it is a function of the blood-
bearing vessel density.
Figure 5.9: Anti CXCL8 therapy applied on the first day of implantation delays both tumor growth
and vascular development. (A,B), Numerical simulations of anti CXCL8 therapy applied
from the first day, predict that after 21 days, the tumor cell density is about 32% lower
than its value in the case when no therapy is applied (A). Likewise, the vessel density
in the anti CXCL8 case is 50% lower than its value in the case with no therapy applied
(B). (C) Comparison of experimental and numerical predictions of microvessel densities
(vessels per mm3) after 21 days of exposure to anti CXCL8 therapy. Experimental data
taken from (97), where sponges seeded with HDMECs and Kaposi’s sarcoma cells were
implanted in severe combined immunodeficient mice. Polyclonal antihuman CXCL8
antibody was delivered by incorporation into scaffolds implanted in the mice. (D) Time
to both maximal tumor cell and vessel densities increases by about 6 days for a 100%
efficacious therapy level, as opposed to the no therapy case. εl = 0.589 corresponds to
the in vivo therapy in (97).
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Anti Bcl-2 Therapy
Numerical simulations of the clinically interesting situation corresponding to in-
tercepting the effect of VEGF on Bcl-2 levels within HDMECs both in vitro and
in vivo were performed. In (59) in vitro capillary sprouting assays with HDMECs
exposed to 50 ng/ml of VEGF are compared to HDMECs cultured in the presence
of 50 ng/ml VEGF and exposed to anti Bcl-2 therapy starting on day 5, in the form
of a small molecule inhibitor BL193. The model equations are modified to simu-
late the in vitro experiments. Notably, there are no tumor cells present and free
VEGF concentration is held fixed at 50 ng/ml. Constitutive CXCL8 production rate
by endothelial cells and environmental carrying capacity for endothelial cells are re-
evaluated from the control (no therapy) simulations. To model the effect of anti Bcl-2
therapy, a parameter εa is introduced as a measure of the level of blockage of Bcl-2
up-regulation by BL193. This affects the cell death terms in the free HDMEC and
vessel equations, and CXCL8 up-regulation by HDMECs in the presence of VEGF.
The equations (5.11), (5.18) and (5.19) change as follows.
dL
dt
= −ηl1 klf LRl + ηl2 klr Cl − λl L + βl M + εa βa φa M(5.49)
dV
dt
= (α2 φa + α3 φl) M − α4 (λm − εa δ φa) α1 V(5.50)
dM
dt






−α1 (α2 φa + α3 φl) M(5.52)
The level of Bcl-2 up-regulation blockage εa may be varied between 1 (no therapy)
and 0 (complete blockage of Bcl-2 up-regulation), and the results compared with
experimental outcomes. Note that setting εa = 0 forces Bcl-2 to remain at its normal,
constitutive levels and ensures that production of CXCL8 is not up-regulated. It is
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observed that the model provides a good fit to the no therapy case (Figure 5.10C).
The numerical and experimentally observed vessel densities are seen to be in good
agreement when the blockage level of Bcl-2 up-regulation by VEGF is between 85%
and 100% (Figure 5.10D, complete blockage of Bcl-2 up-regulation).
Next, the effect of small molecule inhibition of Bcl-2 may be numerically inves-
tigated in vivo. The model predicts that after 21 days, when Bcl-2 up-regulation
is blocked completely (εa = 0), post-therapy tumor cell and vasculature densities
drop to levels 27.5% and 14% respectively of their values when no therapy is applied,
(Figures 5.10A,B). Further, the maximal tumor cell and vessel densities may also be
plotted as the level of blocking of Bcl-2 up-regulation is varied (Figure 5.10E). Inter-
estingly, there appears to be a minimum level of blockage of Bcl-2 up-regulation by
VEGF required for the therapy to be effective. For εa < 0.4, anti Bcl-2 therapy has
comparatively little effect on tumor development, and maximal tumor cell and vessel
densities do not change appreciably. With a reduction in Bcl-2 up-regulation levels,
the endothelial cell death rate increases, and CXCL8 production by endothelial cells
decreases, but these effects are balanced out to some extent by an unchanged tumor
cell VEGF production rate. However, as εa is reduced further, the endothelial cell
apoptosis rate becomes very large, and consequently, maximal vessel densities begin
to fall drastically. This causes a drop in maximal tumor cell densities as well, since
there are fewer blood-bearing vessels supplying nutrients and oxygen to the tumor.
Eventually, corresponding to in vitro therapy levels (εa = 0), tumor cell density sta-
bilizes at 68% and vessel density stabilizes at 41% of their values in the no therapy
case. This sensitivity of the tumor to anti Bcl-2 therapy levels is also apparent from
the graphs of time taken to reach maximal cell and vessel densities versus therapy
level (Figure 5.10F). For εa < 0.4, the delay in vessel and tumor development in-
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creases fairly slowly, with an increase in therapy level. Near εa = 0.4, the rates of
change of both these times are maximum. For higher therapy levels, these rates seem
to level out, but are still high. Overall, it takes about 30 days longer for the tumor
to develop when Bcl-2 up-regulation is completely blocked. These results underscore
the use of this model as a predictive tool to guide in vivo experiments aimed at
testing anti Bcl-2 therapies. They suggest that below a certain threshold, anti Bcl-2
therapy elicits little response from the tumor, but as therapy is increased beyond
this threshold, the tumor and vascular development is arrested at much lower levels.
Thus, anti Bcl-2 therapy is considerably more effective than anti CXCL8 therapy,
if given in the right quantities. It should be noted that in Figures 5.10E and F, εa
varies from 1 to 0 on the abscissa, which should be interpreted as level of therapy
increasing from 0 to 100%.
Treatment of Fully-Formed Tumors
We investigate the effect of various anti angiogenic therapies applied to a tumor
that has been allowed to reach maximal tumor cell and microvessel densities (Fig-
ure 5.11A,B). The model predicts that anti CXCL8 treatment has little or no effect
on the tumor when applied at this late stage. The vessel density is seen to decrease
only slightly, but the tumor cells appear to compensate for this decrease in CXCL8
levels by increasing VEGF production. The vessel density soon returns to its pre-
treatment level. However, if the up-regulation of Bcl-2 in HDMECs is blocked, the
tumor begins to regress and finally stabilizes at lower cell and vasculature densities.
This underscores the importance of enhanced HDMEC survival in the progression of
a tumor. Note that in Figure 5.11B, a sudden drop in the vessel density is observed
when anti Bcl-2 therapy is applied. In actual experiments this drop may be more
gradual. In the numerical simulation, at the point of application of the therapy, the
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Bcl-2 levels in the cells are set to non up-regulated levels while in all probability, it
would take some time for these to be achieved in vivo.
5.4.3 Effect of the Delay τ
An important feature of this model is the inclusion of a delay in the microvessel
formation, to account for the various biological steps that precede the differentiation
of free endothelial cells into capillaries. We are not the first to use a delay in this
way - in (68), Kuang et al use a delay to account for the time it takes activated
vascular precursor cells to mature into functional microvessels. Time delays in vessel
formation have also been used in angiogenesis models to rationalize empirical obser-
vations (27). Experimental observations allow us to fix this delay at 5 days. Various
numerical experiments were carried out to test the stability of steady states of the
model revealed that the introduction of the delay did not produce any oscillatory
behavior.
To investigate the importance of the delay, the model equations are simulated with
τ = 0 representing the non-delay case. In setting the delay to zero, we are making the
biologically unreasonable assumption that the endothelial cells begin to form vessels
as soon as they detect any sort of chemical stimulus, and these vessels are also blood
bearing immediately. It is observed that tumor cell density stabilizes almost 12 days
earlier and vessel density stabilizes almost 10 days earlier than if the delay is fixed
at 5 days. In fact, after 21 days, the tumor cell and vessel densities have already
reached their maximal levels, and the vessel density is 27% higher than the value
observed experimentally in the case when the delay is set to zero (Figures 5.12A,B).
Thus, the tumor vasculature is developing at a rate that is much faster than what is
observed in vivo.
Next, the effect of the length of the delay on time taken to reach maximal tumor
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and vessel densities is studied. The delay is varied between biologically realistic values
of 0.5 days to 10 days. The time taken to maximal tumor cell density increases
from 18 days to 34 days - a change of 89%. The time taken to reach maximal
vessel density also increases by about 88% from 16 days to 30 days. (Figure 5.12C)
Interestingly, for τ between 0.5 and 3 days, the delay between tumor cell and vessel
development is about 2 days, but for τ greater than 4 days, this delay increases to 4
days (Figure 5.12D).
5.5 Discussion
There have been numerous advances in the development of experimental models
to study angiogenesis, recasting these in mathematical terms can provide valuable
insights into understanding the processes that govern angiogenesis and suggest new
methods of treatment of cancers. We set out to explore quantitatively one such ex-
perimental model that investigated the importance of the VEGF - Bcl-2 - CXCL8
pathway in sustained angiogenesis of a developing tumor. The main goal of this
research was to derive a mathematical model of the experiments in (97; 98), in order
to better understand those features of the pathway which play the most crucial role
in sustaining the growth of a tumor. Further, numerical simulations of the model
could be used to suggest new areas for the development of anti-angiogenic therapies
targeted at the proteins and chemokines involved in the pathway and to assess their
effects on tumor progression. We recognize that this experimental system does not
exactly replicate the formation of human tumors in vivo, however this experimen-
tal approach has lead to several significant discoveries about the molecular events
involved in angiogenesis, and by developing a model specific to these experiments
we are able to validate our predictions by direct comparison with the available data.
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It would be a straight forward task to change initial conditions to better describe
traditional vascular tumor growth.
Numerical simulations of the full model provide insight into the growth dynamics
of tumors with different sensitivities to oxygen deprivation and various rates of VEGF
production. Results obtained showed that as tumors with increasing sensitivities to
local oxygen concentration were considered, the time taken to reach maximum cell
densities by the tumor increased, and tumor cell growth was significantly affected, but
this had little impact on the vascular development of the tumor. Tumor cells highly
sensitive to local oxygen concentrations were found to give rise to highly vascularized
tumors, with very low tumor cell densities that were at just 7% of their values in
tumors with very low local oxygen concentration sensitivity. The vessel densities in
these two kinds of tumors did not differ significantly. VEGF production rate was
found to have a more significant impact on the time taken to reach maximal cell
and vessel densities. As VEGF production rate was decreased from a maximum by
87.5%, it took 264% more time for tumor cell density to reach its maximal level and
335% more time for the vasculature to fully develop. These results suggested that
possible anti-angiogenic therapies targeting VEGF may result in significant delays
in tumor progression.
The VEGF - Bcl-2 - CXCL8 pathway also presented two new potential areas
for the development of cancer treatment. Numerical results indicated that inhibiting
the production of CXCL8 by HDMECs from day zero delayed the tumor progression,
but did not affect the maximal tumor cell and vessel densities. The most promising
strategy however was to block the up-regulation of Bcl-2 by VEGF in HDMECs, this
resulted in a tumor with low vascular density and a correspondingly low tumor cell
density. The tumor responded much better to treatment after a certain minimum
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level of therapy was applied. Anti Bcl-2 therapy significantly delayed tumor devel-
opment as well. In a simulation carried out to test these two strategies on a fully
developed tumor, we found that blocking CXCL8 production had virtually no effect
on the tumor, but down regulation of Bcl-2 resulted in the tumor stabilizing at low
cell and vessel densities. Hence, the dual role played by VEGF namely, enhanced
endothelial cell survival due to up-regulation of Bcl-2 and increased endothelial cell
proliferation and migration due to up-regulation of CXCL8 played a crucial role in
the development of the tumor. Indeed, it appeared that increased endothelial cell
half life was necessary for rapid growth and progression of the tumor. Finally, the
effect of the delay parameter was investigated numerically, and it was observed that
without any delay, the vasculature developed too rapidly. For the control value of
the delay parameter, a time lag of 4 days was observed between tumor cell and vessel
development.
Nör et al have already demonstrated that BL193, a small molecule inhibitor of
Bcl-2 has a strong inhibitory effect on the angiogenic potential of endothelial cells
in vitro (98; 59). However, the anti-angiogenic potential of BL193 in vivo is not
clear. In Chapter VII we extend the modelling approach present here to explicitly
incorporate the pro-apoptotic as well as anti-apoptotic members of the Bcl family, in
order to better understand the mechanism of action of BL193 and to relate its binding
efficiency to its therapeutic efficacy. For future work, we also plan to investigate in
greater detail the ability of our mathematical model to predict a response to anti-
CXCL8 treatment, as well as to differentiate the response to inhibition of the ligand
(CXCL8) from inhibition of its receptor (CXCR2). The ligand can be experimentally
inhibited by polyclonal anti-human CXCL8 antibody and the receptor by polyclonal
anti-human CXCR2 antibody.
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Figure 5.10: Anti Bcl-2 therapy is highly effective in controlling tumor growth and vascular de-
velopment. (A,B), Numerical simulations of in vivo anti Bcl-2 therapy corresponding
to 100% blockage of Bcl-2 up-regulation by VEGF applied from the first day predict
that after 21 days, the tumor cell density is only about 27.5% of its value in the case
when no therapy is applied (A). Likewise, the vessel density in the anti Bcl-2 case is
about 14% of its value in the case with no therapy applied (B). (C,D), Comparison
of numerical simulations and experimental results of in vitro capillary sprouting as-
says with HDMEC exposed either to 50 ng/ml VEGF (C) or 50 ng/ml VEGF and
anti Bcl-2 therapy starting on day 5 in the form of 0.5 M of BL193, a small molecule
inhibitor of Bcl-2 (D). Experimental data taken from (59). (E,F), Anti Bcl-2 therapy
appears to have a major effect only after a minimum level of therapy, corresponding
to εa = 0.4, is provided. Maximal tumor cell density and maximal microvessel density
show a drop of 30% and 59% respectively as level of anti Bcl-2 therapy is increased
from no therapy to 100% blockage of Bcl-2 up-regulation (E). Time taken to maximal
tumor cell density increases by 90% and to maximal vessel density increases by 112%
for this range of therapy (F).
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Figure 5.11: A fully formed tumor responds to anti Bcl-2 therapy, while anti CXCL8 therapy ap-
pears to have little or no impact.(A,B), Anti CXCL8 and anti Bcl-2 therapies are
applied in turn on a fully developed tumor, and their effects on tumor cell and mi-
crovessel density graphed. The anti CXCL8 therapy is applied on the 40th day, and
the anti Bcl-2 therapy is applied on the 60th day. It can be seen that while the anti
CXCL8 therapy has little affect the tumor cell and microvessel densities, anti Bcl-2
therapy produces a significant drop in both of these.
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Figure 5.12: Effect of the delay τ on tumor growth and vascular development. (A,B), Comparison
of tumor cell and vessel densities in the non-delay case (τ = 0) versus the delay held
at its baseline value (τ = 5). The tumor cell density has already reached its maximal
level by day 16 in the non-delay case (A). The vessel density reaches its maximal level
by day 14 in the non-delay case, and are blood borne as soon as they are formed (B).
(C,D), As the delay is varied between biologically realistic values of 0.5 days to 10
days, the time taken to maximal tumor cell density increases by 89% while the time
taken to reach maximal vessel density increases by about 88% (C). For τ between 0.5
and 3 days, the delay between tumor cell and vessel development is about 2 days, but
for τ greater than 4 days, this delay increases to 4 days (D).
CHAPTER VI
Apoptotic Requirement for Disruption of Microvessels
6.1 Introduction
In the previous chapter, we investigated the importance of the VEGF-Bcl-2-
CXCL8 pathway in intra-tumoral angiogenesis. Model simulations showed that the
pro-survival influence of VEGF on the microvascular endothelial cells was crucial
in the growth and maintenance of tumor vasculature. In fact, anti-Bcl-2 therapy
aimed at inducing endothelial cell death or apoptosis, was predicted to be the most
promising target for the development of anti-angiogenic therapy. Thus, apoptosis
was shown to be an important factor in determining tumor progression.
Apoptosis was first described by Kerr et al, in 1972 (64). They defined it as a
form of programmed cell death that occurs in multicellular organisms. It involves
a series of biochemical events leading to changes in cellular morphology, including
blebbing, chromatin condensation, nuclear fragmentation, and cell shrinkage, which
eventually lead to cell death. Apoptosis is an integral part of the normal development
and maintenance of tissue homeostasis. However, it is also involved in a variety of
pathologic conditions such as neurodegenerative diseases, cardiovascular diseases,
immunological diseases, and cancer (161). In this chapter, we aim to quantify the
role played by programmed cell death, or apoptosis, in the disruption of blood vessels,
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mediated by anti-angiogenic drugs.
6.1.1 Biological Motivation
There exists an abundance of laboratory as well as clinical evidence of the hypoth-
esis that cancer is an angiogenesis-dependent disease (40; 41). Angiogenesis, in turn,
is strongly dependent on the suppression of endothelial cell apoptosis (26). In fact,
pro-angiogenic growth factors such as VEGF have been shown to potently induce
cell survival (46; 59; 97). This has led to a widespread interest in the development of
anti-angiogenic therapies, aimed at blocking pro-survival signals and inducing cellu-
lar apoptosis, in order to treat a growing tumor (41; 162). In particular, it has been
shown that blocking VEGF is sufficient to induce EC apoptosis (65; 66; 120). This
resulted in the development of the first anti-angiogenic agent to be approved by the
FDA - Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody (38).
Other molecules such as angiostatin, endostatin, and thrombospondin-1 have also
been characterized as anti-angiogenic compounds. For instance, angiostatin and en-
dostatin have been shown to inhibit vessel formation, both in vitro and in vivo,
inducing endothelial cell apoptosis (30; 31). Matrix-bound thrombospondin-1 has
been shown to promote endothelial cell apoptosis and inhibit angiogenesis (128).
There has also been considerable interest in the development of therapies targeted
against the anti-apoptotic members of the Bcl family of proteins, which have been
identified as crucial mediators of cell death (59; 154; 160).
The mechanism of action of the anti-angiogenic agents described above, is largely
based on the induction of endothelial cell apoptosis, resulting in vessel disruption.
A question that arises with regard to the evaluation of these compounds is ’what is
the minimum level of endothelial cell apoptosis required for significant microvascular
regression?’ Apoptosis in cells is brought about by the activation of intra-cellular
106
Figure 6.1: Figure showing two distinct pathways leading to cellular apoptosis, taken from (7).
Apoptosis can be initiated by internal events involving the release of cytochrome C
from the mitochondria, in turn leading to the downstream activation of caspases. Al-
ternatively, cell surface receptors can be activated by specific ligands that bind to ’death
receptors’. This pathway is typically mediated by immune cells, to initiate intracellular
signaling and the downstream activation of relevant caspases.
cysteine proteases called caspases (3) (Figure 6.1). Dong et al (32) constructed an
experimental system based on an inducible caspase (iCaspase-9) in order to address
this question. Upon exposure to a dimerizer drug, this caspase induced selective and
controlled cellular apoptosis. Using this artificial death switch construct, Dong et al
were able to identify the minimum value for the apoptotic threshold. However, the
determination of the exact proportion of apoptotic cells needed for vessel disruption,
required the formulation of a mathematical model of the experimental system. In
the following sections, we present a brief introduction to this experimental setup,
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followed by model development and simulation results.
6.2 Experimental Setup
In (32), Dong et al generated HDMECs stably expressing the death switch, or
iCaspase-9 (HDMEC-iCaspase-9). These cells underwent apoptosis in vitro upon
exposure to the dimerizer drug AP20187. The drug was non toxic to untransduced
cells, so that empty vector control or parental HDMECs (HDMEC-LXSN) were left
unharmed upon application of AP20187. Next, capillary sprouts were engineered in
vitro with varying proportions (6:0, 5:1, 4:2, 3:3, 2:4, 1:5, 0:6) of HDMEC-iCaspase-
9, and empty vector control HDMECs. Application of the dimerizer drug to this
system induced apoptosis of a pre-determined cohort of ECs. Thus, it was possible
to determine the resistance of blood vessels to EC apoptosis, before a significant drop
in vessel density was observed. This experiment was then replicated in vivo. Human
blood vessels were generated in vivo, with the same proportions of HDMEC-iCaspase-
9 and HDMEC-LXSN, as in the in vitro case. Again, application of AP20187 induced
apoptosis of a known percentage of ECs causing blood vessels lined with these cells
to be disrupted. Hence, a range for the apoptotic requirement percentage in both in
vitro, and in vivo, was obtained.
6.2.1 In vitro Capillary Tube Assays
A total of 1.5×105 cells (in varying ratios of HDMEC-iCaspase-9 and empty vector
control) were cultured in 1.5 ml of type-I collagen, in the presence of 50 ng/ml VEGF.
Starting on day 4, and continuing to day 11, the cells were exposed to 0 (control) or
100 nM of AP20187. The number of capillary tubes were counted daily. A significant
decrease (p-value≤ 0.05) in the number of capillary tubes was observed, when at least
33.33% (HDMEC-iCaspase-9:HDMEC-LXSN = 2:4) of the HDMECs were killed. It
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Figure 6.2: Figure showing a schematic of the in vitro capillary sprouting assays described in (32).
Briefly, HDMEC-iCaspase-9 and empty vector control HDMECs were cultured in the
presence of 50 ng/ml VEGF. Starting on day 4, and continuing to day 11, the cells
were exposed to 0 (control) or 100 nM of the dimerizer drug AP20187. Capillaries lined
with HDMEC-iCaspase-9 were observed to regress. The number of capillary tubes were
counted at daily intervals.
was also observed that VEGF did not affect the ability of AP20187 to mediate cell
death. A schematic of these experiments is shown in Figure 6.2.
6.2.2 In vivo Model of Human Angiogenesis
The mouse experimental system used to generate human blood vessels in vivo
has already been described in Chapter V. Briefly, varying proportions of HDMEC-
iCaspase-9 and HDMEC-LXSN were seeded on PLLA biodegradable scaffolds, and
implanted subcutaneously in SCID mice. Eleven days post transplantation, 2 mg/kg
AP20187 was given daily for 3 days. Sprouts were counted on day 14, and once again
a significant decrease (p-value ≤ 0.05) in the number of capillary tubes was observed,
when at least 33.33% of the HDMECs were killed.
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6.3 Mathematical Model Development
Results from the in vitro capillary tube assays suggest that an initial ratio of
2:4 HDMEC-iCaspase-9:HDMEC-LXSN, which is equivalent to killing 33% of the
endothelial cells by day 8, leads to significant (p=0.002 (32)) reduction in vessel
density. However, the next experimental ratio tested here (1:5 HDMEC-iCaspase-
9:HDMEC-LXSN) results in a p-value of 0.495, which does not reflect a significant
reduction in vessel density. In order to further rigorously investigate the proportion
of endothelial cells that must be killed in order obtain a significant reduction in blood
vessel density, a mathematical model of the experimental procedure described above
is formulated. In the preceding chapter, we have already developed a model for
capillary tube formation in vitro, as well as tumor vascularization in vivo wherein,
we were able to capture the process of vessel formation from free HDMECs. This
modelling framework can easily be adapted to represent the experimental system
described above. The resulting model consists of a system of five differential equa-
tions describing the temporal changes in the two populations of endothelial cells -
HDMEC-LSXN (M1) and HDMEC-iCaspase-9 (M2) - the angiogenic factors VEGF
(A) and CXCL8 (L), and the capillary tubes (V ), coupled with a further five equa-
tions describing the binding dynamics of CXCL8 and VEGF to their endothelial cell
surface receptors.
6.3.1 Pre-treatment Equations
Prior to treatment, the endothelial cells are assumed to follow the following state-
ment of balance.
rate of change VEGF and CXCL8- VEGF- VEGF and CXCL8-
of HDMEC = dependent - dependent - dependent
density proliferation death vascular inclusion
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This translates to the following equations. Note that our terminology and notation
remains the same as in preceding chapters.
dM1
dt
= (µa φa + µl φl − (λm − δ φa)) M1
(




−α1 (α2 φa + α3 φl) M1
dM2
dt
= (µa φa + µl φl − (λm − δ φa)) M2
(




−α1 (α2 φa + α3 φl) M2
where,
φl = φl(Cl,M1,M2, V ) =
Cl
M1 + M2 + α1V
(6.3)
φa = φa(Da,M1,M2, V ) =
Da
M1 + M2 + α1V
(6.4)
Equations (6.1) and (6.2) give the rates of change of HDMEC-LXSN (M1) and
HDMEC-iCaspase9 (M2) densities, respectively. Both VEGF and CXCL8 stimu-
late HDMEC division and the proliferation rate depends on the functions φa and φl,
which represent amounts of these chemokines bound to cell surface receptors on the
HDMECs. The function φa is computed by writing down the biochemical reaction
diagram corresponding to dimeric binding of VEGF to its receptors on endothelial
cell surfaces (cf. Chapter IV, Da is the density of activated dimerized VEGFR2-
VEGF complexes). The law of mass action is applied to obtain the corresponding
differential equations for the various species involved. Finally, dividing the dimerized
receptor-ligand complex density by total number of endothelial cells gives the average
density of VEGF bound to cell surface receptors. The function φl is computed in a
similar way, except CXCL8 is assumed to undergo monomeric binding to its receptors
(cf. Chapter V, Cl is the density of activated CXCR1/2-CXCL8 complexes).
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Endothelial cell death incorporates the anti-apoptotic effect of the intracellular
protein Bcl-2, whose expression is up-regulated in presence of VEGF. As assumed
previously in Chapter V, since Bcl-2 is an intracellular protein, a separate equation
for it is not included; instead its effects are modelled using VEGF concentrations.
Natural cell death rate is given by λm, however in the presence of bound VEGF,
this is reduced by a factor δ. The HDMECs are assumed to grow logistically, as
the carrying capacity of this experimental environment is limited. As endothelial
cells grow in number, they begin to come together and arrange themselves into
microvessels. When this happens, they are no longer considered a part of the free
endothelial cell population as they have now become part of the microvasculature.
Thus, vascular inclusion of the HDMECs results in a decrease in the free endothelial
cell density, and a corresponding increase in the microvessel density.
dA
dt




Equation (6.5) gives the rate of change of free VEGF (A) for the in vivo experimental
system. Here a constant, background rate of VEGF production r3, (by mouse cells
or the implanted endothelial cells) is assumed. VEGF undergoes natural decay at a
rate λa, and is taken up by the endothelial cells, as per the uptake function f(.). A
precise form of f is given by equation (5.3) in Chapter V. Equation (6.6) gives the
rate of change of free VEGF for the in vitro experimental system, where the cells
are cultured in the presence of 50 ng/ml of VEGF. The cell surface receptors still
bind to free VEGF but because it is being replenished externally, it is assumed that
this uptake does not significantly change free VEGF concentrations. Thus the rate
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of change is taken to be zero.
dL
dt
= (βl + βa φa) (M1 + M2)− λl L− g(M1,M2, V )(6.7)
Equation (6.7) gives the rate of change of free CXCL8 (L). Endothelial cells natu-
rally synthesize it, which is represented in the equation by the parameter βl. The
production of CXCL8 is up regulated when Bcl-2 levels are elevated (in the presence
of bound VEGF), at a rate proportional to βa. CXCL8 is lost due to natural decay
at a rate λa and uptake by HDMECs as per the uptake function g(.). A precise form
of g is given by equation (5.11) in Chapter V.
dV
dt
= (α2 φa + α3 φl) (M1 + M2)− α4 (λm − δ φa) α1 V(6.8)
Equation (6.8) gives the rate of change of functional microvessel density (V ). The
vessels are produced by the HDMECs in the process of vascular inclusion. Both
VEGF and CXCL8 are strong chemoattractants for the HDMECs, so that they ag-
gregate to form microvessels at rates proportional to the amounts of these chemokines
bound to the endothelial cells, with rate constants α2 and α3. As the endothelial
cells lining vessels apoptose, the vessels become dysfunctional at a rate α4, which is




= (µa φa + µl φl − (λm − δ φa)) M1
(




−α1 (α2 φa + α3 φl) M1
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Treatment using the dimerizer drug AP20187 is given in vitro starting from day 4
of seeding the endothelial cells. Equation (6.9) gives the rate of change of HDMEC-
LXSN density post treatment. HDMEC-LXSN cells are left unharmed by AP20187,




= −χ1 M2 − α1 (α2 φa + α3 φl) M2(6.10)
Equation (6.10) gives the rate of change of HDMEC-iCaspase9 density post treat-
ment. The drug causes these cells to die at a rate χ1 that is determined by forcing
90% of these cells to die 4 days after treatment, as observed in the experiments.
Thus, the growth terms in equation (6.2) is replaced by a constant rate of death.
The rate of change of free VEGF concentration post treatment is not effected by
the addition of the dimerizer drug to the system, and is assumed to be the same as
that pre-treatment, given by equation (6.5) in the in vivo case, or equation (6.6) in
the in vitro case.
dL
dt
= (βl + βa φa) M1 − λl L− g(M1,M2, V )(6.11)
Equation (6.11) gives the rate of change of free CXCL8 concentration post treat-
ment. It is assumed that endothelial cells marked to die (HDMEC-iCaspase9) are
not able to synthesize CXCL8 any more. Thus equation (6.11) may be obtained




= (α2 φa + α3 φl) (M1 + M2)− α4 (λm − δ φa) α1 V − χ2 V(6.12)
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Equation (6.12) gives the rate of change of microvessel density post treatment. Since
the HDMEC-iCaspase9 lining the microvessels die under due to the action of the
drug, an additional term is included in the microvessel equation to incorporate the
resulting loss of functionality. AP20187 induced microvessel dysfunctional rate χ2
is proportional to χ1 times the number of HDMEC-iCaspase9 lining the vessels per
unit volume. It also depends on the proportion of iCaspase9 cells that were lining
the vessels when treatment began.
6.3.3 Parameter Estimation
Most of the model parameters have been already been estimated from existing
experimental literature and by fitting the model to the in vitro data of (97; 98).
This has been discussed in detail in section 5.3 of Chapter V. The remaining param-
eters, relating to the rates of vascular inclusion of HDMECs are estimated so that
microvessel densities best fit pre-treatment experimental data taken from (32).
Briefly, 1.5×105 HDMECs were seeded in a 1.5 ml layer of gelled type I collagen,
and grown in the presence of 50 n/ml VEGF. The number of capillary tubes were
counted at daily intervals. The pre-treatment model equations (6.1)- (6.8) are appli-
cable in this case. The two cell populations need not be distinguished between, since
we are considering pre-treatment data. In this case, the unknown parameters are
α1, the average number of cells per microvessel, α2 and α3, the VEGF and CXCL8
dependent microvessel formation rates, and α4, the rate at which a microvessel be-
comes dysfunctional when the cells lining it die. Note that, as mentioned previously,
we have simplified the vascular network into a series of equal length units, and ’a
microvessel’ is one segment between adjacent branching points that can fit into a
cube of side one millimeter. In this case, α1 may be estimated to have a value of
30 cells per vessel, considering average HDMEC sizes as reported in (74; 100; 126).
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The resultant fit for the remaining three parameters is shown in Figure 6.3. The
parameter values are listed in Table 6.1.
Figure 6.3: Fit to time-course data taken from in vitro capillary sprouting assays, with HDMECs
cultured in the presence of 50 ng/ml VEGF
Table 6.1: List of parameter values relating to microvessel formation rates
Parameter Value Units
α1 30.0 # HDMECs per Microvessel
α2 0.2577 # Microvessels per pg of Da per day
α3 0.6741 # Microvessels per pg of Cl per day
α4 0.24845 # Microvessels per HDMEC
For the post-treatment case, it is known that AP20187 induced HDMEC-iCaspase9
apoptosis level is 90% four days post treatment, which determines drug induced cell
death rate χ1 = 0.5756 per day.
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Figure 6.4: Mathematical modelling of the effect of endothelial cell apoptosis on angiogenesis.
A system of differential equations describing the two populations of endothelial cells
(HDMEC-iCaspase-9 and HDMEC-LSXN), angiogenic factors, and capillary tubes
was derived for evaluation of inaccessible HDMEC-iCaspase-9:HDMEC-LXSN ratios
in vitro. (A,B,D) Data from the in vitro control experiments in which cells were sup-
plemented with 50 ng/ml of VEGF alone (squares) are plotted together the best fit
of the mathematical model (red line) to this data. Post treatment experimental data
(triangles) is plotted along with fits of the mathematical model, obtained by varying
the rate of vessel dysfunction associated with HDMEC-iCaspase-9 cells (χ2) (blue line).
(C) The mathematical prediction of sprout number when a culture containing 19.39%
HDMEC-iCaspase-9 and 80.61% HDMEC-LXSN are exposed to 50 ng/ml VEGF + 100
nM AP20187 (blue line). The model predicts that at this critical percentage (corrected
to 17.45% to account for 90% effectiveness of drug) of apoptotic endothelial cells, there
is a significant decrease (p = 0.0498) in capillary sprouting in vitro.
6.4 Results
6.4.1 Apoptotic Requirement for Capillary Disruption In Vitro
Figures 6.4 shows microvessel counts from the in vitro experiments in which cells
were supplemented with 50 ng/ml of VEGF alone (squares). These are plotted to-
gether with the best fit of the mathematical model in the pre-treatment case (red
line). Using the post-treatment data (triangles), the rate of vessel dysfunction as-
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sociated with HDMEC-iCaspase-9 cells, χ2, is estimated from the experiments in
which varying ratios of HDMEC-iCaspase-9 cells are present. The resultant fits are
shown in Figures 6.4A,B,D (blue line). It should be noted that the only parameter
being varied to get these fits is χ2. The model can now be used to focus on the ex-
perimentally inaccessible ratios between 2:4 and 1:5 HDMEC-iCaspase-9:HDMEC-
LXSN in order to precisely determine the percentage of cells that must be killed so
that a significant reduction in vessel density is obtained. The model predicts that
starting with 19.39% HDMEC-iCaspase-9 and 80.61% HDMEC-LXSN cells leads to
a significant reduction in vessel density (p=0.0498) (Figure 6.4C, blue line). When
corrected for the fact that 90% of the HDMEC-iCaspase-9 cells are dead 4 days after
exposure to AP20187 in vitro, the critical percentage of apoptotic endothelial cells
required to mediate a significant decrease in capillary sprouting is 17.45%.
Further, we can use the mathematical model to investigate the efficacy of AP20187
therapy in vitro versus different VEGF concentrations. The percentage of apoptotic
cells is fixed at 17.45% - a level at which a significant reduction in vessel density
is predicted in the presence of 50 ng/ml VEGF. After 4 days of treatment with
AP20187, the model predicts an increase of 2.6% in the vessel density, if the cells are
cultured in the presence of 100 ng/ml VEGF, as opposed to 50 ng/ml VEGF. Like-
wise, a decrease of 91% is predicted in vessel density on the fourth day of treatment,
if the cells are cultured in the presence of 1 ng/ml VEGF. If no VEGF is added to the
system, the decrease in vessel density is 99.9%. Taken together, this data indicates
that the protective effect of VEGF on in vitro sprouting of endothelial cells is dose
dependent.
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6.4.2 Apoptotic Requirement for Blood Vessel Disruption In Vivo
This mathematical model can be modified to simulate the in vivo data, by adding
background VEGF production by the host. The VEGF production rate r3 in vivo is
obtained from control experiments in which no HDEMC-iCaspase9 cells were present.
This was achieved by fitting the vessel count 14 days post-implantation to the single
data point available. The in vivo experiments indicated that 15-30% of cells need to
be killed for a significant reduction in blood vessel density. Our mathematical model
predicts that starting with 74.08% HDMEC-LXSN and 24.92% HDMEC-iCaspase-9
will cause a significant reduction in vessel density (p=0.0498) (Figure 6.5A). When
adjusted for the percentage of HDMEC-iCaspase-9 cells that undergo apoptosis when
treated with AP20187, the critical percentage for achieving a significant decrease in
microvessel density in vivo comes to 22.43%.
We can also use the model to investigate the effect of anti-VEGF therapy on
the apoptotic requirement of endothelial cells. In modelling terms, we treat the
effect of anti-VEGF therapy to be a reduction in the bio-availability of VEGF to the
endothelial cells. This therapy is applied at the same time as AP20187, starting on
day 11, and is continued for four days. The model predicts that there is a significant
reduction in microvessel density for therapy with an efficacy level greater than 15%,
even when we begin with no HDMEC-iCaspase-9 cells. However, for therapy that
is 10% efficacious, the critical percentage for achieving a significant reduction in
capillary sprouting is predicted as 16.92%, and this increases to 19.73% for anti-
VEGF therapy which is only 5% efficacious (Figure 6.5B).
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6.5 Discussion
One of the hallmarks of tumors is their ability to induce sustained angiogenesis,
and their dependence on it (40; 49). Tumors ’turn on’ the angiogenic switch by the
release of angiogenic factors, of which the most commonly expressed is VEGF (49).
This has led to the development of a number of anti-angiogenic therapies, targeting
VEGF, or its receptors or the endothelial cells lining the newly formed blood ves-
sels themselves. Despite these differences in the target molecule, a feature common
to most of these therapies is the induction of endothelial cell apoptosis resulting in
disruption of the vasculature. Therefore, it is essential to improve our knowledge of
the mechanisms underlying the maintenance of blood vessels. One such experimen-
tal system aimed to fix the percentage of apoptotic cells required for blood vessel
regression, is described in (32). In this chapter, we have devised a mathematical
model representing these experiments in order to evaluate experimentally inaccessi-
ble percentages of apoptotic cells. This can be used to predict this threshold with
greater accuracy.
Experimental data suggested that between 16.67 - 33.33% cells need to be killed
in order to disrupt capillaries in vitro. Using our mathematical model, the exact
percentage was predicted to be 17.45% (Figure 6.4C). It is known that VEGF pro-
motes endothelial cell survival by up-regulating intra-cellular levels of Bcl-2 (59; 98).
However, the target of the dimerizer drug AP20187 used in the experiments to in-
duce cell death is caspase-9, which acts downstream of Bcl-2. Thus, VEGF was
unable to protect the cells against AP20187-induced apoptosis. Interestingly, the
model simulations predicted an increase in the threshold of apoptotic requirement
with increasing VEGF concentrations. This could be due to the fact that VEGF is
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a potent inducer of cell proliferation, and it is likely that this compensates to some
extent for the loss of cells due to apoptosis.
The model was then modified to simulate the experiments designed to fix the
apoptotic requirement of cells in vivo. A percentage of 22% was predicted using
the model (Figure 6.5A). Thus, the apoptotic requirement appears to be slightly
greater in vivo than that predicted in vitro. This could be due to the process of
vessel maturation that occurs in vivo, which would result in the stabilization of
the microvessels. The model was then used to investigate the effect of anti-VEGF
therapy on the apoptotic requirement of endothelial cells. As expected, it was found
that increasing levels of anti-VEGF therapy resulted in lowering of the apoptotic
requirement (Figure 6.5B). This is because the entire cell population is effected by
the anti-VEGF therapy, as opposed to only the caspase-induced cells. However, a
modelling assumption is that VEGF is the only angiogenic factor in the in vivo
system. In reality, there may be many others such as the FGFs, that would offset
the efficacy of anti-VEGF therapy to varying degrees.
Mathematical modelling such that described here can play an important role in the
determination of parameters relating to anti-angiogenic therapy regimes, as well as
aid in evaluation of current anti-vascular compounds under development. We began
with the model of angiogenesis developed in Chapter V, and were able to modify
it easily to simulate the in vitro and in vivo experiments of Dong et al, illustrating
it’s flexibility. Data from the in vivo simulations underscored the capability of blood
vessels to maintain their integrity even under significant loss of endothelial cells. This
provides a reference point for the preclinical testing of new anti-angiogenic drugs
aimed at inducing endothelial cell apoptosis. The results further showed that VEGF
did not prevent EC apoptosis and capillary tube disruption, induced by caspase-9
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activation. The lack of VEGF’s protective effect may reflect the fact that caspase-9
functions downstream from Bcl-2 in the cellular apoptotic pathway. This suggests
that EC apoptosis-inducing therapy may be a promising target for the development
of anti-angiogenic drugs. There is therefore, a need to study cell death pathways
in greater detail. In the next chapter, we develop a model of tumoral angiogenesis
that explicitly incorporates the intra-cellular apoptotic pathways mediated by the
Bcl-family of proteins. We also test the potential of targeting the Bcl-2 molecule as
a possible anti-vascular therapy.
In this chapter, we have demonstrated that it is possible to answer questions relat-
ing to the biology of vascular regression, which would otherwise have been difficult
or even impossible to do experimentally. Taken together, our results support the
concept that anti-angiogenic drugs that induce apoptosis of 17.45% or more cells in
vitro, have the best probability to have a significant anti-angiogenic effect in vivo.
Given the high financial as well as human costs of clinical trials, decisions in regards
to allowing for a new drug to be tested in patients, or not, are of paramount im-
portance. Here, we established a fairly straight-forward criterium - induction of at
least 22% apoptosis in vivo is capable of consistently resulting in a significant drop in
microvessel density. This parameter, together with other analyses of drug effectivity
in laboratory studies and mathematical modelling of response to treatment, might
be helpful to decide in favor or against clinical trial.
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Figure 6.5: Mathematical modelling of the effect of endothelial cell apoptosis on angiogenesis.
A system of differential equations describing the two populations of endothelial cells
(HDMEC-iCaspase-9 and HDMEC-LSXN), angiogenic factors, and capillary tubes was
derived for evaluation of inaccessible HDMEC-iCaspase-9:HDMEC-LXSN ratios in vivo.
(A) The single data point from the in vivo control experiments in which no HDMEC-
iCaspase-9 cells are present (square) is plotted together with the best fit of the math-
ematical model (dashed line) as well as the mathematical prediction of sprout number
when 24.92% of the cells are HDMEC-iCaspase-9 (solid line). The model predicts that
at this critical percentage (corrected to 22.43% to account for 90% effectiveness of drug)
of apoptotic endothelial cells, there is a significant decrease (p = 0.0498) in capillary
sprouting in vivo. (B) Apoptotic requirement of endothelial cells is plotted versus in-
creasing efficacy of anti-VEGF treatment that is applied continuously from day 11 for
four days, along with 100 nM of AP20187. The model predicts that for a level of therapy
at least 15% efficacious, a significant reduction in vessel density is obtained without the
presence of HDMEC-iCaspase-9. As the efficacy of anti-VEGF treatment is reduced
further, the critical percentage of apoptotic cells required increases to a maximum of
22.43% (in the case of no anti-VEGF being applied).
CHAPTER VII
Anti-Bcl-2 Therapy Inhibits Tumor Vascularization and
Retards Tumor Growth
7.1 Introduction
In Chapter V, we developed a model of intra-tumoral angiogenesis, which was
the first to connect the molecular events associated with VEGFR2 dimerization and
intra-cellular signaling with the temporal changes in endothelial cell proliferation,
migration and survival. We were able to use this model to predict the effect of
decreasing the bio-availability of VEGF, CXCL8 and Bcl-2 on tumor growth and
vascular structure. Our preliminary results suggested that Bcl-2 is the most promis-
ing target for anti-angiogenic therapies along the VEGF pathway of interest. These
results also led to the hypotheses that anti-Bcl-2 therapies applied at early and late
stages of tumor growth will significantly affect, with a dose-dependent threshold,
both, the time course of tumor development, as well as the maximum tumor cell and
blood vessel densities. In this chapter, we will test this hypothesis by explicitly mod-
elling the cellular response to the administration of specific anti-angiogenic therapies
targeted against the Bcl-2 molecule at different stages of tumor development.
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7.1.1 Bcl Family of Proteins
The Bcl family of proteins have been identified as crucial mediators of apoptosis,
a form of cell death in which a programmed sequence of events leads to the disin-
tegration of cells without releasing harmful substances into the surrounding tissue.
There are anti-apoptotic Bcl proteins including Bcl-2 and Bcl-XL, as well as their
pro-apoptotic counterparts Bax, Bad, Bak, and Bid. These proteins are constitu-
tively expressed within cells and it is the interaction between these molecules that
determines cellular response to apoptotic signals such as intra-cellular damage and
deprivation of or exposure to cytokines and growth factors (3; 123; 154). Bcl proteins
all differ slightly in size and intra-cellular location. Bcl-2 is a 26-kDa protein (122),
while Bcl-XL is reported to be slightly smaller (14). They are located mainly in
the nuclear envelope, parts of the endoplasmic reticulum, and outer mitochondrial
membrane (122; 129). Bax is a 21-kDa protein (88), and is localized to the outer
mitochondrial membrane (129). The 18.4-kDa protein Bad can be found on the
mitochondrial outer membrane, as well as the cytoplasm (158), while the 23.4-kDa
protein Bak is a single-pass membrane protein (158). Bid is a 22-kDa protein and
resides in the cytoplasm (158).
Apoptosis in cells is brought about by the activation of intra-cellular cysteine
proteases called caspases (3). This occurs due to the presence of cytochrome c in
the cell cytoplasm, which together with Apaf1 activates caspase 9. This in turn
activates downstream effector caspases like caspase 3, which induce cell death (2).
The Bcl family of proteins helps regulate this process by controlling the release of
cytochrome c, typically from the mitochondrial outer membrane. Broadly speaking,
the pro-apoptotic members of the Bcl family may be divided into two sub-families.
Members of the Bax-like sub-family include Bax and Bak, and are very similar to
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Figure 7.1: (A) Ribbons depiction of the average minimized structure for Bcl-2 (113). (B) A Rib-
bons depiction of the averaged, minimized NMR structure of the Bcl-XL-Bad complex.
The BH1, BH2, and BH3 domains of Bcl-xL are colored yellow, red, and green, respec-
tively. The Bad peptide is shown in purple (114).
Bcl-2 in sequence. The BH3-only proteins including Bad, Bid, and Bak are sequen-
tially unrelated to any Bcl family proteins, apart from containing a BH3 binding
domain (2). Members of the BH3-only sub-family bind to BH3 binding pockets that
form on the anti-apoptotic proteins like Bcl-2 and Bcl-XL, preventing them from
inhibiting activation of members of the Bax-like sub-family. It is believed that this
results in the release of cytochrome c into the cell cytoplasm (154; 2). Thus, the
anti-apoptotic function of Bcl-2 and Bcl-XL is at least partly due to their ability
to heterodimerize with Bax, Bad, Bak and Bid, inhibiting their pro-apoptotic func-
tion (154). The various pathways that Bcl-2 and its family are involved in, are shown
in Figure 7.2.
The Bcl family proteins have been shown to play a key role in tumor development
and progression. Tumor cells in several types of cancers such as prostrate, breast,
colorectal, head and neck cancers, and melanoma are known to over-express either
Bcl-2, or Bcl-XL, or both (154). In addition to promoting cell survival, this could
provide cancer cells with some measure of protection from chemo- and radiotherapy,
especially if these therapies directly or indirectly induce apoptosis (154). Further,
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Figure 7.2: Schematic diagram showing intra-cellular functions of the Bcl family of proteins.
VEGF induces Bcl-2 expression via the VEGFR-2, PI3K/Akt signalling pathway. Pro-
apoptotic proteins such as Bad and Bid heterodimerize with Bcl-2/Bcl-XL thus regulat-
ing their ability to inhibit activation of other pro-apoptotic proteins like Bax. Activation
of Bax results in the release of cytochrome c from the mitochondrial outer membrane,
which together with Apaf1, causes caspase activation. This induces cell apoptosis. Bcl-
2 also acts as a pro-angiogenic signalling molecule, by activating the NF-κB signaling
pathway, inducing expression of the pro-angiogenic chemokine, CXCL8.
Nör et al have demonstrated that in the case of some head and neck cancers, can-
cer cells are able to extend this protective effect to the endothelial cells lining the
blood vessels in the vicinity of the tumor by up-regulating levels of Bcl-2 within
these cells, thus enhancing intra-tumoral angiogenesis (97; 98; 99). This makes Bcl-2
and Bcl-XL attractive targets for the development of anti-cancer drugs. In fact, sev-
eral forms of therapy targeting Bcl-2/Bcl-XL are under development. These include
antisense bcl-2 and bcl-XL oligonucleotides that work by inhibiting Bcl-2/Bcl-XL ex-
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pression levels, single chain antibodies and peptides that bind to the Bcl-2 molecule
inhibiting it’s functions, and an anti-bcl-2 ribozyme, that works by degrading bcl-2
mRNA (154). However, Wang et al (154) propose that nonpeptidic, cell-permeable
small molecule inhibitors of Bcl-2 and Bcl-XL may have greater potential as anti-
cancer drugs than the therapies mentioned above for a variety of reasons including
better bio-availability, stability, low cost and the ability to penetrate the blood-brain
barrier of the central nervous system. These inhibitor molecules act as antagonists of
Bcl-2/Bcl-XL by binding to their BH3 binding pocket, thus preventing pro-apoptotic
members such as Bax, Bad, Bak from binding to Bcl-2/Bcl-XL.
7.2 Development of a Multiscale Model of Tumor Vascularization, In-
corporating Interactions of the Bcl-family of Proteins
With all of these new possibilities, a critical challenge in experimental therapeu-
tics for cancer is to decide which drugs are the best candidates for clinical trials.
Mathematical modelling, such as that developed here can help to determine which
anti-cancer drugs have the most potential for therapeutic benefit. In this chapter,
we concentrate on the anti-angiogenic potential of therapies targeted at Bcl-2, in the
form of small molecule inhibitors such as BL193 (59; 160) and TW37 (160); both
of which have been shown to cause a marked decrease in angiogenic potential of en-
dothelial cells in vitro. Since BL193 has similar inhibition constants for both Bcl-2
and Bcl-XL, we focus on this as our drug of choice. Our model is based on the exper-
iments of Nör et al (97; 98; 99). A brief overview of these experiments is included in
Chapter V, where we have already developed and presented a mathematical model
describing them. It is our goal to extend this model to explicitly incorporate the pro-
apoptotic as well as anti-apoptotic members of the Bcl family, so that we can better
understand the implications and effects of therapy targeted against these proteins.
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In particular, our preliminary model could not address the mechanism of action of
BL193 and could not relate its binding efficiency to its therapeutic efficacy. The
model presented here will be able to study both of these important issues as well as
predict tumor response with increased accuracy.
7.2.1 Model Foundation
A biochemically motivated, ordinary differential equation model is developed to
capture the essential intra-cellular dynamics of the Bcl family of proteins governing
programmed cell death. The mathematical model has as its foundation specific
biological assumptions that are based on the accepted knowledge of the function
of and cellular response to various pro and anti-apoptotic proteins. Specifically,
the intra-cellular concentration, in femtograms per cell, of a single anti-apoptotic
protein Bcl-2, and a single pro-apoptotic representative of the Bcl family, Bad, will
be tracked in time. Using one representative of the pro and anti apoptotic family
members allows us to avoid involving a number of intra-cellular binding parameters
for which there is no experimental data. The particular choice of the representative
proteins was made for the following reasons: (1) BL193 has similar binding affinities
to both of the anti-apoptotic proteins, Bcl-2 and Bcl-XL, on which it has been shown
to act (160), (2) it is intra-cellular levels of Bcl-2 that are up-regulated in response
to a VEGF stimulus (98) and (3) Bad binds to Bcl-2 with a higher affinity than the
other Bcl proteins (154). It also acts upstream of the Bax-like members of the Bcl
family, making it the protein of choice to represent the pro-apoptotic members of
the Bcl family. The intra-cellular concentration of Bcl-2 will be represented by the
letter B, while that of Bad will be represented by the letter X.
It is known that Bcl-2 and Bad interact with each other within the endothelial
cell to form heterodimers. This balance between pro- and anti-apoptotic proteins
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regulates cell death rate. In an endothelial cell, unbound Bcl-2, unbound Bad and
Bcl-2-Bad dimers will be present at their respective constitutive levels. We assume
that the amount of unbound protein Bad determines the cell death rate, since it is the
pro-apoptotic members of the Bcl family that are directly responsible for regulating
caspase activation within the cells (2). It has experimentally been shown that Bcl-2
induces the expression of CXCL8 in endothelial cells through its ability to activate the
NF-κB signaling pathway (59). Therefore, we assume that the amount of unbound
Bcl-2 is responsible for CXCL8 production by the endothelial cells. At background
levels of Bcl-2 and Bad, the cell death rate is taken to be 0.12 per day (74) and
HDMEC CXCL8 production rate is fit to experiments in (98). The VEGF-Bcl-2-
CXCL8 pathway discovered in the experiments of Nör et al (97; 98) is explicitly
included in this model by allowing for the up-regulation of Bcl-2 in the presence of
VEGF. In turn, this up-regulates production of CXCL8 by the endothelial cell. This
is due to increase in free Bcl-2 levels within the cell. High levels of Bcl-2 would
mean low levels of Bad in its unbound state since it would be taken up as Bcl-2-Bad
dimers. This would result in a decrease in cell death rate. Thus, we are able to
capture the essential principles of cell death regulation by the Bcl family proteins, as
well as account for the pro-survival, and pro-angiogenic effect of Bcl-2 in particular.
The complete derivation of equations is discussed in the sections that follow.
Note that throughout this chapter, we adopt the following notation for the various
species being modelled.
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M = Human dermal microvascular endothelial cell density
A = Unbound VEGF concentration
Ra = VEGFR-2 density
Ca = VEGF - VEGFR-2 complex density
Da = VEGF- VEGFR-2 - VEGF complex density
L = Unbound CXCL8 concentration
Rl = CXCL8 receptor density
Cl = CXCL8-receptor complex density
V = Microvessel density
B = Intracellular unbound Bcl-2 concentration
X = Intracellular unbound Bad concentration
Cbx = Intracellular Bcl-2 - Bad complex concentration
I = Intracellular unbound BL193 concentration per cell
Cbi = Intracellular Bcl-2 - BL193 complex concentration
N = Tumor cell density
7.2.2 Modelling Bcl family protein interactions within a single cell
We begin our model development at the single cell level, so that we may include
the role of the Bcl family proteins in cell apoptosis explicitly. Once we are able to
describe the relevant apoptotic pathways within a single cell, we can scale the model
up to the population level, and thus obtain a better quantitative understanding of the
role of these intra-cellular molecular pathways in determining vascular development
in tumors.
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Bcl-2 - Bad and Bcl-2- BL193 interactions
Following the general approach of Levine et al (75), the law of mass action is
used to translate the reaction diagram in Figure 7.3, which describes the hetero-
dimerization of Bcl-2 and Bad as well as the inhibition of Bcl-2 by BL193, into a
system of differential equations (7.1) - (7.5) that govern the temporal changes in the
intra-cellular concentrations of these proteins. Specifically, the upper case letters in
equations (7.1) - (7.5) represent chemical concentrations, measured in femtograms
per cell. Then, B is unbound Bcl-2 protein per cell, X is unbound Bad protein per
cell, Cbx is the quantity per cell of the heterodimer formed when one molecule of
Bcl-2 binds to one molecule of Bad, I is the amount of small molecule inhibitor or
BL193 per cell, and Cbi is quantity per cell of the complex formed when one molecule
of Bcl-2 binds to one molecule of BL193.
Figure 7.3: Reaction diagram showing the heterodimerization reaction between the Bcl-2 (b) and
Bad (x) molecules, and the inhibition of Bcl-2 by a small molecule inhibitor, BL193 (i).
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It is assumed that upon application of therapy, the inhibitor molecules diffuse
into the endothelial cell across the cell membrane. This is consistent with the design
strategy behind these small molecule inhibitors (BL193 has a molecular weight of
only 0.5 kDa (160)). Thus, there is a source term in equation (7.4), where the rate
of entry of the inhibitor molecules into an endothelial cell is proportional to the
difference of extracellular and intra-cellular BL193 concentrations. The extracellular
concentration, I0, of BL193 in the local environment of a cell is a parameter that
varies as the dosage level of therapy changes, and is fit to match such experiments.
The constant Di is a measure of cell wall permeability to BL193, and has units of
1/day. We can write the rate Di as −(ln 1/2)/t1/2, where t1/2 is the amount of time
it takes half the drug, external to a cell, to be internalized. The inhibition constant




f , is 320 nM (160). The effect on
intra-cellular Bcl-2 and Bad densities of the addition of varying amounts of BL193
can be seen from Figure 7.4A. As BL193 level within a cell increases from 0 to 0.9
femtograms, free Bcl-2 concentration is seen to decrease by 79%, causing free Bad
concentration to increase by 13%, over their respective constitutive levels.
dB
dt
= −kbf B X + kbr Cbx − kif B I + kir Cbi(7.1)
dX
dt
= −kbf B X + kbr Cbx(7.2)
dCbx
dt
= kbf B X − kbr Cbx(7.3)
dI
dt
= −kif B I + kir Cbi + Di (I0 − I)(7.4)
dCbi
dt
= kif B I − kir Cbi(7.5)
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Figure 7.4: Intra-cellular Bcl-2 and Bad concentrations, and their effect on cell death rate and
CXCL8 production rate. (A), Bcl-2 levels within a single cell are seen to decline, as
increasing amounts of BL193 therapy are administered, causing a corresponding increase
in Bad levels. (B), Upon application of 50 ng/ml VEGF, Bcl-2 level within a cell is seen
to increase 3.1 fold, causing a 22% decrease in the level of Bad. As VEGF is consumed,
Bcl-2 and Bad protein levels return to their constitutive state. (C), CXCL8 production
rate by HDMECs increases to a maximum, as intra-cellular Bcl-2 levels increase. At
the constitutive level of Bcl-2, CXCL8 production rate is fixed at 0.0358 pg of CXCL8
per HDMEC per day (see parameter estimation, Chapter V). The model allows for
CXCL8 production independent of Bcl-2 up-regulation as well. (D), HDMEC death
rate is taken to increase exponentially with the amount of intra-cellular Bad protein.
At the constitutive level of Bad, cell death rate is taken to be 0.12 per day (73).
Modelling the effect of VEGF on Bcl-2
Extracellular concentrations of cytokines and growth factors influence intracellular
concentrations of the Bcl family proteins. In order to capture the effect of VEGF on
Bcl-2 and Bad levels within each cell, we postulate that the amount of Bcl-2 produced
is directly proportional to the number of active VEGF-receptor dimer complexes per
cell. A corresponding source term for Bcl-2 may be included in Equation (7.1), which
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changes to equation (7.6) given below.
dB
dt




Here, φa is the density of active VEGF-receptor dimer complexes in pg per cell.
In the presence of 50 ng per ml VEGF, it is observed that Bcl-2 is up-regulated
3.1 fold (98). This is used to fix the constant βa, which determines the level of
up-regulation of Bcl-2 by VEGF. In Figure 7.4B, levels of Bcl-2 and Bad within a
single cell are plotted versus time. An external dose of 50 ng/ml VEGF is given
after 1 day, and lasts for 1 day. It can be observed that unbound Bcl-2 density
increases by 3.1-fold as VEGF is taken up by the cell. Correspondingly, unbound
Bad density decreases. As the VEGF is consumed, the amounts of Bcl-2 and Bad
proteins eventually fall back to constitutive levels.
The VEGF-dependent CXCL8 production rate of HDMECs used in equation (5.11),
in Chapter V, can now be replaced with a rate, denoted by βl, that is dependent
on intracellular Bcl-2 concentration, B. The functional form of βl(B) is taken as
follows:
βl(B) = βm + ap (1− e−bp B)(7.7)
The CXCL8 production rate by HDMECs is assumed to increase to a maximum
level, as intra-cellular Bcl-2 concentration increases, under the effect of VEGF. We
also allow for the possibility that CXCL8 could be produced by endothelial cells
independent of Bcl-2. Thus, if intra-cellular Bcl-2 levels fall to zero, there is still a
constant background rate of CXCL8 production, namely βm. Figure 7.4C shows a
graph of the CXCL8 production rate. We can see that as intra-cellular Bcl-2 levels
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increase, which may be in response to the presence of VEGF, the production rate of
CXCL8 also increases.
7.2.3 Modelling programmed cell death regulation at the population level
Temporal changes in Bcl-2 concentration, within a single cell, will now be ex-
plicitly incorporated into the population level model of tumor growth and sustained
angiogenesis described in Chapter V. To accomplish this, the VEGF-dependent death
rate used in equation (5.19), in Chapter V, is replaced with a rate, denoted by λm,
that is dependent on intracellular Bad concentration, X. In this way, the behavior
predicted by the single cell model described in the previous section is used to deter-
mine the response of a population of cells to their microenviroment. The functional
form of λm is taken as follows:
λm(X) = ad e
bd X(7.8)
In the absence of experiments designed to determine the precise functional depen-
dence of cell death on pro-apoptotic members of the Bcl family, we choose an expo-
nential form of the death rate. This reflects the fact that cells are highly sensitive
to pro-apoptotic signals such as intra-cellular Bad levels, which are normally tightly
controlled and balanced by anti-apoptotic proteins like Bcl-2. There is some indirect
experimental justification for this, which can be seen from a comparison of the model
predictions to in vitro therapy results, presented in the next section. Figure 7.4D
shows a graph of HDMEC death rate as a function of its intra-cellular environment.
The graph also gives insight into the effect of extracellular events on the fate of the
cell. For instance, if as a result of anti Bcl-2 therapy, 0.5 femtograms of BL193 are
incorporated by an endothelial cell, then free Bcl-2 level within the cell falls by 66%,
136
and free Bad level increases by 11 %, over their respective constitutive values (Fig-
ure 7.4A). This causes an increase in cell death rate from 0.12 per day to 0.37 per
day.
We have thus developed a truly multi-scale model of intra-tumoral angiogenesis;
providing greater insight into vascular development and tumor growth dynamics.
The complete model equations are listed in Appendix C.
7.3 Parameter Estimation
Most of the parameters in the model have already been determined in Chap-
ter V. However, the addition of equations governing the rates of change of Bcl-2,
Bad, and BL193 introduces new parameters relating to these rates, and the effect of
these molecules on cellular behavior such as CXCL8 production and death rates.The
estimation of these parameters is described in greater detail below.
7.3.1 Experimental conditions
In a series of in vitro capillary sprouting assays described in (97), 3× 105 human
dermal microvascular endothelial cells (HDMECs) were seeded with 1.5 ml collagen
(type I), and treated with 50 pg/mm3 VEGF. The total (free + differentiated) num-
ber of HDMECs were counted every day. We can reduce the full model system to


















= −ηl1 klf LRl + ηl2 klr Cl − λl L + βl(B) M(7.10)
dRl
dt
= −klf LRl + ηl3 klr Cl + ηl3 klp Cl(7.11)
+Rlt Prod(M)−
Rl






f LRl − klr Cl − klp Cl(7.12)
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= −2 ηa1 kaf1 ARa + ηa2 kar1 Ca − λa A + sa(t)(7.13)
dRa
dt
= −2 kaf1 ARa + ηa3 kar1 Ca − kaf2 Ca Ra + 2 ηa4 kar2 Da + 2 ηv4 kap Da(7.14)
+Rat Prod(M)−
Ra






= −2 ηa5 kaf1 ARa + kar1 Ca − ηa5 kaf2 Ca Ra + 2 ηa6 kar2 Da(7.15)
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Death(M) = λm(X) M(7.21)
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The function sa(t) = da (e
−((t−2)2)/.01 + e−((t−4)
2)/.01), corresponds to the dosage of
VEGF given externally, around day 2, and day 4. The parameter da is fixed by
ensuring that the area under sa equals the total amount of chemokine administered.
The initial condition for VEGF is also set at 50 pg per mm3, to reflect the first dose.
It is known that at constitutive intracellular Bad concentration, the death rate of
HDMECs is 0.12 per day (74). Further, in the presence of 50 ng per ml VEGF, it is
observed that Bcl-2 is up-regulated 3.1 fold (98). Consequently the level of Bad falls
by a factor of 0.77 (Figure 7.4B) . We assume a very low death rate (0.005 per day,
for example) corresponding to this low level of Bad. From these two observations, the
constants ad and bd may be fixed. Next, a relation between the constants βm, ap and
bp may be found by observing that at constitutive Bcl-2 levels, the production rate
of CXCL8 is 0.0358 pg of CXCL8 per HDMEC per day (as estimated in Chapter V).
βa is a constant that determines the level of Bcl-2 up-regulation by activated VEGF-
receptor complexes on a cell surface. Its value may be fixed since we know that
50 ng/ml of VEGF up-regulates intracellular Bcl-2 amounts by a factor of 3.1 (98).
A list of parameter values relating to VEGF - VEGFR2 binding dynamics available
from existing literature are given in Table 4.1, and Section 4.3.2 in Chapter IV, while
those relating to Bcl-2 - Bad binding dynamics are given in Table 7.1.
Table 7.1: List of parameter values relating to Bcl-2 and Bad interactions
Parameter Value Units Source
kbf 4 per Bad concentration per day
4
kbr 8.832 per day (154)
ηb1 0.5856 fg Bcl-2 per fg Cbx (122), (158)
ηb2 0.4144 fg Bad per fg Cbx (122), (158)
ηb3 0.7077 fg Bad per fg Bcl-2 (122), (158)
ηb4 1.7077 fg Cbx per fg Bcl-2 (122), (158)
βa 40.0 fg Bcl-2 per pg of Da (98)
4In the absence of experimental data, it is assumed that forward rates of reaction for Bcl-2 binding to Bad are
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Figure 7.5: Fits to experimental data taken from (95), with cells cultured in the presence of 50
ng/ml VEGF
Thus, the unknown parameters/functions are µa (VEGF dependent HDMEC pro-
liferation rate), ap and bp (governing the rate of CXCL8 production by HDMECs).
These are determined by fits in the least squares sense to experimental data pre-
sented in (97). The resultant fit is shown in Figure 7.5. The parameter values thus
obtained are listed in Table 7.2.
Table 7.2: List of parameter values relating to the effect of VEGF on HDMECs
Parameter Value Units
µa 12.8810 HDMECs per pg of Da per day
ad 3.878× 10−6 5 per day
bd 1.7329 5 per Bad concentration
βm 8.1139×10−4 6 pg of CXCL8 per HDMEC per day
ap 6.9620×10−4 6 pg of CXCL8 per HDMEC per day
bp 1.6185 6 per Bcl-2 concentration
about the same order of magnitude as CXCL8 binding to its receptors, or VEGF binding to its receptors.
5Note that ad and bd which determine HDMEC death rate were fixed prior to running the curve fitting algorithm.
6Note that we had derived a relation between the parameters βm, ap and bp, so that effectively only two of these
was an unknown while running the curve fitting algorithm.
140
7.3.2 Anti-Bcl-2 Therapy in the Form of a Small Molecule Inhibitor BL193
To incorporate the effect of anti Bcl-2 therapy in the form of the small molecule
inhibitor BL193, we include a further two equations in our model above represent-
ing intracellular concentrations of BL193, and Bcl-2 - BL193 complex The revised
equations for Bcl-2, BL193 and Bcl-2 - BL193 complex are given below.
dB
dt















f B I − kir Cbi(7.24)
A source term is included in the equation for intracellular BL193 concentration.
Briefly, we assume that BL193 is a small enough molecule (it has a molecular weight
of 0.5 kDa (160)) to permeate through the cell wall, and that the rate of change of
intracellular BL193 is proportional to the difference of extracellular and intracellular
BL193 concentrations. The constant Di is a measure of cell wall permeability to
BL193. The extracellular concentration I0 of BL193 in the local environment of a
cell is a parameter that varies as the dosage level of therapy changes. In the absence
of experimental data, we assume that it takes about 4-5 hours for the concentration of
BL193 within a cell to equal half that in its immediate environment. The parameter
values available from existing literature are given in Table 7.3. kiD is the inhibition




A series of numerical experiments using the model described in the previous sec-
tions are carried out to simulate both, microvessel formation in vitro, as well as
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Table 7.3: List of parameter values relating to Bcl-2 and BL193 interactions
Parameter Value Units Source
kiD 64 fg BL193 per cell (160)
ηi1 0.9811 fg Bcl-2 per fg Cbi (122), (160)
ηi2 0.0189 fg BL193 per fg Cbi (122), (160)
ηi3 0.0192 fg Bcl-2 per fg Bcl-2 (122), (160)
ηi4 1.0192 fg Cbi per fg Bcl-2 (122), (160)
tumor induced angiogenesis in vivo. To date, the effect of the small molecule in-
hibitor BL193 of Bcl-2, on sprout formation, has only been tested experimentally in
vitro (59; 160). Therefore, we first validate our model by presenting a comparison of
model simulations to these in vitro experiments. This is followed by in vivo simula-
tions designed to predict the effects of the administration of BL193 on intra-tumoral
angiogenesis. The dependence of drug efficacy on its 50% inhibition constant of Bcl-
2, and on the permeability of the endothelial cell wall to the drug are studied in
particular. These are both key factors in drug design strategy. Therefore the results
of our simulations may be used to guide in vivo experimentation.
7.4.1 In Vitro Therapy Results Provide Model Validation
In a series of in vitro experiments described in (59), capillary sprouting assays
were carried out on HDMECs. The endothelial cells were exposed to 50 ng per mL
VEGF for 5 days and then to 50 ng/mL VEGF in the presence of 0 to 5 µmol
per L BL193 thereafter, and the number of sprouts counted at daily intervals. To
represent this experimental system, our model of intra-tumoral angiogenesis needs
to be modified slightly by removing the tumor cell equation, and keeping free VEGF
concentrations fixed at 50 ng/ml. The resulting system of equations is listed in
Appendix B. The values of all parameters barring the amount of drug administered
I0, were estimated prior to simulation of treatment strategies, and these values were
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kept constant thereafter. This allows us to validate our model by direct comparison
of model predictions of treatment by BL193, with experimental observations.
Numerical and experimental observations are compared in Figures 7.6A, C and
E, where the dosage of BL193 administered starting from day 5 increases from 0.05
µM, to 0.5 µM, and finally to 5 µM. The model predictions of microvessel densities
are seen to match the experimental observations well, thus validating our model. It
should be noted that at this final concentration of BL193, the cells simply die from
too much chemical within them, rather than from a disruption in the Bcl-2 regulated
anti-apoptotic pathway. The model does not account for such a possibility, and the
last data point in Figure 7.6E therefore does not match in vitro observations. The
effect of therapy on intracellular protein levels can be seen in Figures 7.6B, D, and E
which plot the amounts of Bcl-2, Bad and BL193 per cell, corresponding to therapy
levels of 0.05 µM, 0.5 µM, and 5 µM respectively, of BL193.
7.4.2 BL193 Therapy is Highly Effective in Treating Early Stage Tumors
Having validated our model by comparison to in vitro experimental results, we
can now perform a series of numerical simulations to investigate the effect of BL193
therapy on in vivo tumor growth dynamics when applied at an early stage of tumor
development.
First, a series of numerical simulations are performed to investigate the effect
of therapy on tumor growth dynamics when applied at an early stage of tumor
development. Prior to treatment, with parameters at their baseline values, the tumor
cell density reaches it’s maximum level (8.669 × 103 cells per mm3) about 28 days
after implantation (Figure 7.7A). The first blood-bearing vessels are seen 5 days after
implantation, reaching their steady state of about 53 vessels per mm3, 19 days later
(Figure 7.7B). When a dose of 0.05 µM of BL193 is administered, it takes about a
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week longer for the vasculature to fully develop, and the tumor cell density to reach
its maximal value, when compared to the no therapy case. If the dosage is increased
to 0.5 µM, the delay in vascular development increases by 16 days, while the tumor
cells take 18 days longer to reach their steady state. A dosage level of 5 µM BL193
appears to be enough to cause the tumor to regress (Figure 7.7A,B). Thus, based on
these numerical predictions, anti-angiogenic therapies directed at Bcl-2, such as the
use of small molecule inhibitors of Bcl-2, appear to be highly efficacious, especially
when administered to an early stage tumor.
Next, we investigate the effect of application of BL193 to a tumor that has been
allowed to reach maximal tumor cell and microvessel densities (Figure 7.7C,D). Ther-
apy is applied continuously from day 60 of implantation. The model predicts that at
a dosage level of 5 µM BL193, the vessel density is seen to decrease (Figure 7.7D),
leading to a corresponding decrease in tumor cell density (Figure 7.7C). However, the
tumor cells appear to compensate for this loss of blood supply by increasing VEGF
production. The vessel density soon returns to its pre-treatment level, and the tumor
recovers rapidly. In fact, we need to increase the dosage of BL193 to approximately
24.5 mM to induce tumor regression. In this case, the microvessel density is observed
to fall to a level that is too low for the tumor to recover from as a result of anti-Bcl-2
therapy (Figure 7.7D).
7.4.3 Sensitivity analysis on drug design parameters
There are two important considerations behind the design strategy of small molecule
inhibitors of Bcl-2 such as BL193. Firstly, to maximize the inhibition of Bcl-2 by the
molecule. Secondly, to maximize the cell-permeability of the molecule. We therefore
carry out a sensitivity analysis on the inhibition constant KDi of BL193, and the
rate of diffusion Di of BL193 across the cell wall. In all the simulations carried out
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here, the drug is administered to a late stage tumor, and the least amount of drug
required to induce tumor regression is observed. Numerical simulations predict that
decreasing KDi, decreases exponentially the amount of drug required to effect a cure
(Figure 7.8A). For instance, the required dosage of an inhibitor with a KDi 25%
lower than that of BL193 is 0.52 mM, while that of an inhibitor with a KDi 50%
lower than that of BL193 is 11.04 µM. The required dosage for BL193 is 27.26 mM.
Likewise, increasing cell-permeability of BL193, i.e. increasing the rate of diffusion
of BL193 across the cell wall reduces the level of therapy required (Figure 7.8B).
A 10-fold increase in Di reduces the minimum drug dosage needed for a cure by a
factor of 53%, but any increase in Di beyond this does not significantly affect this
dosage further.
7.5 Discussion
A deeper understanding of the cellular and molecular events that govern tumor-
induced blood vessel growth is crucial to the development of anti-cancer therapies
targeted at angiogenesis. Therefore, it has been the focus of intensive research. Sev-
eral experimental models have been developed to study it. One such experimental
model investigated the importance of the up-regulation of Bcl-2 by VEGF in sus-
tained intra-tumoral angiogenesis (97; 98), and the effect of blocking this by means
of a small molecule inhibitor BL193 of Bcl-2 (59). In Chapter V, we presented a
mathematical model describing this experimental setup, at an extracellular and tis-
sue level. Here, we incorporated the intra-cellular dynamics of the Bcl family of
proteins in our existing model. This enabled us to quantify in a more definitive way,
the role Bcl-2 plays in intra-tumoral angiogenesis, and to assess its potential as a
target for anti-angiogenic therapy. By building a model specific to this experimental
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system, we were able to validate it by direct comparison with experimental results.
The model was then used to simulate the application of therapy in vivo, thereby
highlighting its usefulness as a guiding tool in the development of anti-angiogenic
drugs designed to inhibit the function of Bcl-2.
Numerical simulations of the full model provide valuable insight into the growth
dynamics of tumors and their response to the application of BL193 therapy. The
model was first calibrated versus control in vitro capillary sprouting assays. It was
found to be in good agreement with experimental observations taken after the appli-
cation of BL193. The model was then used to predict the effect of therapy applied
at various stages of tumor growth in vivo. Numerical results indicated that even
low levels of BL193 administered to an early stage tumor, induced significant delays
in tumor and vascular development. In fact, 5µM Bl193 was sufficient to cause the
tumor to regress. This could be due to the fact that if the vasculature has not had
a chance to develop in a tumor, then administering anti Bcl-2 therapy has the effect
of preventing further vascular development, by inducing cell death. However, in a
simulation carried out to test this drug on a fully developed tumor, we found that
the amount of therapy required to effect a cure increased by 3-4 orders of magni-
tude. It was observed that below a certain threshold, anti Bcl-2 therapy elicited little
response from the tumor, but as therapy was increased beyond this threshold, the
tumor and vascular development were arrested at much lower levels. However, it is
possible that this threshold corresponds to an amount of therapy that is toxic for
the host, and thus not administrable in practise.
These results accentuated the importance of timely detection and treatment of
tumors, and indicated that a single point of attack at a fully developed tumor may
be insufficient in order to effect a cure. Finally, numerical experiments were run to
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provide an insight into drug design strategies aimed at improving the effectiveness
of the small molecule inhibitor therapy, especially in late stage tumors. A small
molecule that was only 25% more efficient than BL193 in inhibiting Bcl-2, reduced
the required therapy level by as much as 97%. Therefore, even a moderately bet-
ter inhibitor of Bcl-2 may prove to be a much better target for the development of
anti-angiogenic therapy. However, increasing the cell-wall permeability of the drug
molecules could reduce the minimum effective therapy level by at most 56%. These
numerical simulations suggest that improving drug design in terms of permeabil-
ity across cell walls has limited potential as far as minimizing drug efficacy level
is concerned. Continued quantitative modelling in this direction could have a pro-
found impact on the development of anti-angiogenic drugs aimed at the intra-cellular
regulators of cell death.
The mathematical model presented here consists of delay differential equations,
and by keeping track of temporal changes in the tumor and endothelial cell densities,
VEGF and CXCL8 concentrations and microvessel density, we have been able to
study the potential of a number of possible cancer therapies targeted at the VEGF
- Bcl-2 - CXCL8 pathway. As the experimental data available is mostly density
versus time plots, this approach is the natural first choice. However, the vascular
structure within a tumor is highly unorganized and spatially heterogeneous, and
it would be instructive to extend this model to include spatial variations in cell
densities, chemical concentrations and vascular development. As a first step, we
construct a hybrid model of endothelial cell and sprout tip migration in response to
a gradient of VEGF in Chapter VIII. The principal dynamics that we wish to capture
with the model are the binding and uptake of VEGF by the endothelial cells, the
subsequent activation of cell surface receptors, and the chemotactic response of the
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cells to this. This approach will later be generalized to incorporate the VEGF -
Bcl-2 - CXCL8 pathway, in order to gain further insight into the potential of some
of the anti-angiogenic therapies discussed above. This mathematical model together
with the extensions mentioned above can provide a useful framework for enhancing
the understanding of the interplay between mediators of tumor angiogenesis and for
predicting the effectiveness of novel anti-angiogenic treatment strategies.
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Figure 7.6: Comparison of model simulations to in vitro simulations designed to study the effect
of BL193 on capillary formation. (A,C,E), In capillary sprouting assays described in
(59), HDMECs were cultured on type I collagen in the presence of 50 ng per ml VEGF.
Starting on day 5, BL193 was administered in increasing doses from 0.05 µM (A), 0.5
µM (C), and 5 µM (E), and the number of sprouts counted. Numerical simulations of
our model are seen to be in good agreement with experimental data, thus providing a
validation for it. (B,D,F), Intra-cellular Bcl-2, Bad and BL193 levels are tracked with
time, as therapy is administered in increasing doses from 0.05 µM (B), 0.5 µM (D), and
5 µM (F). Starting on day 5, BL193 levels within a cell begin to increase, causing a
decrease in amounts of unbound Bcl-2 protein, and a corresponding increase in unbound
Bad protein.
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Figure 7.7: In vivo simulations of anti-Bcl-2 therapy applied to a tumor at early and late stages
of development. Our model is based on experiments described in (95; 96; 97), wherein
HDMECs along with oral squamous carcinoma cells are transplanted into SCID mice, on
ploy-L lactic acid matrices. The HDMECs are observed to differentiate into functional
microvessels, giving rise to a vascularized tumor. (A,B), BL193 is administered in
starting from the day of implantation and continuing thereafter. As therapy levels
increase from 0 to 0.05 µM, and to 0.5 µM, time taken to reach maximal tumor cell
density increases by 25% and 89% respectively (A). The corresponding increase in time
taken to reach maximal vessel density is 37% and 121% respectively (B). 5 µM of BL193
appears to be enough to effect a cure. (C,D), BL193 is administered to a fully developed
tumor, starting from day 60 of implantation and continuing thereafter. 5 µM of BL193
is insufficient to effect a cure, and only a temporary reduction in tumor cell (C), and
vessel densities (D) is observed. The minimum amount of therapy required in order to
cause tumor regression is predicted to be 27.26 mM.
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Figure 7.8: Simulations to guide drug design strategies for anti Bcl-2 therapy. (A) Minimum amount
of therapy required to induce tumor regression is observed to vary exponentially with
the inhibition constant KDi of BL193 for Bcl-2. Reducing KDi from its baseline value
by 25% decreases the least amount of therapy required from 27.26 mM to 0.52 mM.
(B) As the rate of diffusion Di of BL193 into the cell is increased, the least amount of
efficacious therapy reduces by a maximum amount of 56%, after which no significant
change is observed, when compared to baseline values for Di.
CHAPTER VIII
A Hybrid Model of Capillary Formation
In the preceding chapters, we have developed ordinary and delay differential equa-
tion models of tumor induced angiogenesis. In these, we incorporated the down-
stream molecular signaling pathways of VEGF and investigated the potential of
targeting these pathways as possible anti-angiogenic therapies. As the experimental
data available are mostly density (cellular or microvascular) versus time plots, this
approach is the natural first choice. However, the vascular structure within a tumor
is highly unorganized and spatially heterogeneous, and it would be instructive to ex-
tend this model to include spatial variations in cell densities, chemical concentrations
and vascular development.
Here, we will develop a hybrid model of VEGF-induced angiogenesis, based on the
theory of reinforced random walks. We will include in our model, the chemotactic
response of endothelial cells to angiogenic factors bound to cell-surface receptors,
rather than approximating this as a function of extracellular chemical concentrations.
This will allow us to capture biologically observed phenomena such as activation and
polarization of endothelial cells in response to VEGF gradients across their lengths.
We will also propose a novel and more biologically reasonable functional form for the
chemotactic sensitivity of cells, than those currently used. Model validation will be
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provided by comparison of simulation results directly with experimental data.
As in (5), we consider a 2 dimensional domain, with a tumor source at x = 1,
and a parent vessel at x = 0, as shown in Figure 8.1. The tumor secretes angiogenic
factors under conditions of hypoxia, which diffuse outwards, towards the parent
vessel. While an entire panel of factors are known to be secreted by tumors, the
primary of these is VEGF, and for the purposes of modelling, this shall be the factor
of choice. As mentioned earlier, VEGF will be taken up by cells lining the parent
vessel, transforming them into sprout tip cells. These will migrate up the chemical
gradient, pulling behind them capillaries. The principal dynamics that we wish to
capture with the model are the binding and uptake of VEGF by the sprout tip cells,
the subsequent activation of cell surface receptors, and the chemotactic response
of the cells to this. To our knowledge, this level of molecular detail has not been
implemented previously in a model of tumor induced angiogenesis.
8.1 Single Cell Motion under the Influence of VEGF
We begin our model development by first simulating a single endothelial cell mov-
ing under the influence of VEGF. The cell starts out at x = 0, y = 0.5, and will move
in response to a gradient of VEGF, that has its source at x = 1, as in Figure 8.1. For
the purpose of simplicity, we do not explicitly incorporate an extra cellular matrix.
Following Plank et al, we base our spatial discretization on purely biological consid-
erations, by interpreting the cell as a (biased) random walker. As per the approach
developed in (116; 117; 118), the following master equation is used to describe a
biased random walk (in two dimensions) of the endothelial cell, moving under the
influence of VEGF in its local environment.
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Figure 8.1: (A), Geometry of the model domain. A tumor is present at x = 1, which under
conditions of hypoxia, secretes angiogenic factors such as VEGF. These diffuse towards
a parent vessel located at x = 0, and are taken up endothelial cells lining it. The
activated cells migrate up gradients of the angiogenic factors, laying down behind them
capillaries. (B,C,D), Motion of a cell on a 2-d lattice in response to a chemical stimulus.
The cell begins at position (n,m) in B. Chemoattractant molecules are shown in red.
The length of the cell in motion is taken to be 40 µm (C), while at resting state to
be 20 µm (B,D). The number of activated cell surface receptors is greatest on the cell
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Here, pn(t) describes the probability that a walker is at site (n,m), at time t. T̂ H±n,m (·)
and T̂ V±n,m (·) are the transition probabilities per unit time for a one step horizontal
jump to (n± 1,m), or a one step vertical jump to (n,m± 1) respectively. The mean
waiting time at the (n,m)th site is given by (T̂ H+n,m (W ) + T̂ H−n,m (W ) + T̂ V +n,m (W ) +
T̂ V−n,m (W ))−1. The vector W gives the concentration of the chemoattractant c, at the
lattice sites. In order that the master equation translates to the standard diffusion-
chemotaxis equation for cell movement in the continuum limit, it is assumed that the
dependence of transition rates at lattice site (n, m) is localized to chemoattractant
concentration at sites (n ± 1/2,m) and (n,m ± 1/2). This is reasonable, since we
may think of a cell present at lattice site (n,m), with its boundaries extending
to half the lattice length. It can therefore sense the chemical concentrations at
these half lattice sites, and make a decision where to move. This is illustrated in
Figure 8.1B,C,D. Therefore, W = (. . . , c−n−1/2, c−n, c−n+1/2, c−n+1, . . . ). Further, it
is assumed that the decision where to move is independent of the decision when to
move. Mathematically, this is equivalent to setting
T̂ H+n,m (W ) + T̂ H−n,m (W ) + T̂ V +n,m (W ) + T̂ V−n,m (W ) = 4λ(8.2)
for some constant λ. That is to say, the cell makes a decision to move (or to stay
still) after a constant interval of time, say k, also called the mean waiting time at
a grid point. In this case, k =
1
4λ
. One way to satisfy these assumptions is the
following choice of transition probabilities, as made by Othmer et al (105):
T H±n,m = 4λ
τ(cn±1/2,m)
τ(cn+1/2,m) + τ(cn−1/2,m) + τ(cn,m+1/2) + τ(cn,m−1/2)
T V±n,m = 4λ
τ(cn,m±1/2)
τ(cn+1/2,m) + τ(cn−1/2,m) + τ(cn,m+1/2) + τ(cn,m−1/2)
(8.3)
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for some function τ(c) of the chemoattractant. This choice of this function is based
on the particular form of the chemotactic sensitivity desired, and is explained in
Appendix D.2. A grid of mesh size h is taken, and x = nh is set. Passing to the
continuum limit h → 0 and λ → ∞ such that h2λ = Dp where Dp is the diffusion
coefficient of the endothelial cells, Othmer et al show that the master equation (8.1)
translates to the familiar diffusion-chemotaxis equation, as given in (8.4), for the
motion of a cell. Here, χ(c) is the chemotactic sensitivity, and it equals Dp (ln τ(c))
′.
To get a completely discretized model of the motion of the cell, the time derivative
of p in equation (8.1) is approximated by a simple forward difference scheme, with k
as the time step. For details, refer to Appendix D.1.
∂p
∂t
= Dp ∆ p−∇ · (p χ(c)∇c)(8.4)
A diagrammatic representation of the motion of the cell is shown in Figure 8.1. The
cell starts out at time t with its center at the lattice site (n,m) (Figure 8.1B). It
detects bio-available VEGF by taking it up at the half-lattice sites(Figure 8.1B). The
model can thus make the crucial distinction between VEGF that is free to bind to the
cell, versus VEGF that might be sequestered in the underlying extracellular matrix,
unavailable to the cell. This also ensures that molecular fluctuations in VEGF con-
centrations are significant enough to alter the polarization of the cell, and hence its
direction of motion. This is consistent with experimental observations (84). Based
on the numbers of activated receptors at its four sides, the cell becomes polarized and
attains a bias in a particular direction. It correspondingly elongates in this direction
(Figure 8.1C). Finally, the rear of the cell detaches from the underlying matrix and
contracts, the cell has now moved to the site (n + 1,m) (Figure 8.1D).
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8.1.1 Chemotactic Sensitivity Function - A Biochemical Approach
An important difference that sets this model apart from those preceding it, is the
choice of the chemotactic sensitivity function χ(c). Since ECs respond chemotac-
tically to the presence of activated cell surface receptors rather than extracellular
VEGF (47), we propose that χ(.) should in fact be a function of the activated recep-
tor densities on a cell surface, a. In this case, equation (8.4) for the motion of a cell
in 2 dimensions transforms to the following.
∂p
∂t
= Dp ∆ p−∇ · (χ(a) p∇a)(8.5)
Correspondingly, the transition probabilities in (8.1) will now be functions of con-
centration of activated receptor complexes on the cell surface a, and not extracellular
VEGF. We of course have to add equations for the binding of chemokine to their cell
surface receptors, which will need to be solved wherever a cell is present. Biologically,
the chemotactic sensitivity χ(a)∇a can be interpreted by breaking it down as follows
- a velocity χ(a) imparted to the cell due to the presence of bound chemokine on
its surface, and a gradient ∇a which governs the direction of motion. This gradient
simply means that the cell is able to sense the amount of chemokine bound to its
various faces, and is correspondingly able to align itself for motion in this direction.
Therefore, a is in fact taken to be the amount of activated receptors per cell face. We
choose a velocity function that satisfies the requirements that there can be no chemo-
taxis in the absence of a signal, and that the cell gets desensitized in the presence of
excess signal. One such functional form is:
χ(a) = χ0 a e
−a/B(8.6)
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This is a significant improvement over existing chemotactic sensitivity functions in
several ways.
• The simplest choice for χ is to take it as a constant (61; 62), χ(c) = χ0. However,
this predicts a constant chemotactic sensitivity in the presence of stimulus, and
does not account for the desensitization which has been experimentally observed
to occur in regions of high chemokine concentrations (69; 70; 151). Our model
is able to capture both these features.
• Lapidus and Schiller (71), and later Murray (92) used the functional form
χ(c) = χ0/(K + c)
2, also known as the receptor-kinetic law. Yet another popu-
lar phenomenological choice is χ(c) = χ0/(K + c), where K is the dissociation
constant of the chemokine binding to the receptors (5; 11; 117). These have
the advantage that they are able to account for the desensitization of recep-
tors when c is large. However, there are a few issues that these choices do not
address. They indicate that when no chemokine is present at a site, the chemo-
tactic sensitivity is the greatest, and this decreases as chemokine concentrations
increase. This is in contrast to experimental evidence which points towards the
existence of a minimum threshold level of chemical stimulus required for the cell
surface receptors to get activated, and for the cell to start moving in a directed
fashion (33; 77). Our choice for χ accounts for the fact that the cells need a
minimum amount of stimulus in order to get activated. A similar threshold has
also been incorporated in a Cellular Potts model of tumor-induced angiogenesis
by Bauer et al (12).
• Further, the above functions do not account for the fact that the amount of
chemokine required to desensitize cells depends on the concentration of cells
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present at the lattice site. For instance, while 5 pM VEGF is enough to desen-
sitize a single cell, it is not enough for 10 cells. This issue is taken care of in
our model, since desensitization of cells occurs if there is excess VEGF bound
to their surface.
• Finally, for an external chemical signal to elicit a chemotactic response from
a cell, it needs to be detected by the cell, and transduced into an internal
signal controlling cell motion. Neutrophils have been shown to sense chemical
gradients of 1% across their lengths, under optimal conditions (76; 153), while
this number can be as low as 0.1% for axons (153). In general, eukaryotic
cells are reported to be able to polarize and migrate in a directed fashion in
alignment with chemical gradients of about 2% across their lengths (43). It is
therefore biologically more reasonable to assume that the chemotactic response
is dependent on the gradients of activated receptor complexes formed on the
cell surface when the chemokine binds to its receptors, rather than gradients of
unbound extracellular chemokine concentration.
The maximum of the chemotactic sensitivity function given by equation (8.6)
occurs at a = B, while its maximum value is given by χ0Be
−1. In order for this choice
to be consistent with the discrete formulation, the function τ(a), from equation (8.3)






B − (B + a) e−a/B)
]
(8.7)
The parameter B is an unknown in our model formulation, and must be fixed via
experimentation. It determines the fractional occupancy of the receptors on the
cell surface at which its chemotactic response is the greatest. The parameter χ0
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determines the maximum value of this response. In tumor induced angiogenesis, new
capillaries can grow up to a rate of 1 mm per day (9). Once B is determined, this can
be used to fix the value of χ0. For baseline simulations, the value of B is fixed at 7.42
fg of activated VEGF-VEGFR2 receptor complexes. This allows us to fix the value
of χ0 at 4×105. It has units area (of a lattice site) per activated VEGF-VEGFR2
receptor complex density (in pg per cell face) per time (in hours). Figure 8.2A shows
the fractional occupancy of receptors on a cell face, and chemotactic sensitivity as a
function of activated receptors on a cell face, versus total VEGF at a lattice site, for
a particular choice of the parameters B and χ0. We can see that at zero fractional
occupancy, the cell remains inactive. The sensitivity peaks at fairly low fractional
occupancy, and decays thereafter. It should be noted that the units of free VEGF
at a lattice site are in pg, so that if the concentration of VEGF changes by even 1
pM, cell behavior will be influenced. Figure 8.2B shows the distribution of VEGF at
steady state across the domain. For illustration purposes, a line source of tumor cells
is considered at x = 1, so that VEGF concentration is invariant along the y-axis.
8.1.2 Model Equations Describing VEGF Concentrations in Single Cell Motion
Equations (8.1), (8.3) and (8.7) that describe the biased random walk of a cell
under the influence of VEGF have been explained in the preceding sections. No flux
boundary conditions are imposed on the cell equation. Equation (8.8) describes the
rate of change of free VEGF in the system.
∂c
∂t
= Dc ∆ c− αc c(8.8)
The units of concentration of free VEGF are taken as pg per lattice site volume
(taken to have a height equal to a cell length and a base equal to the surface area
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Figure 8.2: (A), Chemotactic sensitivity of an HDMEC to VEGF bound to its surface receptors, as
a function of unbound VEGF, in pg per lattice site. Also plotted is the corresponding
fractional occupancy of receptors on the cell face. (B), Typical steady state profile of
unbound VEGF, the source of which is located at x = 1.
of a cell). Here, Dc is the diffusion coefficient of VEGF, and αc is the rate of decay
in tissue. Following (5), the case of a line of tumor cells is considered at the right
boundary. Zero flux conditions are imposed on free VEGF at x = 0 and y = 0, 1.
Since VEGF is also taken up by the cell, this introduces new moving boundaries in
the system, namely, at the four faces of the cell. Equations (8.9)- (8.10) govern the
binding of VEGF to its receptors on the cell surface, to create activated receptor
ligand complexes. These are solved at each cell face.
∂c
∂t
= −η1 kf c r + kr a(8.9)
∂r
∂t
= −kf c r + η2 kr a + η2 kp a(8.10)
∂a
∂t
= η1 kf c r − kr a− kp a(8.11)
Here, r is the free VEGF receptor density, with units of concentration pg per cell
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face, and a is the amount of activated receptor complexes, also in pg per cell face.
For simplicity, we consider monomeric binding of VEGF to its receptors on the cell
surface. The constants kf and kr are the forward and backward rates of reaction
of VEGF with its receptor, VEGFR2. The rate of internalization of the activated
receptor-ligand complex, and subsequent recycling of free receptors is given by kp.
These equations are scaled to units of pg per cell face by appropriate constants ηi,
that represent ratios of the weights of the different molecules involved in the reaction.
Conservation of total receptor numbers is ensured by setting the sum of the free and
bound receptor densities to the average VEGFR2 density per endothelial cell.
The entire system is re-scaled to introduce non-dimensional variables. x and y
are scaled by the distance of the tumor from the parent vessel, L. VEGF density c
is scaled by a factor of c0, the maximum amount of unbound VEGF in the system.
This maximum is attained at the source, at x = L. r and a are scaled by factors
of r0 and a0, the maximum possible free receptor density per cell face and activated
receptor density per cell face respectively. Finally, the time variable t is scaled by
a factor T = L2/Dc, which corresponds to the diffusion time-scale of VEGF. The
non-dimensional system reduces to the following.
∂c∗
∂t∗
= ∆ c∗ − α c∗(8.12)
The equations at the cell surface transform as follows.
∂c∗
∂t∗
= −β1 c∗ r∗ + β2 a∗(8.13)
∂r∗
∂t∗




∗ r∗ − β4 a∗ − β5 a∗(8.15)
162
where the ∗ superscripts denote non-dimensional quantities. The movement proba-
bility dependence function in non-dimensional terms becomes
τ(a∗) = exp
[
ν (1− (1 + γ a∗)) e−γ a∗](8.16)
The non-dimensional parameters are listed below. Henceforth ∗ superscript shall be





α = αv T β1 = η1 kf T r0 p0 β2 =
kr a0 T p0
v0




Table 8.1: List of parameter values
Parameter Value Units Source
Dp 3.6×10−4 mm2 per hour (117)
Dv 3.6×10−1 mm2 per hour (79)
αv 0.6498 per hour (132)
kf 169 per VEGF concentration per hour (78), (152)
kr 2.0543 per hour (78), (152)
kp 0.6667 per hour (152)
η1 0.2250 pg VEGF per pg of receptor (35), (139)
η2 4.4444 pg receptor per pg of VEGF (35), (139)
r0 0.0191 pg receptors per cell face (78), (139)
a0 0.0234 pg activated receptor complexes per cell face (78), (35), (139)
h 0.02 mm (148), (75)
B 7.42 fg activated receptor complexes per cell face 7
A list of parameter values and sources is given in Table 8.1. The parameter
values for VEGF binding dynamics are taken from studies on human colonic vascular
endothelial cells. These have already been discussed in Section 4.3.2. The size of
4In the absence of experimental data,biologically realistic values for these parameters were chosen.
163
the lattice on which the cell moves is taken to be 20µm, since typical microvascular
endothelial cell volume is about 400µm (148), while thickness is about 1µ (75). This
gives a value for h. Finally, the domain size is taken to be 1 mm × 1 mm.
8.1.4 Numerical Implementation of the Biased Random Walk Model
The time interval over which the movement of the cell is simulated, is divided into
subintervals of length k, given by the mean waiting time of the cell at any lattice
site. The cell moves on a lattice of step size h. VEGF quantity is calculated at half
lattice sites, where the edges of the cell are assumed to exist.
Since the source of VEGF is constant, and it has a very high diffusivity, compared
to that of the cell, we assume that the concentration of free VEGF is not affected
due to uptake by the cell. In fact, the mean waiting time k of the cell at a lattice
site, is much greater than the diffusion time-scale of VEGF, and the constant source
ensures that it quickly recovers to the steady state solution of equation (8.12), within
each time step. This steady state profile is given by the following function. A typical













This also implies that Michaelis-Menten like dynamics for the uptake of VEGF
are valid (see Section 4.4.3). Thus, the amount of activated VEGF in cell surface
receptor-ligand complexes is given by the steady state solution of equation (8.15),
or a = v/(K + v), where K = km/v0. Here km is the Michaelis-Menten constant for
VEGF given by km = (kr +kp)/kf . It should be noted that we are keeping account of
VEGF taken up by the cell at each half-lattice site, in other words, by each cell face.
Consequently, we assume an equal density of receptors on all the four cell faces, so
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that r0, the maximum receptor density per cell face is one fourth of the total receptor
density per cell.
The method of simulation of cell movement is based on that described in (117).
Briefly, at each time step, the movement of the cell is simulated according to the
master equation (8.1), with the probabilities of moving up, down, left and right
calculated according to (8.3). These probabilities depend on the levels of VEGF
taken up by the cell via the transition probability function (8.16). This uptake
occurs at the half lattice sites, nearest to the site at which the cell is centered. The
real interval [0, 5λ] is divided into five subintervals, each of length proportional to
the probabilities of moving or staying still. A random number q lying within this
interval is generated, and depending on the sub-interval in which it lies, the cell
either executes a motion in the corresponding direction or stays stationary. Thus,
the cell moves left if q ∈ [0, T H−n,m ), moves right if q ∈ [T H−n,m , T H−n,m + T H+n,m ) and so on.
8.2 Results for the Motion of a Single Cell
Figure 8.3: Average migration times (in hours) for a single cell to travel across a 1 mm × 1 mm
domain, for various values of the maximum free VEGF concentration
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Simulations of the system governing the motion of a single cell given by equa-
tions (8.1), (8.3), and (8.16) were run in two dimensions, with unbound VEGF
profile given by (8.17). Figure 8.3 shows the average time in hours it took the cell to
travel across the domain (a distance of 1 mm), for various values of c0, the maximum
VEGF concentration. Standard deviations and average times are computed over 500
runs of the model. Figures 8.4-8.6 show typical trajectories followed by the cell,
and movement probabilities at any lattice site. Note that since the VEGF profile is
invariant along the y-axis, the movement probabilities are also invariant along this
axis - they only vary as x varies.
Figures 8.4A considers the case when the maximum concentration of VEGF c0
is very low, taken to be 0.0021 pg here. Fractional occupancies of receptors on
any cell face range from a low of 0.06% to a high of 0.12%. Also shown is the
gradient of activated receptor complexes across the length of the cell. This ranges
from 0.05% when the cell is at its starting position at x = 0, to 3.04% when the cell
has reached the source of VEGF at x = 1. We can see that the cell exhibits a high
degree of randomness in its motion, and takes on average almost 2 days to reach
x = 1 (Figure 8.3. This is despite the high gradient of activated complexes across
the cell length, the maximum of which is well above the reported value of 1-2% at
which eukaryotic cells become polarized. Due to the low concentration of VEGF
in the system, and hence low fractional occupancies of receptors, the probabilities
of stepping up, down, left or right have fairly similar values. This can be seen in
Figure 8.4B. It is only close to x = 1, that a definite bias is apparent for motion
to the right. Thus, the model is able to account for the fact that if chemokine
concentrations are too low, cell surface receptors do not achieve a sufficient degree
of activation. In this case, the cell will not exhibit a high degree of directed motion,
166
Figure 8.4: Typical trajectories of a cell migrating across a 2-dimensional domain under the in-
fluence of VEGF (A,C), and corresponding movement probabilities (B,D) for various
values of the maximum VEGF concentration, c0. Also indicated are maximum and
minimum fractional occupancies on any cell face, and upper and lower bounds for the
gradient of VEGF in activated receptor complexes across the length of the cell. (A,B)
c0 = 0.0021 pg per lattice site. (C,D) c0 = 0.0043 per lattice site.
even if there is enough chemokine present to polarize the cell.
As c0 is increased, migration times for the cell are observed to decrease, to a low
of 13.7 hours, when c0 = 0.0172 pg. (Figure 8.3). The corresponding trajectory is
plotted in Figure 8.5C. Here, fractional occupancies of receptors range from 0.35%
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Figure 8.5: Typical trajectories of a cell migrating across a 2-dimensional domain under the in-
fluence of VEGF (A,C), and corresponding movement probabilities (B,D) for various
values of the maximum VEGF concentration, c0. Also indicated are maximum and
minimum fractional occupancies on any cell face, and upper and lower bounds for the
gradient of VEGF in activated receptor complexes across the length of the cell. (A,B)
c0 = 0.0086 pg per lattice site. (C,D) c0 = 0.0172 per lattice site.
to 0.52%, while activated receptor gradients vary from 0.03% to 1.57% across the
cell length. For our chosen values of the parameters B and χ0, which determine the
chemotactic sensitivity function χ(a), the above value of c0 appears to be optimal
for the cell to migrate across the domain. A plot of the movement probabilities
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shows a large bias towards stepping to the right, while steps to the left are very
unlikely to occur (Figure 8.5D). This is due to the following two reasons. Firstly,
typical gradients of activated receptors on the cell fall within the reported range of
1-2% required for directed motion, allowing the cell to get polarized in the direction
of increasing chemokine. Secondly, the receptors themselves have a high enough
occupancy level, so that they are in a highly activated state.
As c0 is increased further, the model replicates the desensitization effect which has
been observed to occur when receptors are over-exposed to chemokines. As can be
seen from Figure 8.3, when c0 = 0.086 pg, it takes the cell an average of 1.5 days to
migrate across the domain. Typical cell trajectories exhibit a fair degree of random
motion, even though there is an overall bias for stepping to the right (Figure 8.6C). A
combination of high fractional occupancies, which range from 0.68% to 0.81%, along
with low activated receptor gradients across the cell, the maximum of which is only
0.56% contribute to keeping this bias of motion to the right at a low level. This is
illustrated in a graph of the corresponding movement probabilities, in Figure 8.6D.
8.3 VEGF-induced Capillary Network Formation
We have developed a model for the motion of a single cell under the influence of
VEGF. In this model, we were able to capture biologically observed phenomena such
as the polarization of cells in response to activated VEGF-VEGFR2 complexes on
their surfaces, requirement of a minimum stimulus in order for the cells to exhibit
directed motion and desensitization as a result of excess VEGF signalling. We are
now in a position to apply the techniques developed thus far to simulate capillary
network formation under the influence of VEGF.
We base our model on the experiments of Sholley et al (134). Briefly, they in-
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Figure 8.6: Typical trajectories of a cell migrating across a 2-dimensional domain under the in-
fluence of VEGF (A,C), and corresponding movement probabilities (B,D) for various
values of the maximum VEGF concentration, c0. Also indicated are maximum and
minimum fractional occupancies on any cell face, and upper and lower bounds for the
gradient of VEGF in activated receptor complexes across the length of the cell. (A,B)
c0 = 0.0344 pg per lattice site. (C,D) c0 = 0.0688 per lattice site.
duced inflammatory neovascularization of the rat cornea by cauterization using silver
nitrate. Levels of endothelial cell proliferation and degree of vascular profusion were
measured periodically at days 1, 2, 4 and 7 post cauterization. The importance of
EC mitosis in the formation of new sprouts was also investigated. The key findings
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of this paper were:
1. The first sprouts were formed between day 1 and day 2. The initial vascu-
lar sprouting did not depend on cellular mitosis. Rather, these sprouts were
likely formed by the migration and redistribution of existing endothelial cells,
originating from the limbal vessels.
2. However, continued growth of the sprouts required cellular proliferation. If EC
mitosis were prevented, the resulting sprouts stopped growing beyond 4 days,
and were severely stunted. The resultant network extended an average of only
0.55 mm into the stroma.
3. If mitosis were allowed to occur, the sprouts continued to grow and by day 4,
a dense network of vessels exhibiting branching and anastomoses was formed,
extending a mean distance of 1.05 mm into the cornea. By day 7, this network
had reorganized itself into fewer, and larger vessels which were radially oriented,
extending a distance of 1.88 mm into the stroma. This reorganization was
possibly the result of vessel maturation.
4. Proliferative activity of the ECs was observed to be concentrated near the ad-
vancing edge of the vessels, extending to 0.5 mm behind the sprout tips.
Several models of the process of vascularization similar to that described here,
have been developed. These, together with their limitations, have already been
discussed in Chapter III. In the model of angiogenesis developed here, we will aim to
improve on these models by incorporating a higher level of detail of the biochemical
forces guiding angiogenesis.
For the purposes of our model, we will focus on the vessel growth occurring be-
tween days 1 and 4 of the Sholley experiments. The first sprouts are seen after day
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Figure 8.7: The geometry of the domain over which vascular growth in response to tumor-secreted
VEGF is being modelled. Capillary growth is modelled from day 1 to day 4. At day 1,
the initial sprouts have already formed along the parent vessel. Vessel growth resulting
from EC mitosis is assumed to begin at x = 0, with the source of growth factors located
at a distance 2 mm from the parent vessel between x = 1.6 and 1.73
1 in the experiments, and we take this as the starting point of our model. Indeed, a
model for capillary network formation in the rat cornea, in the absence of EC pro-
liferation has already been proposed by Anderson and Chaplain in 1998 (4). Since
we do not account for vessel maturation, the model simulations are not carried out
beyond day 4, after which time this process is observed to occur. The geometry of
the domain is shown in Figure 8.7. Initial sprouts, together with the parent vessels,
are assumed to extend to a short distance into the cornea. For our simulations this is
taken to be approximately 0.27 mm, in keeping with experimentally observed average
vessel extension speeds. Vessel growth resulting from EC mitosis begins at x = 0.
The source of growth factor (assumed to be VEGF) is the center of the lesion which
lies at x = 1.73. Thus the distance of the lesion from the limbal vessels is about 2
mm, as reported in the experiments. In order that the vessels reach the lesion by day
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7, it is taken to have a radius of 0.12 mm, which means that the vessels extend to a
mean length of 1.88 mm. Note that, since the initial vascular network is assumed to
extend a distance of 0.27 mm by day 1, the sprouts must travel 0.78 mm in 3 days
so that a total distance of 1.05 mm is covered in 4 days.
8.3.1 Adaptation of Single Cell Motion to Capillary Formation Model
While the general setup remains the same as described in equations (8.1), (8.16), (8.3),
and (8.17), a few changes are implemented to account for the creation of microves-
sels, under a slightly altered VEGF profile. VEGF is now being secreted at x = 1.73,
and no flux boundary conditions are imposed at y = 0, y = 1, and x = −0.27. The
equation (8.12) for free VEGF is solved for its steady state under these new boundary
conditions, and this profile of VEGF is kept constant throughout (see Section 8.1.4).
It is known that specialized ECs situated at the tips of the sprouts, called tip
cells, are activated by, and respond to VEGF, by chemotactic migration (47; 50).
We therefore keep track of these leading cells in our simulations. We have already
presented a model for the motion of a single cell, responding to a gradient of VEGF
formed on its surface as a result of receptor activation. This is modified to capture
the motion of tip cells, with the only difference being that since a tip cell pulls behind
it a vessel, receptors on its tail are made unavailable for binding VEGF at any given
time. This eliminates the possibility for the tip cell to back-track. Initially, 5 sprouts
are assumed to have formed along x = 0.
Empirical evidence points to the existence of a region of proliferating stalk cells
just behind the tip cell (47; 110; 134). Sholley et al have also demonstrated that
sprout extension cannot occur in the absence of cell division. To account for this, we
assume that a tip cell has the freedom to occupy a new lattice site only when a stalk
cell has had time to undergo mitosis. Vessel elongation speeds must be approximately
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0.27 mm a day in order that a distance of 1.05 mm is traversed in 4 days, as per
the observed time-course of vessel formation in (134). Given that typical EC lengths
are 0.02 mm, this implies that at least 14 cell divisions must occur per day, which
allows us to fix an upper bound for the time-step k, to be 1.7 hours. Recall that
k is the mean waiting time at a lattice site. In reality, the mean waiting time is
expected to be lower since not every motion of the tip cell is in necessarily in the
forward direction. This is a parameter that will be fitted to ensure that simulation
and experimental vessel elongation speeds are in agreement. Further, no more than
25 cell divisions may occur at any point of time, since the proliferating zone extends
to no more than 0.5 mm behind the tip cell.
Finally, while the migratory response of the tip cell is a result of gradient sensing,
. Since the process of branch formation is a result of proliferation of the cells lining
the developing microvessel,
The process of branch formation is included explicitly in the model. It is assumed
that the generation of new sprouts occurs only from existing sprout tips. This is in
keeping with the fact that there is a region of proliferating cells just behind the tip
cell, which could give rise to new branches. The proliferation of cells is regulated
by total VEGF concentrations on their cell-surface receptors (47). Thus, in our
model, the tip cell integrates the total VEGF bound to it, and the higher the bound
VEGF quantity, the greater the branching probability. Conversely, if the amount of
VEGF bound to the cell is very low, branching cannot occur. As the bound VEGF
increases, the frequency of branching increases, creating the brush-border effect (5;
112). Similar rules for branching have been applied previously by Anderson et al (5).
It is also assumed that branching into a space occupied by another sprout is not
possible.
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The process of anastomoses or formation of loops by capillary sprouts is also
incorporated in the model. At each time step, as the tip cells migrate under the
influence of VEGF, probabilities of motion to adjacent lattice sites are calculated. In
order to prevent back-tracking, the probability of moving to the lattice site occupied
currently is set to zero. Anastomoses may occur if another sprout is present at a
neighboring site. Following Anderson et al (5), it is assumed that if another tip cell
is encountered at a site, only one of these cells continues to grow, while the rest of
the time, a loop is created with the loss of both cells.
8.3.2 Degree and Morphology of Tumor Vascularization is Crucially Mediated by the
Bio-availability of VEGF
Simulations of the system governing capillary network formation under the influ-
ence of VEGF, described above were run in two-dimensions. The first case considered
is when the sprout tips move across the domain in the least amount of time. This
occurs at a maximal concentration of VEGF of 0.0047 pg per lattice site. Taking
an average over 500 simulations, it is observed that the sprout tips require 49 steps
to migrate across the domain, in order to travel 0.78 mm into the stroma after 3
days. Note that the chemotaxis parameters chi0 and B are fixed in order to mini-
mize this number of steps. Thus, the time-step k must equal 1.47 hours. This is less
than the upper bound of 1.7 hours as estimated from (134), due to the fact that even
though the bias for movement is overwhelmingly in the forward direction, a few steps
are invariably taken in the lateral directions. The results from a typical simulation
are shown in Figure 8.8A. We begin with 5 initially formed sprout tips at x = 0.
As these tip cells migrate across the domain, they lay down behind them capillary
sprouts. As the vascular network penetrates deeper into the stroma, branching is
observed to occur. Anastomoses is also seen as the sprouts branch further. These
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results are qualitatively similar to the networks observed at day 4 in Sholley et al. In
Figure 8.8B, we can see the probability of movement for the tip cell across the length
of the domain. There is a bias towards forward motion, as the fractional occupancies
of receptors on the tip cell increase from a minimum of 20% at x = 0, to a maximum
of 40% at x = 1.
Recent studies have focused on the role of various VEGF isoforms in vascular
morphogenesis (47; 72) and have found that VEGF in soluble versus matrix-bound
form has a different effect on vascular appearance. Lee et al (72) demonstrated
that endothelial cell receptor activation by soluble VEGF induced significant cell
proliferation and broad invasion of the stroma.
Recent studies have focused on the role of various VEGF isoforms in vascular
morphogenesis (47; 72) and have found that VEGF in soluble versus matrix-bound
form has a different effect on vascular appearance. In order to simulate the presence
of a more soluble isoform of VEGF, the quantity of bio-available VEGF is increased
by increasing c0. Figure 8.8C shows the vascular network formed in response to
these increased levels of bio-available VEGF. As the sprout grows, a greater number
of cells are activated and stimulated to proliferate. Thus, extensive branching and
anastomoses is observed. In fact, a number of ’loops’ in the vasculature can be
seen which have been formed by are only a single cell thick. It is reasonable to
expect that the cells lining these regions would fuse into one another to give rise to
a thicker and more dilated vessel, which is a morphology consistent with vascular
hyperplasia, as seen in (72). Furthermore, since the fractional occupancies of tip cell
receptors is very high, the tip cell does not have a very strong directional preference
(Figure 8.8D). Thus lateral movement of vessels as well as movement against the
gradient of VEGF are observed to occur. These are observed phenomenon in vivo,
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and have been numerically simulated previously (142).
Finally, the effect of a low maximum VEGF concentration on vascular formation
is investigated. c0 is fixed at a very low value of 5.4×10−5 pg per lattice site. Frac-
tional occupancies of receptors on the tip cell now vary from a minimum of 3% to
a maximum of 7%. The cell is no longer polarized sufficiently to display directed
motion. The total VEGF bound to the cell is also too low to induce proliferation,
and hence branch formation. Instead, the vessels tends to loop back on themselves,
or loop back towards the limbal vessel, without moving a significant distance into
the stroma (Figure 8.8E). Corresponding movement probabilities are shown in Fig-
ure 8.8F.
8.4 Discussion
We have developed and presented here an agent based model of cellular chemo-
taxis, under the influence of VEGF. The first step was the formulation of a chemotaxis
sensitivity function that incorporated biological detail hitherto ignored by sensitiv-
ity functions currently in use. A stochastic approach to simulate the movement of
the cell was followed, based on the theory of biased random walks, popularized by
Davis. Using this, the motion of a single cell was simulated on a two-dimensional
grid, following the gradient of VEGF laid down by a constant source. An important
difference that sets this model apart from those preceding it is the inclusion of a
molecular level of detail, used to guide the motion of the cell. VEGF was allowed to
bind to cell surface receptors, resulting in polarization of the cell, and a bias toward
motion in a particular direction. This is observed experimentally as well - endothe-
lial cells respond to gradients of chemokines across their lengths, rather than to free
chemokine concentrations. In vitro, these gradients are calculated to be as low as
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1%, which was seen in the numerical simulations as well, thus validating our model.
Using this setup, we were able to demonstrate its capacity to capture realistic dy-
namics, such the requirement of a minimum activation level of cell surface receptors,
and receptor desensitization in high concentrations of VEGF.
Next, this model was adapted to simulate the neovascularization of the rat cornea,
as in the experiments of Sholley et al. Events such as branching and anastomoses,
which are observed to occur in vivo, were incorporated explicitly in the model. The
time-step was fixed to ensure that vessels elongation speeds matched those observed
experimentally. Thus a value of 1.47 hours was fixed for k. It is known that the time
taken by a lymph EC to undergo mitosis can be as low as 12 hours (6), while that for
pulmonary ECs is about 13 hours (1). This does not, of course, include inter-mitotic
times. Given that vessel penetration into the cornea may take place only if ECs lining
it undergo mitosis, and assuming an cell cycle time of 13 hours, this implies that at
any time 8-9 cells are undergoing division. Further, since we take the length of a
resting EC to be 0.02 mm, this allows us to calculate that cell division is occurring
in a total length of 0.16-0.18 mm, behind the tip cell. Sholley et al reported that the
proliferative region is located up to a distance of 0.5 mm behind a tip cell. Thus,
numerical simulation indicate that 32-36% of the cells in the proliferative regions
are undergoing mitosis at any point of time, which is in good agreement with the
value of 30% as observed empirically (134). This provides excellent validation for
our model. Using this framework, we were also able to test the effects of excessive
VEGF signalling, which may result if the VEGF isoform is freely soluble, as well as
very low levels of VEGF signalling, on vascular development.
Angiogenesis is a highly complex process, and the mechanisms driving it are still
unclear to a large extent. Mathematical modelling can go a long way in shedding
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light on some of the these mechanisms. To this end, it is vital that modelling effort
keeps up with current advances in experimentation. Our model provides such a
framework, in which it is easy to build in biochemical and biomechanical forces
guiding vessel formation. We have already incorporated VEGF binding to the tip
cell. Currently, it is assumed that the tip cell gives rise to new sprouts. In this way,
it follows that proliferation occurs just behind the tip. However, it is straightforward
to keep track of the ECs lining the vessels as well, so that VEGF uptake by these
may be monitored. Since the cell integrates the total amount of VEGF bound to
it, in order to decide whether or not to divide (47), proliferation may be kept track
of in an explicit manner, and more direct comparisons with experiments that report
proliferative regions along the stalk of the capillary may be made. We also plan to
include vessel maturation, so that even if there is ample signal for a stalk cell to
proliferate, if it is of a certain age, it may not do so. Maturation of the ECs lining
a vessel is modulated by the angiopoietins. Ang-1 has been shown to stabilize the
blood vessel by maintaining periendothelial cell coverage whereas Ang2 permits the
removal of pericytes from the vessel. This induces angiogenesis in the presence of
VEGF, and causes regression in the absence of VEGF (10). The angiopoietins exert
their influence through the Tie-2 receptors, which are tyrosine kinases like the VEGF
receptors. Thus including this system in our model would not be a difficult task.
A vital component that governs vessel formation is the extra cellular matrix or
ECM. ECs require the ECM to gain traction in order to move. Activated ECs up-
regulate cell surface receptors known as integrins, that help the cell adhere to fibers
in the ECM (16; 130). To facilitate their migration, ECs also secrete proteolytic
enzymes such as the matrix metalloproteinases (MMPs), that degrade collagen and
elastin and clear a path for the ECs to follow. In addition, the plasminogen activator
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system plays an important part in the degradation of fibronectin (87). As ECs
interact with the matrix, they also cause the release of matrix bound angiogenic
factors such as VEGF, which are then available to induce further pro-angiogenic
activity (84). The framework presented here is highly flexible, and would allow for
the inclusion of the above processes, grounding it further in biology, and enhancing
its usefulness as a tool to understanding the process of angiogenesis.
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Figure 8.8: Typical vascular networks formed by 5 initial sprouts at x = 0, migrating across a
2-dimensional domain under the influence of VEGF (A,C,E), and corresponding move-
ment probabilities (B,D,F) for various values of the maximum VEGF concentration c0
secreted by the tumor source. (A,B) c0 = 0.0047 pg per lattice site. The bias of move-
ment is overwhelmingly in the forward direction (B). (A) Branching and anastomoses
is observed to occur as the vasculature penetrates deeper into the stroma. The result-
ing networks are qualitatively similar to those observed experimentally in (131). (C,D)
c0 = 0.0188 pg per lattice site. (C) Due to high VEGF concentrations, over-stimulation
of ECs occurs, and extensive branching, and anastomoses is observed. The resulting
vasculature is morphologically consistent with vascular hyperplasia, observed to occur
in the presence of high VEGF concentrations. (D) De to high fractional occupancies,
the tip cell tends to lose its directional bias. (E,F) c0 = 0.000054 pg per lattice site. (E)
The amount of VEGF is too low to induce proliferation or polarization of the tip cell,
leading to a poorly developed vasculature that does not reach the tumor source. (F)
Due to low fractional occupancies of receptors, the tip cell does not display sufficient
bias towards forward motion.
CHAPTER IX
Summary and Future Directions
9.1 Impact of Dissertation Research
Morphologically, tumor vessels and healthy blood vessels are very different. Tumor
blood vessels are highly irregular and disorganized structures. They tend to be leaky,
tortuous, containing an abnormal basement membrane. As a result, the blood flow
in tumors is chaotic. The tumor vessels generally contain poorly oxygenated blood,
so that the tumor tissue is relatively hypoxic. This has lead to the theory that
normalization of tumor vessels and blood supply achieved by angiogenesis inhibitors
could improve drug delivery to the tumor as well as prevent cancer metastasis by
limiting the access of cancer cells to the vasculature. Today, therapeutic strategies
targeted against angiogenesis are clinically recognized has having enormous potential
in the treatment of cancer. Several potent angiogenesis inhibitors have been identified
and are currently in various stages of development and clinical trials. However,
their underlying mechanisms of action remain poorly understood. Consequently,
mathematical modelling of angiogenesis has an increasingly important role in the
development and testing of these strategies.
While significant progress has been made in the development of models of tumor-
induced angiogenesis, none have been able to capture the dynamics of pro- and
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anti-angiogenic molecules, and the downstream signalling cascades that they initi-
ate, at an intracellular or molecular level. Vascular endothelial cell behavior has
been treated as a function of free chemokine density, instead of a response to the
presence of activated growth factor receptors on their surfaces. This makes it difficult
to accurately predict cellular response to therapeutic blockage of angiogenic growth
factors. Furthermore, generic chemokines have often been used to represent an entire
panel of angiogenic factors. However, many anti-angiogenic molecules being investi-
gated currently target specific chemokines; any mathematical investigation designed
to evaluate their potential or elucidate their anti-angiogenic mechanisms would need
to incorporate specific details relating to that particular chemokine.
To advance the current state of mathematical investigations of tumor-induced
angiogenesis, we developed a multiscale tumor vascularization model explicitly de-
scribing the intricate interplay between intracellular regulation in the form of molec-
ular signalling pathways, growth factor-receptor crosstalk at a cellular level, and the
resulting intercellular interactions. This model makes novel and significant contri-
butions to the field of angiogenesis modelling in several ways.
We began with a detailed quantitative analysis of the validity of various assump-
tions such as monomeric uptake of VEGF by VEGFR2, and the quasi-steady state
assumption commonly made in modelling VEGF interactions with VEGFR2. The
results of this analysis highlighted the impact that incorporating molecular level de-
tail of the biochemical processes that control angiogenesis can have in enhancing the
accuracy and usefulness of a mathematical model of angiogenesis. Subsequently, a
model of intra-tumoral angiogenesis was developed. This model is the first to con-
nect the molecular events associated with VEGFR2 dimerization and intracellular
signaling with the temporal changes in endothelial cell proliferation, migration and
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survival. It is also the first to explicitly incorporate details of intracellular molec-
ular events, such as interactions of the Bcl-family of proteins that control cellular
apoptosis. This put us in a unique position to explore the therapeutic potential of a
small molecule inhibitor of the pro-survival protein Bcl-2. Another novel feature of
this model is that it captures the process of microvessel formation from individual
endothelial cells which align themselves to form blood vessels.
Finally, a hybrid model of tumor vascularization was proposed. A significant fea-
ture that sets this apart from previous such mathematical investigations is that it is
the first to allow endothelial cells to detect gradients of bound VEGF across their
lengths, and polarize and migrate in response to this gradient. Another important
contribution of this model is a novel chemotactic sensitivity function that incorpo-
rates a level of biological detail ignored by sensitivity functions currently in use. We
are thus able to capture empirically observed phenomena, such the requirement of
a minimum activation level of cell surface receptors, and receptor desensitization in
high concentrations of VEGF.
The modelling techniques developed here use the behavior predicted by a single
cell, guided by cellular and molecular level events, to determine the response of a
population of cells. These techniques are useful in studying the relationship be-
tween intra-cellular molecular pathways and multicellular behavior. Therefore, they
have have applications in other complex biological systems such as immune system
response to cancer cells and other pathogens.
Our model of tumor angiogenesis is borne out of close interactions with experi-
mentalists working in the field of anti-angiogenic drug development. This has allowed
us to validate the model at every step of development by direct comparison with ex-
perimental data, enhancing its usefulness as a predictive tool to experimentalists and
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clinicians. Using this modelling framework, we were able to test the potential of a
number of targets for the development of anti-angiogenic therapy, and allowed us to
answer questions relating to the biology of vascular regression, which would other-
wise have been difficult or even impossible to do experimentally. A great strength of
the model lies in the flexibility of its framework; it can easily be modified to simulate
other experimental assays designed to elucidate the mechanisms of angiogenesis-
dependent diseases from a therapeutic point of view. Given the high financial and
human costs of clinical trials, such quantitative modelling can have a far-reaching
impact in the field of angiogenetic therapeutics.
9.2 Future Directions
A number of questions regarding anti-angiogenic therapy remain unanswered. A
deeper understanding of the molecular mechanisms of their action is required to
evaluate their potential as a cure for cancer, whether used alone, or in combination
with other forms of anti-cancer therapy. To this end, several additional extensions
and improvements to the models of tumor angiogenesis developed in this research
are planned. These include incorporating the effects of various angiogenic inhibitors
targeting different aspects of vessel growth. In addition, other growth factors and
their downstream intracellular signaling pathways, as well as regulators of vessel
maturation, regression and sprouting, will also be incorporated. The role of the
ECM in vascular network formation and modulation, and blood flow through the
capillaries will also be considered. Below, we present additional ideas for future
model extensions.
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9.2.1 An Evaluation of Anti-VEGF Therapy
It has been shown that tumor angiogenesis is crucially mediated by VEGF. Tumor
vessels require VEGF for survival and function. It also plays an important part in
determining vascular morphology. Consequently, anti-VEGF strategy is considered
as the most promising anti-angiogenesis therapy for the treatment of human can-
cers (21; 58). Several of the anti-VEGF compounds that were efficacious in animal
models are currently undergoing clinical trials. However, many of these compounds
including avastin, SU5416 (a small molecule inhibitor of the VEGF receptor) and
IM862 (a small molecule that blocks VEGF and other targets) have produced disap-
pointing results (45).
Cao (21) considers several possible reasons for this difficulty in replicating results
from the animal models in humans. For instance, a late stage tumor may produce
many more angiogenic factors than an early stage tumor, so that the efficacy of anti-
VEGF treatment becomes crucially dependent on early detection. Variance in growth
rates of human tumors versus mouse tumors could also mean that their angiogenic
profiles are different resulting in different levels of VEGF receptor expression. A
faster growth rate could thus explain a greater dependency of mouse tumors on
VEGF. VEGF can be generated as various spliced isoforms and, it is possible that
not all VEGF antagonists can block the functions of all VEGF isoforms. In addition,
the treatment may not be effective if it relies on blocking intracellular signalling
mediated by VEGF receptors, since there may exist other receptor-like molecules on
an endothelial cell surface, that bind VEGF (such as neuropilin, which binds several
VEGF isoforms) and thereby transduce pro-angiogenic signalling.
Furthermore, anti-VEGF agents may be accompanied by distinct adverse side-
effects, hypertension and proteinuria being the most common.These could lead to
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renal toxicity and thromboembolic events (58; 104). It is believed that these are
downstream effects of VEGF-signalling suppression in ECs of normal organs (58).
Despite these setbacks, certain success stories do exist that have kept the inter-
est in this field alive. In spite of its failure as a treatment option in breast can-
cer, Avastin has been approved by the FDA as a first- or second-line treatment of
metastatic carcinoma of the colon, in combination with chemotherapy, as well as
first-line treatment for nonsquamous, non-small lung cancer. Sunitinib has been
approved for the treatment of advanced renal cell carcinoma and gastrointestinal
stromal tumors (58). Furthermore, anti-VEGF therapy does not lead to side-effects
such as myelosuppression, and neutropenia found with conventional chemotherapy.
Thus, it is essential to gain a better understanding of the mechanisms of action of
anti-VEGF therapy, and its side-effects, in order to evaluate its therapeutic potential
and predict optimal dosing. The kind of modelling developed here provides an ideal
platform for such investigations. This could also answer questions relating to variance
in efficacy with tumor type, as well as predicting outcomes of clinical trials. We
also plan to mathematically and computationally investigate the effect of the small
molecule inhibitor of VEGFR2, PTK787/ZK222584, which does not interfere with
VEGF binding, though it does neutralize the intracellular signaling that VEGFR2
triggers in order to promote proliferation and survival. The molecular level detail
of the biochemical processes guiding angiogenesis incorporated in our model makes
it sensitive enough to distinguish between therapy targeted at the VEGF molecule
and that targeted against VEGFR2. For instance, the model can differentiate the
response of PTK787/ZK222584 and the humanized monoclonal anti-VEGF antibody
Avastin on tumor vasculature.
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9.2.2 Towards a Comprehensive Multiscale Hybrid Model of Tumor Angiogenesis
In Chapter VIII, we developed a hybrid model of tumor angiogenesis, in which
EC response to cell-surface bound VEGF was explicitly included. However, for the
purposes of computational ease, certain simplifying assumptions were made. Most
notably, unbound VEGF was assumed to be in quasi steady-state. Further only the
tip cell was kept track of, while VEGF uptake by stalk cells was ignored. Cell death
was also omitted, while cell proliferation was implicit, rather than explicit. We plan
to extend this model by relaxing some of these assumptions.
Lattice-based models of angiogenesis face the criticism that the capillary networks
generated by them are artificial to a certain extent, as they are forced to follow the
lattice used to discretize the model. A first step would therefore be to develop
a lattice-free version of our model of capillary formation, in which the ECs move
without geometric constraints. Such models have been applied to capillary formation
previously (119). Each tip cell is assigned a speed, and a direction of motion. This
would be determined by gradient of bound VEGF on its surface.
As mentioned in section 8.1.2, the edges of the tip cell and stalk cells of each
capillary represents moving boundaries serving as sinks for free VEGF via cell-surface
receptor uptake. The following equations would need to be solved at each such cell




= −2 kaf1 A Ra + kar1 Ca(9.1)
dRa
dt
= −2 kaf1 A Ra + kar1 Ca − kaf2 Ca Ra + 2 kar2 Da + 2 kap Da(9.2)
dCa
dt
= 2 kaf1 ARa − kar1 Ca − kaf2 Ca Ra + 2 kar2 Da(9.3)
dDa
dt
= kaf2 Ca Ra − 2 kar2 Da − kap Da(9.4)
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Thus, gradients of activated receptors would form on the leading cell, thereby guiding
its motion.
Proliferation has been reported to occur in widely different parts of the sprout.
While it is generally believe to occur right behind the tip cell, after the ECs have
already migrated into the stroma some distance (134), there is evidence of mitotic
activity occurring at the base of a newly formed sprout, some distance behind the
tip cell, and directly behind the tip cell (110). It is also known that ECs integrate
the total amount of VEGF bound to their surfaces before making a decision to
proliferate (47). Keeping track of the amount of VEGF bound on each cell would
enable us to simulate these various proliferative regions on the capillary, and examine
their effect on sprout development. Proliferation also results in branching, thus we
would be able to model this in a biochemically motivated fashion rather than laying
down phenomenological rules for it, as is currently the trend.
Finally, cell death, regulated by intracellular pathways such as the VEGF-Bcl-
2-CXCL8 would be incorporated in the model. This would allow us to investigate
the various anti-angiogenic therapies simulated on our DDE model on a biologically
more realistic platform.
9.2.3 Other Targets for Development of Anti-angiogenic Therapy
Over-expression of the pro-survival members of the Bcl-family proteins is fre-
quently observed in tumors of diverse origin. This confers a measure of protection
to the cancer cells while making them resistant to treatment that induces cell death
by targeting the mitochondrial pathway (39). In certain types of tumors, cancer
cells are able to extend this protective effect to ECs lining tumor blood vessels (97;
98; 99). Consequently, the Bcl-family of proteins have emerged as key targets for
the design of therapeutic strategies aimed at controlling tumor-induced angiogenesis.
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Several small molecule compounds such as Tetrocarcin A and H-14A interfering with
Bcl-2/Bcl-xL function have been recently identified, and are undergoing preclinical
studies (39). Others such as TW37 are still under development (160). The model
developed in this dissertation already incorporates the apoptotic regulating pathway
of the Bcl-family of proteins. It would therefore be a straightforward task to test the
anti-cancer potential of these molecules.
Experimental evidence has shown that ECM regulates angiogenesis by providing
not only scaffold support, but also plays an active signaling roles by serving as a
reservoir and modulator for angiogenic growth factors. Cellular interactions with
the ECM can have a significant impact on new capillary sprout formation and mor-
phology. Consequently, ECM-targeted strategies are being widely accepted as having
significant therapeutic potential as a treatment for cancer. Adding ECM as a dy-
namic variable in our hybrid model of angiogenesis can play an important role in the
development and testing of these strategies.
The research carried out in this thesis is noteworthy in the respect that it aids
efficient drug design and administration. It has the potential to save significant time
and costs relating to drug development and enhances patient care. The research has
aided experimentalists in choosing anti-Bcl-2 therapy as the more effective target
for the development of an anti-angiogenic drug. One such small molecule inhibitor
of Bcl-2 is in pre-clinical trials. The research has also addressed the issue of the
minimum level of drug required to significantly impair tumor vasculature. As many
anti-angiogenic drugs may have toxic side-effects, this can be an effective method for






The full system of equations describing ligand-induced dimerization of cell surface




= −2 ηa1 kaf1 A Ra + ηa2 kar1 Ca − λa A(A.1)
dRa
dt
= −2 kaf1 ARa + ηa3 kar1 Ca − kaf2 Ca Ra + 2 ηa4 kar2 Da + 2 ηa4 kap Da(A.2)
dCa
dt
= 2 ηa5 k
a





f2 Ca Ra − 2 kar2 Da − kap Da(A.4)
The full system of equations describing activation of pre-dimerized receptors by
VEGF in a single binding step (1:1 model) are presented below.
dA
dt
= −ηa8 kaf1 APa + ηa0 kar1 Da − λa A(A.5)
dPa
dt





f1 APa − kar1 Da − kap Da(A.7)
Here, Pa is the pre-dimerized VEGFR2 density. As in the full dimer model, the above
equations have been scaled to units of pg/mm3 by appropriate constants (ηai ). These
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Table A.1: List of parameter values relating to the molecular weights of VEGF and VEGFR2
Parameter Value Units
ηa8 0.1125 pg of VEGF per
pg of VEGFR2-VEGFR2 complex
ηa9 0.8989 pg of VEGFR2-VEGFR2 complex per
pg of VEGFR2-VEGFR2-VEGF complex
ηa10 1.1125 pg of VEGFR2-VEGFR2-VEGF complex per
pg of VEGFR2-VEGFR2 complex
represent ratios of the weights of the different molecules involved in the reaction.
The values of these constants are given in the table below.
A.1 Non-dimensionalization of the Model Equations
The system of equations listed above is re-scaled to introduce non-dimensional
variables. t is scaled by the slowest time-scale in the reactions, 1/kar1. VEGF con-
centration A is scaled by a factor of A0, the initial amount of VEGF. The free and
occupied receptor densities are scaled by their maximum possible values. For in-
stance, free VEGFR2 density Ra is scaled by a factor of R
a
t M0, where R
a
t is the
weight in pg of VEGFR2 per cell. M0 is the carrying capacity of the environment

























2 P ∗a =
Pa
Rat M0/2
where, the ∗ superscripts denote non-dimensional quantities. Dropping the asterisks
for clarity, the non-dimensional system corresponding to the dimeric uptake model
reduces to the following.
1In the case of the dimer model, Da is scaled by a factor proportional to the maximum free VEGFR2 density,




= −ζa1 ARa + ζa2 Ca − ψa A(A.8)
dRa
dt
= −ζa3 ARa + Ca − ζa5 Ca Ra + ζa6 Da + ζa7 Da(A.9)
dCa
dt
= ζa3 ARa − Ca − ζa5 Ca Ra + ζa6 Da(A.10)
dDa
dt








































































ψa = λa kr1
It should be noted that the dimer model approximates the 1:1 model under the
condition that the binding of the intermediary complex Ca with a free receptor Ra
proceeds forward at a very rapid rate. In other words, if kaf2 is very high, the two
models will predict similar fractional occupancies of receptors. In non-dimensional
terms, this corresponds to high values for the parameter
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−α1 (α2 φa + α3 φl) Mτ
dA
dt










= −2 kaf1 ARa + ηa3 kar1 Ca − kaf2 Ca Ra + 2 ηa4 kar2 Da + 2 ηa4 kap Da(B.3)
+Rat Prod(M, V )−
Ra






= 2 ηa5 k
a
f1 ARa − kar1 Ca − ηa5 kaf2 Ca Ra + 2 ηa6 kar2 Da(B.4)
− Ca
Ra + ηa3 Ca + 2 η
a
4 Da





f2 Ca Ra − 2 kar2 Da − kap Da(B.5)
− Da
Ra + ηa3 Ca + 2 η
a
4 Da
Rat Death(M, V )
dL
dt







= −klf LRl + ηl3 klr Cl + ηl3 klp Cl(B.7)
+Rlt Prod(M,V )−
Rl
Rl + ηl3 Cl





f LRl − klr Cl − klp Cl(B.8)
− Cl
Rl + ηl3 Cl
Rlt Death(M, V )
dV
dt
















C(V ) = Cm
V0 + V
k + V0 + V
(B.11)





















B.1 Non-dimensionalization of the Model Equations
The system of equations listed above is re-scaled to introduce non-dimensional
variables. t is scaled by the value of the delay, τ . HDMEC density M is scaled
by M0, the carrying capacity of the environment for endothelial cells. Microvessel
density V is scaled by a factor of
M0
α1
, the carrying capacity of the environment for
microvessels. Tumor cell density N is scaled by a factor of N0, the maximum possi-
ble concentration of tumor cells under conditions of optimal oxygen concentration.
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Oxygen concentration C is scaled by Cm, the oxygen concentration under normoxia.
VEGF concentration A is scaled by a factor of A0, chosen chosen so as to elimi-
nate the parameter associated with its rate of production by tumor cells. Likewise,
CXCL8 concentration L is scaled by a factor of L0, chosen chosen so as to eliminate
the parameter associated with its rate of production by HDMECs. The free and oc-
cupied receptor densities are scaled by their maximum possible values. For instance,
free VEGFR2 density Ra is scaled by a factor of R
a
t M0, where R
a
t is the weight in





























































A0 = r3 N0 τ(B.17)
L0 = βl M0 τ(B.18)
and the ∗ superscripts denote non-dimensional quantities. Dropping the asterisks for






ρa φ̄a + ρl φ̄l −
(























= −ζa3 ARa + ζa4 Ca − ζa5 Ca Ra + ζa6 Da + ζa7 Da(B.21)

























= −ζ l3 LRl + ζ l4 Cl + ζ l5 Cl(B.25)













ξa φ̄a + ξl φ̄l
)

















The non-dimensional parameters are listed below.
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t τ ψm = λm τ
ω = δ ηa7 R
a







































t M0 τ ζ
a
6 = 2 k
a
r2 τ
ζa7 = 2 k
a










ε ᾱ = α1 α4



















































































The Bcl-family of Proteins in Intra-tumoral Angiogenesis
The full system of equations in Chapter VII, used to model sustained angiogenesis
in vivo are given below.
dM
dt
= (µa φa + µl φl − λm(X)) M
(




−α1 (α2 φa + α3 φl) Mτ
dA
dt










= −2 kaf1 ARa + ηa3 kar1 Ca − kaf2 Ca Ra + 2 ηa4 kar2 Da + 2 ηa4 kap Da(C.3)
+Rat Prod(M, V )−
Ra






= 2 ηa5 k
a
f1 ARa − kar1 Ca − ηa5 kaf2 Ca Ra + 2 ηa6 kar2 Da(C.4)
− Ca
Ra + ηa3 Ca + 2 η
a
4 Da





f2 Ca Ra − 2 kar2 Da − kap Da(C.5)
− Da
Ra + ηa3 Ca + 2 η
a
4 Da
Rat Death(M, V )
dL
dt




= −klf LRl + ηl3 klr Cl + ηl3 klp Cl(C.7)
+Rlt Prod(M,V )−
Rl
Rl + ηl3 Cl





f LRl − klr Cl − klp Cl(C.8)
− Cl




































f B X − kbr Cbx(C.13)
dI
dt





f B I − kir Cbi(C.15)
where,
C(V ) = Cm
V0 + V
k + V0 + V
(C.16)
Prod(M, V ) = (µa φa + µl φl) M
(




Death(M, V ) = λm(X) M
(
1− M + α1V
M0
)









λm(X) = ad e
bd X(C.21)
βl(B) = βm + ap (1− e−bp B)(C.22)
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C.1 Non-dimensionalization of the Model Equations
The system of equations listed above is re-scaled to introduce non-dimensional
variables. Most of the variables are re-scaled as described in Appendix B. Note that
the only change is in the definition of the scaling factor for L, which is now defined as
L0 = βm M0 τ . The new variables are scaled as follows. Intra-cellular Bcl-2 concen-
tration B and Bad concentration X are scaled by values B0 and X0 respectively, that
represent their constitutive levels of expression. Intra-cellular BL193 concentration
I is scaled by its extra-cellular concentration I0. The intra-cellular concentrations
of the intermediary complexes Cbx and Cbi are scaled by their respective maximum
















where the ∗ superscripts denote non-dimensional quantities. Dropping the asterisks





ρa φ̄a + ρl φ̄l − ψ̄m(X)
)
M (1− (M + V ))(C.23)















= −ζa3 ARa + ζa4 Ca − ζa5 Ca Ra + ζa6 Da + ζa7 Da(C.25)




















= −ζ l1 LRl + ζ l2 Cl − ψl L + β̄l(B) M(C.28)
dRl
dt
= −ζ l3 LRl + ζ l4 Cl + ζ l5 Cl(C.29)













ξa φ̄a + ξl φ̄l
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= −ζb3 B X + ζb4 Cbx(C.34)
dCbx
dt
= ζb1 B X − ζb2 Cbx(C.35)
dI
dt
= −ζ i3 B I + ζ i4 Cbi + νi (1− I)(C.36)
dCbi
dt
= ζ i1 B I − ζ i2 Cbi(C.37)
The additional non-dimensional parameters are listed below.
ζb1 = k
b

























νi = Di τ
ζ i1 = k
i



























k̄ + V̄0 + V
(C.38)
Prod(M, V ) =
(
ρa φ̄a + ρl φ̄l
)
M (1− (M + V ))(C.39)









ψ̄m(X) = ād e
b̄d X(C.43)
β̄l(B) = 1 + āp (1− e−b̄p B)(C.44)
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APPENDIX D
Biased Random Walk Model for Cell Chemotaxis
D.1 Continuum Limit of the Probability Master Equation
A derivation of the continuous diffusion-advection equation from the probability
master equation for the biased random walk of a cell is presented here. The basic
steps are as in (105). For ease of notation, the derivation is carried out for the 1-d
case. The master equation (8.1) in 1-d is:
∂pn
∂t
= T̂ +n−1(W ) pn−1 + T̂ −n+1(W ) pn+1(D.1)
−
(




T̂ ±n (W ) = 2λ
τ(cn±1/2)
τ(cn+1/2) + τ(cn−1/2)
≡ 2λN±n (W )(D.3)
Define a function N(., .) as follows








Note that, by symmetry, N(u, v) + N(v, u) = 1. This renormalization introduces
longer range dependence of the transition rates on the chemoattractant, since
T̂ +n−1(W ) = 2λN+n−1(W ) = 2λN(cn−1/2, cn−3/2)(D.5)
T̂ −n+1(W ) = 2λN−n+1(W ) = 2λN(cn+1/2, cn+3/2)(D.6)





= N(cn−1/2, cn−3/2) pn−1 + N(cn+1/2, cn+3/2) pn+1(D.7)
− (N(cn+1/2, cn−1/2) + N(cn−1/2, cn+1/2)
)
pn
= N(cn−1/2, cn−3/2) pn−1 + N(cn+1/2, cn+3/2) pn+1 − pn
Consider a grid of mesh size h, and let x = nh. Then,














































+ · · ·
= N − h
2
(N1 + 3N2) cx +
h2
8




(N11 + 9N22 + 6N12) c
2
x + · · ·
Here, c(.) ≡ c(x), N(., .) ≡ N(u, v), Nk ≡ ∂kN(., .), where ∂k denotes a deriva-
tive with respect to the kth argument, evaluated at (c(x), c(x)). As noted earlier,
N(u, v) + N(v, u) = 1, so that N1(u, v) + N2(u, v) = 0 and N12(u, v) = 0. Equa-
tion (D.8) then becomes
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N(cn−1/2, cn−3/2) = N − hN2 cx + h2 N2 cxx + h2 N22 c2x(D.9)
Likewise,
N(cn+1/2, cn+3/2) = N + hN2 cx + h




Next, we expand pn−1 and pn+1 in a Taylor series about x = nh to second order, as
well, and substitute these in equation (D.7). The various terms on the right hand
side are
Constant term = 0
Coefficient of h = 0
Coefficient of h2 =
1
2






p − (N1 −N2) cx px − (N1 −N2) cxx p− (N11 −N22) c2x p
Equation (D.7) translates to
∂p
∂t
= h2 λ pxx − 2 h2 λ (p (N1 −N2) cx)x(D.11)
→ Dp pxx − 2 Dp (p (N1 −N2) cx)x
where Dp = limh→0λ→∞ h2 λ is the diffusion coefficient of endothelial cells. Note also
that since N(c(x), c(y)) = τ(c(x))/(τ(c(x))+τ(c(y))), by definition, N1(c(x), c(x)) =














This computation can be easily repeated in two dimensions, where the continuous
equation for motion of an endothelial cell becomes
∂p
∂t
= Dp ∆ p−Dp∇ · (p (ln τ(c))′∇c)(D.13)
The chemotactic sensitivity function is
χ(c) = Dp (ln τ(c))
′(D.14)
D.2 Choice of Transition Probability Function
The function τ(.), from equation (8.3) determines the transition probability func-
tions T̂ in equation (8.1). Its choice will also determine the form of the chemotactic
sensitivity χ(.), through the relationship given in equation (D.14). In equation (8.6),
a choice was made for this sensitivity. We now derive the corresponding form of τ ,
as follows. By (D.14),
Dp (ln τ(a))
′ = χ(a)
= χ0 a e
−a/B
















B − (B + a) e−a/B]
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